{"feb25c9a9dbc1800d43c52b03616c7a4d3e2a709": [["O ver the past decade, reported cases of malaria and associated deaths have declined in Africa (1).", [["malaria", "DISEASE", 41, 48], ["deaths", "DISEASE", 64, 70], ["malaria", "PROBLEM", 41, 48], ["malaria", "OBSERVATION", 41, 48]]], ["This decrease has led to a search for other causes of fever in Africa, where unexplained febrile illnesses are one of the major health problems.", [["fever", "DISEASE", 54, 59], ["febrile illnesses", "DISEASE", 89, 106], ["fever", "PROBLEM", 54, 59], ["unexplained febrile illnesses", "PROBLEM", 77, 106], ["fever", "OBSERVATION", 54, 59]]], ["In some sub-Saharan Africa countries, malaria treatments are still administered without a biologic diagnosis.", [["malaria", "DISEASE", 38, 45], ["malaria treatments", "TREATMENT", 38, 56], ["some", "OBSERVATION_MODIFIER", 3, 7], ["sub", "OBSERVATION_MODIFIER", 8, 11]]], ["For example, an assessment of complicated malaria and other severe febrile illness cases in a pediatric ward in Libreville, Gabon, showed that 43.5% of the children who received an antimalarial treatment had microscopy test results negative for malaria (2) .", [["malaria", "DISEASE", 42, 49], ["febrile illness", "DISEASE", 67, 82], ["malaria", "DISEASE", 245, 252], ["children", "ORGANISM", 156, 164], ["children", "SPECIES", 156, 164], ["an assessment", "TEST", 13, 26], ["complicated malaria", "PROBLEM", 30, 49], ["other severe febrile illness", "PROBLEM", 54, 82], ["an antimalarial treatment", "TREATMENT", 178, 203], ["microscopy test", "TEST", 208, 223], ["malaria", "PROBLEM", 245, 252], ["complicated", "OBSERVATION_MODIFIER", 30, 41], ["malaria", "OBSERVATION", 42, 49], ["severe", "OBSERVATION_MODIFIER", 60, 66], ["febrile", "OBSERVATION_MODIFIER", 67, 74]]]], "3ee377ece8b8a1fb6a4468d39d410f0f33042051": [["episode was documented.", [["episode", "PROBLEM", 0, 7]]], ["Three hundred and five episodes of respiratory illnesses were captured in the cohort.", [["respiratory", "ANATOMY", 35, 46], ["respiratory illnesses", "DISEASE", 35, 56], ["respiratory illnesses", "PROBLEM", 35, 56], ["respiratory illnesses", "OBSERVATION", 35, 56]]], ["Nasal specimens were available in 166 episodes, 92 of which were diagnosed as asthma exacerbations, and 74 nonasthma related episodes.", [["Nasal specimens", "ANATOMY", 0, 15], ["asthma exacerbations", "DISEASE", 78, 98], ["nonasthma", "DISEASE", 107, 116], ["Nasal specimens", "CANCER", 0, 15], ["Nasal specimens", "TEST", 0, 15], ["asthma exacerbations", "PROBLEM", 78, 98], ["74 nonasthma related episodes", "PROBLEM", 104, 133], ["asthma", "OBSERVATION", 78, 84]]], ["Respiratory viruses were detected in 61 of 166 episodes (36.7%).", [["Respiratory viruses", "DISEASE", 0, 19], ["Respiratory viruses", "TEST", 0, 19], ["viruses", "OBSERVATION", 12, 19]]], ["There was no significant difference in virus detection rate between asthma exacerbations (32 out of 97 episodes, 34.8%) and non-asthma respiratory illnesses (29 out of 79 episodes, 39.2%).", [["respiratory", "ANATOMY", 135, 146], ["asthma exacerbations", "DISEASE", 68, 88], ["respiratory illnesses", "DISEASE", 135, 156], ["significant difference in virus detection rate", "PROBLEM", 13, 59], ["asthma exacerbations", "PROBLEM", 68, 88], ["non-asthma respiratory illnesses", "PROBLEM", 124, 156], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35], ["virus", "OBSERVATION", 39, 44], ["respiratory illnesses", "OBSERVATION", 135, 156]]], ["Although newly discovered respiratory viruses were identified in these episodes, rhinovirus was the commonest organism associated with both asthma exacerbations and non-asthma related episodes.", [["respiratory viruses", "DISEASE", 26, 45], ["asthma exacerbations", "DISEASE", 140, 160], ["non-asthma", "DISEASE", 165, 175], ["rhinovirus", "ORGANISM", 81, 91], ["newly discovered respiratory viruses", "PROBLEM", 9, 45], ["these episodes", "PROBLEM", 65, 79], ["rhinovirus", "PROBLEM", 81, 91], ["both asthma exacerbations", "PROBLEM", 135, 160], ["non-asthma related episodes", "PROBLEM", 165, 192], ["respiratory viruses", "OBSERVATION", 26, 45], ["rhinovirus", "OBSERVATION", 81, 91], ["both", "OBSERVATION_MODIFIER", 135, 139], ["asthma", "OBSERVATION", 140, 146]]], ["Plausible explanations for much lower virus detection rate than previously reported include improved personal hygiene and precautionary measures taken during respiratory tract infections in the immediate post-severe acute respiratory syndrome period together with a significant contribution of other adverse factors like environmental air pollution.", [["respiratory tract", "ANATOMY", 158, 175], ["respiratory tract infections", "DISEASE", 158, 186], ["acute respiratory syndrome", "DISEASE", 216, 242], ["tract", "ORGANISM_SUBDIVISION", 170, 175], ["much lower virus detection rate", "PROBLEM", 27, 58], ["precautionary measures", "TREATMENT", 122, 144], ["respiratory tract infections", "PROBLEM", 158, 186], ["severe acute respiratory syndrome", "PROBLEM", 209, 242], ["other adverse factors", "PROBLEM", 294, 315], ["environmental air pollution", "PROBLEM", 321, 348], ["respiratory tract", "ANATOMY", 158, 175], ["severe", "OBSERVATION_MODIFIER", 209, 215], ["acute", "OBSERVATION_MODIFIER", 216, 221], ["respiratory syndrome", "OBSERVATION", 222, 242], ["air pollution", "OBSERVATION", 335, 348]]], ["We conclude that not all viral infections in children with asthma lead to an asthma exacerbation and the attributing effect of different triggers of asthma exacerbations in children vary across different time periods and across different localities.IntroductionViral respiratory tract infection, with rhinovirus accounted for two thirds, was found to be associated with greater than 80% of asthma exacerbations in children in studies in the 1990s [14] .", [["respiratory tract", "ANATOMY", 267, 284], ["viral infections", "DISEASE", 25, 41], ["asthma", "DISEASE", 59, 65], ["asthma", "DISEASE", 77, 83], ["asthma", "DISEASE", 149, 155], ["respiratory tract infection", "DISEASE", 267, 294], ["rhinovirus", "DISEASE", 301, 311], ["asthma", "DISEASE", 390, 396], ["children", "ORGANISM", 45, 53], ["children", "ORGANISM", 173, 181], ["IntroductionViral respiratory tract", "ORGANISM", 249, 284], ["children", "ORGANISM", 414, 422], ["children", "SPECIES", 45, 53], ["children", "SPECIES", 173, 181], ["children", "SPECIES", 414, 422], ["all viral infections", "PROBLEM", 21, 41], ["asthma", "PROBLEM", 59, 65], ["an asthma exacerbation", "PROBLEM", 74, 96], ["asthma exacerbations", "PROBLEM", 149, 169], ["IntroductionViral respiratory tract infection", "PROBLEM", 249, 294], ["rhinovirus", "PROBLEM", 301, 311], ["asthma exacerbations", "PROBLEM", 390, 410], ["viral", "OBSERVATION_MODIFIER", 25, 30], ["infections", "OBSERVATION", 31, 41], ["asthma", "OBSERVATION", 77, 83], ["asthma", "OBSERVATION", 149, 155], ["respiratory tract", "ANATOMY", 267, 284], ["infection", "OBSERVATION", 285, 294], ["rhinovirus", "OBSERVATION", 301, 311], ["asthma", "OBSERVATION", 390, 396]]], ["However, the prevalence of respiratory viral infection varies greatly across different places; for example, influenza is associated with more hospitalization among children in Hong Kong compared with temperate region [7] .", [["respiratory viral infection", "DISEASE", 27, 54], ["influenza", "DISEASE", 108, 117], ["children", "ORGANISM", 164, 172], ["children", "SPECIES", 164, 172], ["respiratory viral infection", "PROBLEM", 27, 54], ["influenza", "PROBLEM", 108, 117], ["respiratory", "OBSERVATION", 27, 38], ["viral infection", "OBSERVATION", 39, 54]]], ["Recent observational studies have shown that influenza infection can be associated with asthma exacerbations.", [["influenza infection", "DISEASE", 45, 64], ["asthma", "DISEASE", 88, 94], ["Recent observational studies", "TEST", 0, 28], ["influenza infection", "PROBLEM", 45, 64], ["asthma exacerbations", "PROBLEM", 88, 108], ["influenza", "OBSERVATION_MODIFIER", 45, 54], ["infection", "OBSERVATION", 55, 64]]], ["Nevertheless, a metaanalysis failed to support the protective effect of influenza vaccination in asthma exacerbations [3] .", [["influenza", "DISEASE", 72, 81], ["asthma", "DISEASE", 97, 103], ["a metaanalysis", "TEST", 14, 28], ["influenza vaccination", "TREATMENT", 72, 93], ["asthma exacerbations", "PROBLEM", 97, 117], ["influenza", "OBSERVATION", 72, 81]]], ["Newly discovered respiratory viruses such as human metapneumovirus may also play a role [20] .", [["respiratory viruses", "DISEASE", 17, 36], ["human metapneumovirus", "DISEASE", 45, 66], ["human", "ORGANISM", 45, 50], ["metapneumovirus", "ORGANISM", 51, 66], ["human", "SPECIES", 45, 50], ["metapneumovirus", "SPECIES", 51, 66], ["human metapneumovirus", "SPECIES", 45, 66], ["Newly discovered respiratory viruses", "PROBLEM", 0, 36], ["human metapneumovirus", "PROBLEM", 45, 66], ["respiratory viruses", "OBSERVATION", 17, 36]]], ["Triggers other than respiratory tract infection, like air pollutions may become more prevalent over time and supersede respiratory tract infections as a major trigger.", [["respiratory tract", "ANATOMY", 20, 37], ["respiratory tract", "ANATOMY", 119, 136], ["respiratory tract infection", "DISEASE", 20, 47], ["air pollutions", "DISEASE", 54, 68], ["respiratory tract infections", "DISEASE", 119, 147], ["tract", "ORGANISM_SUBDIVISION", 32, 37], ["respiratory tract", "ORGANISM_SUBDIVISION", 119, 136], ["respiratory tract infection", "PROBLEM", 20, 47], ["air pollutions", "PROBLEM", 54, 68], ["supersede respiratory tract infections", "PROBLEM", 109, 147], ["respiratory tract", "ANATOMY", 20, 37], ["infection", "OBSERVATION", 38, 47], ["air pollutions", "OBSERVATION", 54, 68], ["respiratory tract", "ANATOMY", 119, 136]]], ["Thus, we carried out a prospective study to delineate the current role of different viral respiratory tract infections including newly discovered respiratory viruses in asthma exacerbation in children in our locality.Design and subjectsChildren aged 6-14 years who attended regular follow-up at the asthma clinic were invited to participate.", [["respiratory tract infections", "DISEASE", 90, 118], ["respiratory viruses", "DISEASE", 146, 165], ["asthma", "DISEASE", 169, 175], ["asthma", "DISEASE", 299, 305], ["viral respiratory tract", "ORGANISM", 84, 107], ["children", "ORGANISM", 192, 200], ["Children", "ORGANISM", 236, 244], ["children", "SPECIES", 192, 200], ["Children", "SPECIES", 236, 244], ["a prospective study", "TEST", 21, 40], ["different viral respiratory tract infections", "PROBLEM", 74, 118], ["newly discovered respiratory viruses", "PROBLEM", 129, 165], ["asthma exacerbation", "PROBLEM", 169, 188], ["respiratory tract", "ANATOMY", 90, 107], ["respiratory viruses", "OBSERVATION", 146, 165], ["asthma", "OBSERVATION", 169, 175]]], ["Children with physician-diagnosed asthma, symptoms of asthma in the preceding year, no hospital admission for exacerbation, and on regular inhaled steroid equivalent to beclomethasone \u2264400 \u03bcg daily for at least 3 months prior to enrolment were recruited.", [["asthma", "DISEASE", 34, 40], ["asthma", "DISEASE", 54, 60], ["steroid", "CHEMICAL", 147, 154], ["beclomethasone", "CHEMICAL", 169, 183], ["steroid", "CHEMICAL", 147, 154], ["beclomethasone", "CHEMICAL", 169, 183], ["Children", "ORGANISM", 0, 8], ["beclomethasone", "SIMPLE_CHEMICAL", 169, 183], ["Children", "SPECIES", 0, 8], ["asthma", "PROBLEM", 34, 40], ["symptoms", "PROBLEM", 42, 50], ["asthma", "PROBLEM", 54, 60], ["exacerbation", "PROBLEM", 110, 122], ["regular inhaled steroid equivalent", "TREATMENT", 131, 165], ["beclomethasone \u2264", "TREATMENT", 169, 185], ["asthma", "OBSERVATION", 34, 40], ["asthma", "OBSERVATION", 54, 60]]], ["Exclusion criteria were those with other known chronic respiratory disease and oral steroid therapy given within 4 weeks of enrolment.", [["respiratory", "ANATOMY", 55, 66], ["oral", "ANATOMY", 79, 83], ["chronic respiratory disease", "DISEASE", 47, 74], ["steroid", "CHEMICAL", 84, 91], ["steroid", "CHEMICAL", 84, 91], ["oral", "ORGANISM_SUBDIVISION", 79, 83], ["other known chronic respiratory disease", "PROBLEM", 35, 74], ["oral steroid therapy", "TREATMENT", 79, 99], ["enrolment", "TREATMENT", 124, 133], ["chronic", "OBSERVATION_MODIFIER", 47, 54], ["respiratory disease", "OBSERVATION", 55, 74]]], ["The participants were followed up to cover a full calendar year to reduce potential biases associated with temporal and age-related differences in respiratory tract infections.ProcedurePatient's demographic data, treatment at enrolment, family history of atopy and asthma, and exposure to environmental tobacco smoke were recorded at the time of recruitment.", [["respiratory tract", "ANATOMY", 147, 164], ["respiratory tract infections", "DISEASE", 147, 175], ["atopy", "DISEASE", 255, 260], ["asthma", "DISEASE", 265, 271], ["respiratory tract", "ORGANISM_SUBDIVISION", 147, 164], ["tobacco", "ORGANISM", 303, 310], ["participants", "SPECIES", 4, 16], ["tobacco", "SPECIES", 303, 310], ["potential biases", "PROBLEM", 74, 90], ["respiratory tract infections", "PROBLEM", 147, 175], ["treatment", "TREATMENT", 213, 222], ["atopy", "PROBLEM", 255, 260], ["asthma", "PROBLEM", 265, 271], ["respiratory tract", "ANATOMY", 147, 164], ["asthma", "OBSERVATION", 265, 271], ["tobacco smoke", "OBSERVATION", 303, 316], ["recruitment", "OBSERVATION", 346, 357]]], ["Measurement of lung function using Vitalograph Model 2120 was obtained according to American Thoracic Society recommendations in children who were able to perform spirometry [1] .", [["lung", "ANATOMY", 15, 19], ["lung", "ORGAN", 15, 19], ["children", "ORGANISM", 129, 137], ["children", "SPECIES", 129, 137], ["Vitalograph Model", "TEST", 35, 52], ["lung", "ANATOMY", 15, 19], ["Thoracic", "ANATOMY", 93, 101]]], ["Skin prick test was done according to the standardized International Study of Asthma and Allergies in Childhood Phase 2 protocol [12] .", [["Skin", "ANATOMY", 0, 4], ["Asthma", "DISEASE", 78, 84], ["Allergies", "DISEASE", 89, 98], ["Skin", "ORGAN", 0, 4], ["Skin prick test", "TEST", 0, 15], ["Asthma", "PROBLEM", 78, 84], ["Allergies", "PROBLEM", 89, 98], ["Asthma", "OBSERVATION", 78, 84]]], ["Ten aeroallergens including Dermatophagoides pteronyssinus, Dermatophagoides farinae, cat, Alternaria tenuis, mixed tree pollen, mixed grass pollen, dog, cockroach (American and German), and mixed moulds were tested.", [["pollen", "ANATOMY", 121, 127], ["Dermatophagoides pteronyssinus", "ORGANISM", 28, 58], ["Dermatophagoides farinae", "ORGANISM", 60, 84], ["cat", "ORGANISM", 86, 89], ["Alternaria tenuis", "ORGANISM", 91, 108], ["dog", "ORGANISM_SUBDIVISION", 149, 152], ["cockroach", "ORGANISM_SUBDIVISION", 154, 163], ["Dermatophagoides pteronyssinus", "SPECIES", 28, 58], ["Dermatophagoides farinae", "SPECIES", 60, 84], ["cat", "SPECIES", 86, 89], ["Alternaria tenuis", "SPECIES", 91, 108], ["dog", "SPECIES", 149, 152], ["Dermatophagoides pteronyssinus", "SPECIES", 28, 58], ["Dermatophagoides farinae", "SPECIES", 60, 84], ["Alternaria tenuis", "SPECIES", 91, 108], ["Ten aeroallergens", "PROBLEM", 0, 17], ["Dermatophagoides pteronyssinus", "TREATMENT", 28, 58], ["mixed moulds", "PROBLEM", 191, 203], ["Dermatophagoides pteronyssinus", "OBSERVATION", 28, 58], ["Dermatophagoides farinae", "OBSERVATION", 60, 84], ["Alternaria tenuis", "OBSERVATION", 91, 108]]], ["A wheal diameter of 3 mm greater than the diameter of the negative control was defined as positive response.", [["wheal", "ANATOMY", 2, 7], ["A wheal diameter", "TEST", 0, 16], ["wheal", "OBSERVATION_MODIFIER", 2, 7], ["diameter", "OBSERVATION_MODIFIER", 8, 16], ["3 mm", "OBSERVATION_MODIFIER", 20, 24], ["greater", "OBSERVATION_MODIFIER", 25, 32], ["diameter", "OBSERVATION_MODIFIER", 42, 50], ["negative", "OBSERVATION", 58, 66], ["positive response", "OBSERVATION", 90, 107]]], ["Children with \u22651 positive responses were defined as atopic.ProcedureEach child was given an asthma diary chart and a peak flow meter (Mini-Wright AFS Low range peak flow meter) during the run-in period.", [["atopic", "DISEASE", 52, 58], ["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8], ["atopic", "PROBLEM", 52, 58], ["a peak flow meter", "TEST", 115, 132]]], ["Parents and children were taught on data entry, use of peak flow meter, and record twice daily peak expiratory flow rate (PEFR) and any upper and lower respiratory symptoms for 2 weeks as baseline.", [["respiratory", "ANATOMY", 152, 163], ["children", "ORGANISM", 12, 20], ["upper", "ORGANISM_SUBDIVISION", 136, 141], ["children", "SPECIES", 12, 20], ["peak expiratory flow rate", "TEST", 95, 120], ["PEFR", "TEST", 122, 126], ["any upper and lower respiratory symptoms", "PROBLEM", 132, 172], ["upper", "ANATOMY_MODIFIER", 136, 141], ["lower", "ANATOMY_MODIFIER", 146, 151], ["respiratory", "ANATOMY", 152, 163]]], ["[14] (Appendix).", [["Appendix", "ANATOMY", 6, 14]]], ["Parents were instructed to start to record PEFR twice daily and respiratory symptoms in a new log sheet when the symptoms scored >3.", [["respiratory symptoms", "DISEASE", 64, 84], ["respiratory symptoms", "PROBLEM", 64, 84], ["the symptoms", "PROBLEM", 109, 121]]], ["They were to call the research nurse if PEFR fell to below 80% of the child's baseline, if total upper or lower respiratory symptom score totalled \u22654, or if parents subjectively felt the child was developing a cold even though PEFR fell by <20% of baseline.", [["upper", "ORGANISM_SUBDIVISION", 97, 102], ["child", "ORGANISM", 187, 192], ["PEFR", "TEST", 40, 44], ["total upper or lower respiratory symptom score", "PROBLEM", 91, 137], ["a cold", "PROBLEM", 208, 214], ["PEFR", "TEST", 227, 231], ["lower", "ANATOMY_MODIFIER", 106, 111], ["respiratory", "ANATOMY", 112, 123]]], ["During the unscheduled visit, upper and lower respiratory symptoms and physical signs were recorded.", [["respiratory", "ANATOMY", 46, 57], ["upper", "ORGANISM_SUBDIVISION", 30, 35], ["upper and lower respiratory symptoms", "PROBLEM", 30, 66], ["physical signs", "TEST", 71, 85], ["upper", "ANATOMY_MODIFIER", 30, 35], ["lower", "ANATOMY_MODIFIER", 40, 45], ["respiratory", "ANATOMY", 46, 57]]], ["An asthma exacerbation was defined as a fall in morning PEFR to below 80% of baseline in the absence of expiratory wheeze for \u22652 two consecutive days.", [["asthma", "DISEASE", 3, 9], ["expiratory wheeze", "DISEASE", 104, 121], ["An asthma exacerbation", "PROBLEM", 0, 22], ["a fall", "PROBLEM", 38, 44], ["expiratory wheeze", "PROBLEM", 104, 121], ["asthma", "OBSERVATION", 3, 9]]], ["The presence of wheeze detected by the attending paediatrician at the time of visit (Lee SL/Chiu SS), or an increase in the use of shortacting beta 2 agonists on at least two occasions per day for \u22652 consecutive days.", [["wheeze", "DISEASE", 16, 22], ["beta 2 agonists", "GENE_OR_GENE_PRODUCT", 143, 158], ["wheeze", "PROBLEM", 16, 22], ["shortacting beta 2 agonists", "TREATMENT", 131, 158], ["wheeze", "OBSERVATION", 16, 22], ["increase", "OBSERVATION_MODIFIER", 108, 116]]], ["Diagnoses other than asthma exacerbation were also captured.", [["asthma", "DISEASE", 21, 27], ["asthma exacerbation", "PROBLEM", 21, 40], ["asthma", "OBSERVATION", 21, 27]]], ["Chest radiograph were ordered if clinically indicated.", [["Chest radiograph", "TEST", 0, 16]]], ["Respiratory secretions from children were obtained using nasal swabs.", [["Respiratory secretions", "ANATOMY", 0, 22], ["nasal swabs", "ANATOMY", 57, 68], ["children", "ORGANISM", 28, 36], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 57, 68], ["children", "SPECIES", 28, 36], ["Respiratory secretions", "PROBLEM", 0, 22], ["nasal swabs", "TREATMENT", 57, 68], ["secretions", "OBSERVATION", 12, 22]]], ["The cotton-tipped swab was inserted into the nostril for 2 to 3 cm and rotated three times against the respiratory epithelial surface of the nasal cavity.", [["swab", "ANATOMY", 18, 22], ["nostril", "ANATOMY", 45, 52], ["respiratory epithelial surface", "ANATOMY", 103, 133], ["nasal cavity", "ANATOMY", 141, 153], ["swab", "ORGANISM_SUBSTANCE", 18, 22], ["nostril", "ORGAN", 45, 52], ["epithelial surface", "TISSUE", 115, 133], ["nasal cavity", "MULTI-TISSUE_STRUCTURE", 141, 153], ["The cotton-tipped swab", "TREATMENT", 0, 22], ["cotton", "OBSERVATION_MODIFIER", 4, 10], ["tipped", "OBSERVATION_MODIFIER", 11, 17], ["swab", "OBSERVATION", 18, 22], ["nostril", "ANATOMY", 45, 52], ["2 to 3 cm", "OBSERVATION_MODIFIER", 57, 66], ["respiratory", "ANATOMY_MODIFIER", 103, 114], ["epithelial", "ANATOMY_MODIFIER", 115, 125], ["surface", "ANATOMY_MODIFIER", 126, 133], ["nasal cavity", "ANATOMY", 141, 153]]], ["Once collected, the specimen was put in a virus transport medium and immediately transported to the microbiology laboratory for processing.", [["specimen", "ANATOMY", 20, 28], ["a virus transport medium", "TREATMENT", 40, 64]]], ["The child was treated as appropriate.", [["child", "ORGANISM", 4, 9]]], ["The parents and child continued to record daily PEFR and symptoms in the subsequent 2 weeks or longer until symptoms subsided completely.", [["symptoms", "PROBLEM", 57, 65], ["symptoms", "PROBLEM", 108, 116]]], ["All participants also attended scheduled clinic visit every 3 months.", [["participants", "SPECIES", 4, 16]]], ["At each scheduled visit, all respiratory symptoms at follow-up or any respiratory problems in between visits that were not reported would be recorded.Detection of respiratory virusesPart of the aliquot was used for routine detection of viral antigen using immunofluorescence (IF) detection of viral antigens for five respiratory viruses, viz. influenza viruses types A & B, respiratory syncytial virus (RSV), parainfluenza virus, and adenovirus.", [["respiratory", "ANATOMY", 29, 40], ["respiratory", "ANATOMY", 70, 81], ["respiratory viruses", "DISEASE", 163, 182], ["respiratory viruses", "DISEASE", 317, 336], ["influenza viruses", "DISEASE", 343, 360], ["respiratory syncytial virus (RSV), parainfluenza virus", "DISEASE", 374, 428], ["influenza viruses types A & B,", "ORGANISM", 343, 373], ["respiratory syncytial virus", "ORGANISM", 374, 401], ["RSV", "ORGANISM", 403, 406], ["parainfluenza virus", "ORGANISM", 409, 428], ["adenovirus", "ORGANISM", 434, 444], ["viral antigen", "PROTEIN", 236, 249], ["viral antigens", "PROTEIN", 293, 307], ["influenza", "SPECIES", 343, 352], ["respiratory syncytial virus", "SPECIES", 374, 401], ["RSV", "SPECIES", 403, 406], ["parainfluenza virus", "SPECIES", 409, 428], ["respiratory syncytial virus", "SPECIES", 374, 401], ["RSV", "SPECIES", 403, 406], ["parainfluenza virus", "SPECIES", 409, 428], ["adenovirus", "SPECIES", 434, 444], ["all respiratory symptoms", "PROBLEM", 25, 49], ["any respiratory problems", "PROBLEM", 66, 90], ["respiratory viruses", "PROBLEM", 163, 182], ["routine detection", "TEST", 215, 232], ["viral antigen", "PROBLEM", 236, 249], ["immunofluorescence", "TEST", 256, 274], ["viral antigens", "PROBLEM", 293, 307], ["five respiratory viruses", "PROBLEM", 312, 336], ["influenza viruses types", "PROBLEM", 343, 366], ["A & B", "TEST", 367, 372], ["respiratory syncytial virus", "PROBLEM", 374, 401], ["RSV", "PROBLEM", 403, 406], ["parainfluenza virus", "PROBLEM", 409, 428], ["adenovirus", "PROBLEM", 434, 444], ["respiratory viruses", "OBSERVATION", 163, 182], ["respiratory viruses", "OBSERVATION", 317, 336], ["respiratory syncytial", "ANATOMY", 374, 395], ["parainfluenza virus", "OBSERVATION", 409, 428]]], ["It was also cultured for virus isolation.", [["virus isolation", "TREATMENT", 25, 40]]], ["The remaining aliquot was used for polymerase chain reaction (PCR) detection of rhinovirus, human metapneumonvirus, human coronavirus NL 63, OC43, 229E, HKU1, and bocavirus.", [["rhinovirus", "ORGANISM", 80, 90], ["human", "ORGANISM", 92, 97], ["human", "ORGANISM", 116, 121], ["coronavirus NL 63", "ORGANISM", 122, 139], ["OC43", "GENE_OR_GENE_PRODUCT", 141, 145], ["229E", "GENE_OR_GENE_PRODUCT", 147, 151], ["HKU1", "GENE_OR_GENE_PRODUCT", 153, 157], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 116, 121], ["coronavirus", "SPECIES", 122, 133], ["human metapneumonvirus", "SPECIES", 92, 114], ["human coronavirus", "SPECIES", 116, 133], ["The remaining aliquot", "TREATMENT", 0, 21], ["polymerase chain reaction", "TEST", 35, 60], ["PCR", "TEST", 62, 65], ["rhinovirus", "PROBLEM", 80, 90], ["human metapneumonvirus", "TEST", 92, 114], ["human coronavirus NL", "TEST", 116, 136], ["OC43", "TEST", 141, 145], ["HKU1", "TEST", 153, 157], ["bocavirus", "PROBLEM", 163, 172], ["rhinovirus", "OBSERVATION", 80, 90]]], ["[6, 8, 19, 21] Ethical approvalDetection of respiratory virusesThe study was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster.", [["respiratory viruses", "DISEASE", 44, 63], ["respiratory viruses", "PROBLEM", 44, 63], ["The study", "TEST", 63, 72], ["respiratory viruses", "OBSERVATION", 44, 63]]], ["The study was conducted in accordance with the Declaration of Helsinki.", [["The study", "TEST", 0, 9]]], ["Verbal consent was obtained from the participants and written consent was obtained from their parents or legal guardians.Statistical analysisPrevious studies showed virus identification rate ranged from 32% to 85% of asthma exacerbation in children [14, 19] .", [["asthma", "DISEASE", 217, 223], ["children", "ORGANISM", 240, 248], ["participants", "SPECIES", 37, 49], ["children", "SPECIES", 240, 248], ["Statistical analysisPrevious studies", "TEST", 121, 157], ["virus identification rate", "TEST", 165, 190], ["asthma exacerbation", "PROBLEM", 217, 236], ["asthma", "OBSERVATION", 217, 223]]], ["The conservative estimation of virus detection rate of 50% would give the largest sample size estimate of 96 exacerbations with level of confidence at 95% and precision of detection rate of 10%.", [["virus detection rate", "TEST", 31, 51], ["confidence", "TEST", 137, 147], ["detection rate", "TEST", 172, 186], ["largest", "OBSERVATION_MODIFIER", 74, 81], ["size", "OBSERVATION_MODIFIER", 89, 93]]], ["As the number of urgent visits due to asthma was 1.2 per person-year in children on regular inhaled steroids in another study, the number of subjects required would be around 80 [22] .", [["asthma", "DISEASE", 38, 44], ["steroids", "CHEMICAL", 100, 108], ["steroids", "CHEMICAL", 100, 108], ["children", "ORGANISM", 72, 80], ["children", "SPECIES", 72, 80], ["asthma", "PROBLEM", 38, 44], ["regular inhaled steroids", "TREATMENT", 84, 108]]], ["We performed simple descriptive analyses of demographic data.", [["demographic data", "TEST", 44, 60]]], ["The frequencies of presenting symptoms and physician diagnoses of unscheduled visits, virus detection rate and the distribution of different types of viruses were described.", [["presenting symptoms", "PROBLEM", 19, 38], ["virus detection rate", "TEST", 86, 106], ["viruses", "PROBLEM", 150, 157], ["viruses", "OBSERVATION", 150, 157]]], ["Student T test (+\u2212 Mann-Whitney U test) was used to compare continuous variables; for example, age and Pearson's chi-square test (with Yates'correction/Fisher's exact test) was used to compare categorical variables; for example, sex (female or male), atopic status (yes or no) between children with and without unscheduled visits.", [["children", "ORGANISM", 285, 293], ["children", "SPECIES", 285, 293], ["Student T test", "TEST", 0, 14], ["Whitney U test", "TEST", 24, 38], ["Pearson's chi-square test", "TEST", 103, 128], ["Fisher's exact test", "TEST", 152, 171]]], ["A p value less than 0.05 was considered to be statistically significant.", [["A p value", "TEST", 0, 9]]], ["All statistical analyses were carried out by the SPSS 11.0 software (SPSS Inc., Chicago, IL).ResultThere were totally 122 participants recruited from the end of September to the end of December 2003 and were followed up until the end of December 2004.", [["participants", "SPECIES", 122, 134], ["All statistical analyses", "TEST", 0, 24]]], ["Eight of these participants withdrew early as their parents found it inconvenient to attend unscheduled visit.", [["participants", "ORGANISM", 15, 27], ["participants", "SPECIES", 15, 27]]], ["One hundred and fourteen children aged 6 to 13 years completed the study.", [["children", "ORGANISM", 25, 33], ["children", "SPECIES", 25, 33], ["the study", "TEST", 63, 72]]], ["Among these 114 children, 16 children (14.0 %) did not report any exacerbations or respiratory illnesses.", [["respiratory", "ANATOMY", 83, 94], ["respiratory illnesses", "DISEASE", 83, 104], ["children", "ORGANISM", 16, 24], ["children", "ORGANISM", 29, 37], ["children", "SPECIES", 16, 24], ["children", "SPECIES", 29, 37], ["any exacerbations", "PROBLEM", 62, 79], ["respiratory illnesses", "PROBLEM", 83, 104], ["respiratory", "ANATOMY", 83, 94], ["illnesses", "OBSERVATION", 95, 104]]], ["Children with respiratory illnesses were younger than children without respiratory illnesses (p<0.05) and there was greater proportion with normal pulmonary lung function test at the time of recruitment (p=0.02).", [["respiratory", "ANATOMY", 14, 25], ["respiratory", "ANATOMY", 71, 82], ["pulmonary lung", "ANATOMY", 147, 161], ["respiratory illnesses", "DISEASE", 14, 35], ["respiratory illnesses", "DISEASE", 71, 92], ["Children", "ORGANISM", 0, 8], ["children", "ORGANISM", 54, 62], ["pulmonary", "ORGAN", 147, 156], ["lung", "ORGAN", 157, 161], ["Children", "SPECIES", 0, 8], ["children", "SPECIES", 54, 62], ["respiratory illnesses", "PROBLEM", 14, 35], ["respiratory illnesses", "PROBLEM", 71, 92], ["respiratory", "ANATOMY", 14, 25], ["illnesses", "OBSERVATION", 26, 35], ["normal", "OBSERVATION", 140, 146], ["pulmonary lung", "ANATOMY", 147, 161]]], ["Fifteen children had reported 20 episodes of mild respiratory illness with symptoms with remaining 83 children had experienced \u22651 episode of respiratory illnesses with symptoms score >3 and the maximum number of episodes per children was seven in two children.", [["respiratory", "ANATOMY", 50, 61], ["respiratory", "ANATOMY", 141, 152], ["respiratory illness", "DISEASE", 50, 69], ["respiratory illnesses", "DISEASE", 141, 162], ["children", "ORGANISM", 8, 16], ["children", "ORGANISM", 102, 110], ["children", "ORGANISM", 225, 233], ["children", "ORGANISM", 251, 259], ["children", "SPECIES", 8, 16], ["children", "SPECIES", 102, 110], ["children", "SPECIES", 225, 233], ["children", "SPECIES", 251, 259], ["mild respiratory illness", "PROBLEM", 45, 69], ["symptoms", "PROBLEM", 75, 83], ["respiratory illnesses", "PROBLEM", 141, 162], ["symptoms score", "PROBLEM", 168, 182], ["mild", "OBSERVATION_MODIFIER", 45, 49], ["respiratory", "ANATOMY", 50, 61], ["illness", "OBSERVATION", 62, 69], ["respiratory", "ANATOMY", 141, 152], ["illnesses", "OBSERVATION", 153, 162]]], ["There were a total of 211 episodes with a symptom score >3.", [["a symptom score", "PROBLEM", 40, 55]]], ["Nasal swab specimens were obtained in 166 and the interval between onset of respiratory symptoms and nasal swab collection ranged from 0.5 to 6 days.", [["Nasal swab specimens", "ANATOMY", 0, 20], ["respiratory", "ANATOMY", 76, 87], ["nasal swab", "ANATOMY", 101, 111], ["respiratory symptoms", "DISEASE", 76, 96], ["Nasal swab specimens", "ORGANISM_SUBSTANCE", 0, 20], ["nasal swab", "MULTI-TISSUE_STRUCTURE", 101, 111], ["Nasal swab specimens", "TEST", 0, 20], ["respiratory symptoms", "PROBLEM", 76, 96], ["nasal swab collection", "PROBLEM", 101, 122], ["respiratory", "ANATOMY", 76, 87], ["nasal", "ANATOMY", 101, 106]]], ["Nasal swab specimens were not available in the remaining 45 episodes as the children attended general practitioner (GP) instead.", [["Nasal swab specimens", "ANATOMY", 0, 20], ["Nasal swab specimens", "CANCER", 0, 20], ["children", "ORGANISM", 76, 84], ["children", "SPECIES", 76, 84], ["Nasal swab specimens", "TEST", 0, 20]]], ["There were 74 episodes of mild respiratory illnesses with symptom score \u22643 reported in these 83 children that were also managed by GP.", [["respiratory", "ANATOMY", 31, 42], ["respiratory illnesses", "DISEASE", 31, 52], ["children", "ORGANISM", 96, 104], ["children", "SPECIES", 96, 104], ["mild respiratory illnesses", "PROBLEM", 26, 52], ["symptom score", "PROBLEM", 58, 71], ["mild", "OBSERVATION_MODIFIER", 26, 30], ["respiratory illnesses", "OBSERVATION", 31, 52]]], ["The distribution of these episodes of respiratory illnesses among the children was illustrated in Fig. 1 .", [["respiratory", "ANATOMY", 38, 49], ["respiratory illnesses", "DISEASE", 38, 59], ["children", "ORGANISM", 70, 78], ["children", "SPECIES", 70, 78], ["respiratory illnesses", "PROBLEM", 38, 59], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["episodes", "OBSERVATION_MODIFIER", 26, 34], ["respiratory illnesses", "OBSERVATION", 38, 59]]], ["Thus, there were a total of 305 episodes of respiratory illnesses including asthma and non-asthma related episodes in our study cohort over the 14-month study period.", [["respiratory", "ANATOMY", 44, 55], ["respiratory illnesses", "DISEASE", 44, 65], ["asthma", "DISEASE", 76, 82], ["non-asthma", "DISEASE", 87, 97], ["respiratory illnesses", "PROBLEM", 44, 65], ["asthma", "PROBLEM", 76, 82], ["non-asthma related episodes", "PROBLEM", 87, 114], ["respiratory illnesses", "OBSERVATION", 44, 65], ["asthma", "OBSERVATION", 76, 82]]], ["The mean number of asthma exacerbations, other respiratory illnesses, and all episodes as diagnosed at unscheduled visits were 0.69, 1.6, and 2.29 per person-year, respectively.ResultThe presenting symptoms of 166 episodes of unscheduled visits with nasal swab specimens obtained are tabulated in Table 2 .", [["respiratory", "ANATOMY", 47, 58], ["nasal swab specimens", "ANATOMY", 250, 270], ["asthma", "DISEASE", 19, 25], ["respiratory illnesses", "DISEASE", 47, 68], ["nasal swab specimens", "CANCER", 250, 270], ["asthma exacerbations", "PROBLEM", 19, 39], ["other respiratory illnesses", "PROBLEM", 41, 68], ["all episodes", "PROBLEM", 74, 86], ["The presenting symptoms", "PROBLEM", 183, 206], ["nasal swab specimens", "TEST", 250, 270], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["number", "OBSERVATION_MODIFIER", 9, 15], ["asthma", "OBSERVATION_MODIFIER", 19, 25], ["exacerbations", "OBSERVATION", 26, 39], ["respiratory illnesses", "OBSERVATION", 47, 68], ["nasal", "ANATOMY", 250, 255]]], ["Ninety-two episodes were diagnosed as asthma exacerbations and 74 non-asthma related.", [["asthma", "DISEASE", 38, 44], ["non-asthma", "DISEASE", 66, 76], ["asthma exacerbations", "PROBLEM", 38, 58], ["asthma", "OBSERVATION", 38, 44]]], ["Among 92 episodes of asthma exacerbations, physician also made a diagnosis of concomitant respiratory tract infection in 69 (59 with upper respiratory tract infection, 5 with lower respiratory tract infection, and 5 with sinusitis) of these episodes based on history and physical findings.ResultRespiratory viruses were detected in 61 of these 166 episodes (36.7 %) ( Table 3 ).", [["respiratory tract", "ANATOMY", 90, 107], ["upper respiratory tract", "ANATOMY", 133, 156], ["lower respiratory tract", "ANATOMY", 175, 198], ["asthma exacerbations", "DISEASE", 21, 41], ["respiratory tract infection", "DISEASE", 90, 117], ["respiratory tract infection", "DISEASE", 139, 166], ["lower respiratory tract infection", "DISEASE", 175, 208], ["sinusitis", "DISEASE", 221, 230], ["respiratory tract", "ORGANISM_SUBDIVISION", 90, 107], ["upper", "ORGANISM_SUBDIVISION", 133, 138], ["respiratory tract", "ORGANISM_SUBDIVISION", 139, 156], ["tract", "ORGANISM_SUBDIVISION", 193, 198], ["asthma exacerbations", "PROBLEM", 21, 41], ["concomitant respiratory tract infection", "PROBLEM", 78, 117], ["upper respiratory tract infection", "PROBLEM", 133, 166], ["lower respiratory tract infection", "PROBLEM", 175, 208], ["sinusitis", "PROBLEM", 221, 230], ["these episodes", "PROBLEM", 235, 249], ["ResultRespiratory viruses", "TEST", 289, 314], ["asthma", "OBSERVATION", 21, 27], ["respiratory tract", "ANATOMY", 90, 107], ["infection", "OBSERVATION", 108, 117], ["upper", "ANATOMY_MODIFIER", 133, 138], ["respiratory tract", "ANATOMY", 139, 156], ["infection", "OBSERVATION", 157, 166], ["respiratory tract", "ANATOMY", 181, 198], ["infection", "OBSERVATION", 199, 208]]], ["There was no significant difference in virus detection rate between asthma (32 out of 97 episodes, 34.8 %) and non-asthma related episodes (29 out of 74 episodes, 39.2 %).", [["asthma", "DISEASE", 68, 74], ["non-asthma", "DISEASE", 111, 121], ["significant difference in virus detection rate", "PROBLEM", 13, 59], ["asthma", "PROBLEM", 68, 74], ["non-asthma related episodes", "PROBLEM", 111, 138], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35], ["virus", "OBSERVATION", 39, 44]]], ["Rhinovirus was detected in 41 episodes, influenza in 7, coronavirus in 6, parainfluenza virus in 2, RSV in 1, and mixed viruses in the remaining 4.", [["Rhinovirus", "CHEMICAL", 0, 10], ["influenza", "DISEASE", 40, 49], ["parainfluenza virus", "DISEASE", 74, 93], ["coronavirus", "ORGANISM", 56, 67], ["parainfluenza virus", "ORGANISM", 74, 93], ["RSV", "ORGANISM", 100, 103], ["parainfluenza virus", "SPECIES", 74, 93], ["Rhinovirus", "SPECIES", 0, 10], ["parainfluenza virus", "SPECIES", 74, 93], ["RSV", "SPECIES", 100, 103], ["Rhinovirus", "PROBLEM", 0, 10], ["influenza", "PROBLEM", 40, 49], ["coronavirus", "PROBLEM", 56, 67], ["parainfluenza virus", "PROBLEM", 74, 93], ["RSV", "PROBLEM", 100, 103], ["mixed viruses", "PROBLEM", 114, 127], ["mixed viruses", "OBSERVATION", 114, 127]]], ["The patterns of distribution of respiratory viruses were quite similar in asthma exacerbations and non-asthma related episodes.", [["respiratory viruses", "DISEASE", 32, 51], ["asthma", "DISEASE", 74, 80], ["non-asthma", "DISEASE", 99, 109], ["respiratory viruses", "PROBLEM", 32, 51], ["asthma exacerbations", "PROBLEM", 74, 94], ["non-asthma related episodes", "PROBLEM", 99, 126], ["distribution", "OBSERVATION_MODIFIER", 16, 28], ["respiratory viruses", "OBSERVATION", 32, 51], ["asthma", "OBSERVATION", 74, 80]]], ["(Table 4 )DiscussionA community study carried out in Southampton, UK over a decade ago found viral infections in >80% of asthma exacerbations in 9-11-year-old children [14] .", [["viral infections", "DISEASE", 93, 109], ["asthma", "DISEASE", 121, 127], ["children", "ORGANISM", 159, 167], ["children", "SPECIES", 159, 167], ["community study", "TEST", 22, 37], ["viral infections", "PROBLEM", 93, 109], ["asthma exacerbations", "PROBLEM", 121, 141], ["viral", "OBSERVATION_MODIFIER", 93, 98], ["infections", "OBSERVATION", 99, 109], ["asthma", "OBSERVATION", 121, 127]]], ["Our virus detection rate was only 36.7 % of all unscheduled sick visit in children aged 6 to 14 years old and the rate was not significantly different between asthma exacerbations (34.8 %) and that of other diagnoses (39.2 %).", [["asthma exacerbations", "DISEASE", 159, 179], ["children", "ORGANISM", 74, 82], ["children", "SPECIES", 74, 82], ["Our virus detection rate", "TEST", 0, 24], ["the rate", "TEST", 110, 118], ["asthma exacerbations", "PROBLEM", 159, 179], ["significantly different", "OBSERVATION_MODIFIER", 127, 150]]], ["This low detection rate was not due to inadequate power based on a priori sample size calculation.", [["This low detection rate", "TEST", 0, 23], ["inadequate power", "PROBLEM", 39, 55], ["a priori sample size calculation", "TEST", 65, 97], ["size", "OBSERVATION_MODIFIER", 81, 85]]], ["Neither was it due to virus detection method as we included PCR detection of more scores \u22643 that did not warrant unscheduled visits.", [["virus detection method", "TEST", 22, 44], ["PCR detection", "TEST", 60, 73]]], ["The recently discovered respiratory viruses including human metapneumonvirus, human coronavirus NL 63, OC43, 229E, HKU1, and bocavirus in addition to the virus detection method adopted in the Southampton study, i.e., using IF detection of viral antigens and culture for five respiratory viruses, viz. influenza viruses types A & B, RSV, parainfluenza virus, and adenovirus and PCR for detection of rhinovirus.", [["respiratory viruses", "DISEASE", 24, 43], ["respiratory viruses", "DISEASE", 275, 294], ["influenza viruses", "DISEASE", 301, 318], ["parainfluenza virus", "DISEASE", 337, 356], ["rhinovirus", "DISEASE", 398, 408], ["human", "ORGANISM", 54, 59], ["human coronavirus NL 63", "ORGANISM", 78, 101], ["OC43", "GENE_OR_GENE_PRODUCT", 103, 107], ["229E", "GENE_OR_GENE_PRODUCT", 109, 113], ["HKU1", "GENE_OR_GENE_PRODUCT", 115, 119], ["bocavirus", "GENE_OR_GENE_PRODUCT", 125, 134], ["influenza viruses", "ORGANISM", 301, 318], ["A & B", "ORGANISM", 325, 330], ["RSV", "ORGANISM", 332, 335], ["parainfluenza virus", "ORGANISM", 337, 356], ["adenovirus", "ORGANISM", 362, 372], ["rhinovirus", "ORGANISM", 398, 408], ["viral antigens", "PROTEIN", 239, 253], ["human", "SPECIES", 54, 59], ["human", "SPECIES", 78, 83], ["coronavirus", "SPECIES", 84, 95], ["influenza", "SPECIES", 301, 310], ["RSV", "SPECIES", 332, 335], ["parainfluenza virus", "SPECIES", 337, 356], ["human metapneumonvirus", "SPECIES", 54, 76], ["human coronavirus", "SPECIES", 78, 95], ["RSV", "SPECIES", 332, 335], ["parainfluenza virus", "SPECIES", 337, 356], ["adenovirus", "SPECIES", 362, 372], ["respiratory viruses", "PROBLEM", 24, 43], ["human metapneumonvirus", "TEST", 54, 76], ["human coronavirus NL", "TEST", 78, 98], ["OC43", "TEST", 103, 107], ["HKU1", "TEST", 115, 119], ["bocavirus", "PROBLEM", 125, 134], ["the virus detection", "TEST", 150, 169], ["the Southampton study", "TEST", 188, 209], ["viral antigens", "PROBLEM", 239, 253], ["culture", "TEST", 258, 265], ["five respiratory viruses", "PROBLEM", 270, 294], ["influenza viruses", "PROBLEM", 301, 318], ["RSV", "PROBLEM", 332, 335], ["parainfluenza virus", "PROBLEM", 337, 356], ["adenovirus", "TREATMENT", 362, 372], ["PCR", "TEST", 377, 380], ["rhinovirus", "PROBLEM", 398, 408], ["respiratory viruses", "OBSERVATION", 24, 43], ["rhinovirus", "OBSERVATION", 398, 408]]], ["Our previous study using PCR method in detecting rhinovirus was shown to be comparable to the global literature [5] .", [["rhinovirus", "ORGANISM", 49, 59], ["rhinovirus", "SPECIES", 49, 59], ["Our previous study", "TEST", 0, 18], ["PCR method", "TEST", 25, 35], ["rhinovirus", "PROBLEM", 49, 59]]], ["Our result was comparable to a clinic-based prospective study [19] and more closely matched to the Canadian case-control study conducted in September 2001 before the epidemics of severe acute respiratory syndrome (SARS) in which 62% of asthma children attending emergency department for exacerbations had respiratory viruses isolated [13] .DiscussionWe offered several explanations for our findings.", [["acute respiratory syndrome", "DISEASE", 186, 212], ["SARS", "DISEASE", 214, 218], ["asthma", "DISEASE", 236, 242], ["respiratory viruses", "DISEASE", 305, 324], ["children", "ORGANISM", 243, 251], ["children", "SPECIES", 243, 251], ["prospective study", "TEST", 44, 61], ["severe acute respiratory syndrome", "PROBLEM", 179, 212], ["SARS", "PROBLEM", 214, 218], ["exacerbations", "PROBLEM", 287, 300], ["respiratory viruses", "PROBLEM", 305, 324], ["severe", "OBSERVATION_MODIFIER", 179, 185], ["acute", "OBSERVATION_MODIFIER", 186, 191], ["respiratory syndrome", "OBSERVATION", 192, 212]]], ["Firstly, our study was carried out in the immediate post-SARS period when the population was still highly cautious about infection control and practising good personal hygiene [15] .", [["infection", "DISEASE", 121, 130], ["our study", "TEST", 9, 18], ["infection control", "TREATMENT", 121, 138]]], ["This could greatly reduce common viral infection.", [["viral infection", "DISEASE", 33, 48], ["common viral infection", "PROBLEM", 26, 48], ["common", "OBSERVATION_MODIFIER", 26, 32], ["viral", "OBSERVATION_MODIFIER", 33, 38], ["infection", "OBSERVATION", 39, 48]]], ["The low average number of unscheduled sick visits per person-year compared to previous epidemiology studies [18] inferred excellent general health status in our children population over the study period.", [["children", "ORGANISM", 161, 169], ["person", "SPECIES", 54, 60], ["children", "SPECIES", 161, 169], ["previous epidemiology studies", "TEST", 78, 107], ["low average", "OBSERVATION_MODIFIER", 4, 15]]], ["The beneficial effect of improved community hygienic measures was also supported by a local study which showed significantly lower respiratory virus circulation in the community in the immediate post-SARS period [17] .DiscussionSecondly, we used three criteria so as to capture as many as possible asthma exacerbations.", [["SARS", "DISEASE", 200, 204], ["asthma", "DISEASE", 298, 304], ["a local study", "TEST", 84, 97], ["significantly lower respiratory virus circulation", "PROBLEM", 111, 160], ["asthma exacerbations", "PROBLEM", 298, 318], ["improved", "OBSERVATION_MODIFIER", 25, 33], ["respiratory virus", "OBSERVATION", 131, 148]]], ["The use of a symptom score that included both upper and lower airway symptoms and that parents could attend the study clinic if they subjectively felt that the child develop a cold were less stringent than the first criteria of a fall of 80% of baseline PEFR.", [["lower airway", "ANATOMY", 56, 68], ["upper", "ORGANISM_SUBDIVISION", 46, 51], ["airway", "MULTI-TISSUE_STRUCTURE", 62, 68], ["a symptom score", "PROBLEM", 11, 26], ["both upper and lower airway symptoms", "PROBLEM", 41, 77], ["a cold", "PROBLEM", 174, 180], ["upper", "ANATOMY_MODIFIER", 46, 51], ["lower", "ANATOMY_MODIFIER", 56, 61], ["airway", "ANATOMY", 62, 68], ["symptoms", "OBSERVATION", 69, 77]]], ["Thus, 74 of 166 unscheduled visits were not asthma exacerbations.", [["asthma", "DISEASE", 44, 50], ["asthma exacerbations", "PROBLEM", 44, 64]]], ["We might have overdiagnosed respiratory tract infection as a trigger in [16] .DiscussionOne other possibility is that all of our participants had better control of asthma symptoms that was reflected in the lower overall number of episodes of unscheduled sick visits per person time year compared to the Southampton cohort.", [["respiratory tract", "ANATOMY", 28, 45], ["respiratory tract infection", "DISEASE", 28, 55], ["asthma", "DISEASE", 164, 170], ["respiratory tract", "ORGANISM_SUBDIVISION", 28, 45], ["participants", "SPECIES", 129, 141], ["overdiagnosed respiratory tract infection", "PROBLEM", 14, 55], ["asthma symptoms", "PROBLEM", 164, 179], ["respiratory tract", "ANATOMY", 28, 45], ["infection", "OBSERVATION", 46, 55]]], ["We speculated that the use of regular inhaled steroids might also have some effect.", [["steroids", "CHEMICAL", 46, 54], ["steroids", "CHEMICAL", 46, 54], ["regular inhaled steroids", "TREATMENT", 30, 54]]], ["While most clinical or experimental studies failed to document the efficacy of inhaled steroids in preventing intermittent virus-induced asthma exacerbations [9, 10] , the aforementioned Canadian case-control study [5] showed that children attending emergency department for asthma exacerbations were more likely to have respiratory viruses isolated but less likely to have prescription of anti-inflammatory medications.DiscussionAs in previous studies, rhinovirus was also the most frequent organism detected, accounting for followed by influenza among those asthma exacerbations with virus isolated in our cohort.DiscussionWe must address our limitations.", [["steroids", "CHEMICAL", 87, 95], ["asthma", "DISEASE", 137, 143], ["asthma exacerbations", "DISEASE", 275, 295], ["respiratory viruses", "DISEASE", 321, 340], ["influenza", "DISEASE", 538, 547], ["asthma", "DISEASE", 560, 566], ["steroids", "CHEMICAL", 87, 95], ["children", "ORGANISM", 231, 239], ["rhinovirus", "ORGANISM", 454, 464], ["children", "SPECIES", 231, 239], ["experimental studies", "TEST", 23, 43], ["inhaled steroids", "TREATMENT", 79, 95], ["intermittent virus", "PROBLEM", 110, 128], ["asthma exacerbations", "PROBLEM", 137, 157], ["asthma exacerbations", "PROBLEM", 275, 295], ["respiratory viruses", "PROBLEM", 321, 340], ["anti-inflammatory medications", "TREATMENT", 390, 419], ["previous studies", "TEST", 436, 452], ["rhinovirus", "PROBLEM", 454, 464], ["influenza", "PROBLEM", 538, 547], ["those asthma exacerbations", "PROBLEM", 554, 580], ["virus", "PROBLEM", 586, 591], ["asthma", "OBSERVATION", 137, 143], ["viruses", "OBSERVATION", 333, 340], ["anti-inflammatory medications", "OBSERVATION", 390, 419]]], ["Firstly, nasal swab were not collected in 45 out of 211 of episodes that met the criteria for unscheduled visits.", [["nasal swab", "ANATOMY", 9, 19], ["nasal swab", "ORGANISM_SUBSTANCE", 9, 19], ["nasal swab", "TEST", 9, 19], ["episodes", "PROBLEM", 59, 67], ["nasal", "ANATOMY", 9, 14]]], ["For the extreme case scenario whereby all these 45 episodes were asthma exacerbations with viruses isolated, the virus detection rate would have been 56.2 % but this is still much lower than Southampton study.", [["asthma", "DISEASE", 65, 71], ["asthma exacerbations", "PROBLEM", 65, 85], ["viruses", "PROBLEM", 91, 98], ["the virus detection rate", "TEST", 109, 133], ["Southampton study", "TEST", 191, 208]]], ["For the remaining 94 episodes of mild respiratory illnesses that did not meet the criteria for unscheduled visit, it was difficult to ascertain whether the subjects actually had very mild asthma exacerbations, leading to a possible underestimation.", [["respiratory", "ANATOMY", 38, 49], ["respiratory illnesses", "DISEASE", 38, 59], ["asthma", "DISEASE", 188, 194], ["mild respiratory illnesses", "PROBLEM", 33, 59], ["very mild asthma exacerbations", "PROBLEM", 178, 208], ["mild", "OBSERVATION_MODIFIER", 33, 37], ["respiratory illnesses", "OBSERVATION", 38, 59], ["mild", "OBSERVATION_MODIFIER", 183, 187], ["asthma", "OBSERVATION", 188, 194]]], ["The second limitation was that nasal swab instead of nasopharyngeal aspirate was used for infection control reasons as the study was carried out in the immediate post-SARS period.", [["nasal swab", "ANATOMY", 31, 41], ["nasopharyngeal aspirate", "ANATOMY", 53, 76], ["infection", "DISEASE", 90, 99], ["SARS", "DISEASE", 167, 171], ["nasal swab", "ORGANISM_SUBSTANCE", 31, 41], ["nasopharyngeal aspirate", "MULTI-TISSUE_STRUCTURE", 53, 76], ["nasal swab", "TEST", 31, 41], ["nasopharyngeal aspirate", "TREATMENT", 53, 76], ["infection control", "TREATMENT", 90, 107], ["the study", "TEST", 119, 128], ["nasopharyngeal", "ANATOMY", 53, 67], ["aspirate", "OBSERVATION", 68, 76]]], ["A recent study also showed that the sensitivity of nasal swabs was comparable to that of nasopharyngeal aspirates for the detection of all major respiratory viruses except RSV [11] .", [["nasal swabs", "ANATOMY", 51, 62], ["nasopharyngeal aspirates", "ANATOMY", 89, 113], ["nasal swabs", "ORGAN", 51, 62], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 89, 113], ["RSV", "ORGANISM", 172, 175], ["RSV", "SPECIES", 172, 175], ["A recent study", "TEST", 0, 14], ["nasal swabs", "TEST", 51, 62], ["nasopharyngeal aspirates", "TEST", 89, 113], ["the detection", "TEST", 118, 131], ["all major respiratory viruses", "PROBLEM", 135, 164], ["RSV", "PROBLEM", 172, 175], ["nasopharyngeal", "ANATOMY", 89, 103], ["aspirates", "OBSERVATION", 104, 113], ["respiratory viruses", "OBSERVATION", 145, 164]]], ["Yet, RSV virus is not a common trigger of asthma exacerbations in school-aged children.", [["asthma", "DISEASE", 42, 48], ["RSV virus", "ORGANISM", 5, 14], ["children", "ORGANISM", 78, 86], ["children", "SPECIES", 78, 86], ["RSV virus", "SPECIES", 5, 14], ["RSV virus", "PROBLEM", 5, 14], ["asthma exacerbations", "PROBLEM", 42, 62], ["RSV virus", "OBSERVATION", 5, 14], ["asthma", "OBSERVATION", 42, 48]]], ["The use of a flocked nasopharyngeal swab, which was not available at time of the study, can certainly lead to a better yield should similar study to be conducted in the future [4] .DiscussionWe found that viral infections accounted for about 35% of asthma exacerbations and 39% of non-asthma associated respiratory illnesses in children with stable asthma control during the immediate post-SARS period.", [["nasopharyngeal swab", "ANATOMY", 21, 40], ["respiratory", "ANATOMY", 303, 314], ["viral infections", "DISEASE", 205, 221], ["asthma", "DISEASE", 249, 255], ["non-asthma", "DISEASE", 281, 291], ["respiratory illnesses", "DISEASE", 303, 324], ["asthma", "DISEASE", 349, 355], ["SARS", "DISEASE", 390, 394], ["nasopharyngeal swab", "MULTI-TISSUE_STRUCTURE", 21, 40], ["children", "ORGANISM", 328, 336], ["children", "SPECIES", 328, 336], ["a flocked nasopharyngeal swab", "TEST", 11, 40], ["the study", "TEST", 77, 86], ["similar study", "TEST", 132, 145], ["viral infections", "PROBLEM", 205, 221], ["asthma exacerbations", "PROBLEM", 249, 269], ["non-asthma associated respiratory illnesses", "PROBLEM", 281, 324], ["stable asthma control", "PROBLEM", 342, 363], ["viral", "OBSERVATION_MODIFIER", 205, 210], ["infections", "OBSERVATION", 211, 221], ["respiratory illnesses", "OBSERVATION", 303, 324], ["stable", "OBSERVATION_MODIFIER", 342, 348], ["asthma", "OBSERVATION", 349, 355]]], ["We did not negate the well-established causal relationship between respiratory viral infections and asthma exacerbations.", [["respiratory viral infections", "DISEASE", 67, 95], ["asthma", "DISEASE", 100, 106], ["respiratory viral infections", "PROBLEM", 67, 95], ["asthma exacerbations", "PROBLEM", 100, 120], ["respiratory", "ANATOMY", 67, 78], ["viral infections", "OBSERVATION", 79, 95]]], ["Rather, our study sug- gested that the improved personal hygiene and precautionary measures taken during respiratory tract infections may help to reduce the potential adverse effect at high risk groups, like children with asthma.", [["respiratory tract", "ANATOMY", 105, 122], ["respiratory tract infections", "DISEASE", 105, 133], ["asthma", "DISEASE", 222, 228], ["tract", "ORGANISM_SUBDIVISION", 117, 122], ["children", "ORGANISM", 208, 216], ["children", "SPECIES", 208, 216], ["our study sug", "TEST", 8, 21], ["precautionary measures", "TREATMENT", 69, 91], ["respiratory tract infections", "PROBLEM", 105, 133], ["asthma", "PROBLEM", 222, 228], ["asthma", "OBSERVATION", 222, 228]]], ["In addition, factors like environmental air pollution may also contribute significantly to morbidity of children with asthma in locality where the problem is particularly adverse.", [["asthma", "DISEASE", 118, 124], ["children", "ORGANISM", 104, 112], ["children", "SPECIES", 104, 112], ["environmental air pollution", "PROBLEM", 26, 53], ["asthma", "PROBLEM", 118, 124], ["air pollution", "OBSERVATION", 40, 53]]], ["We conclude that not all viral infections in children with asthma lead to an asthma exacerbation and the attributing effect of different triggers of asthma exacerbations in children varies across different time periods and across different localities.", [["viral infections", "DISEASE", 25, 41], ["asthma", "DISEASE", 59, 65], ["asthma", "DISEASE", 77, 83], ["asthma", "DISEASE", 149, 155], ["children", "ORGANISM", 45, 53], ["children", "ORGANISM", 173, 181], ["children", "SPECIES", 45, 53], ["children", "SPECIES", 173, 181], ["all viral infections", "PROBLEM", 21, 41], ["asthma", "PROBLEM", 59, 65], ["an asthma exacerbation", "PROBLEM", 74, 96], ["asthma exacerbations", "PROBLEM", 149, 169], ["viral", "OBSERVATION_MODIFIER", 25, 30], ["infections", "OBSERVATION", 31, 41], ["asthma", "OBSERVATION", 77, 83], ["asthma", "OBSERVATION", 149, 155]]]], "cb25f73e8099afbab01fdef1b579d2a241ccef6f": [["Interestingly, a consistent number of COVID-19-associated skin manifestations seem to share a certain degree of vascular damage as common pathogenetic mechanism 1 .", [["skin", "ANATOMY", 58, 62], ["vascular", "ANATOMY", 112, 120], ["vascular damage", "DISEASE", 112, 127], ["COVID-19", "GENE_OR_GENE_PRODUCT", 38, 46], ["skin", "ORGAN", 58, 62], ["vascular", "MULTI-TISSUE_STRUCTURE", 112, 120], ["COVID", "TEST", 38, 43], ["skin manifestations", "PROBLEM", 58, 77], ["vascular damage", "PROBLEM", 112, 127], ["number", "OBSERVATION_MODIFIER", 28, 34], ["skin", "ANATOMY", 58, 62], ["manifestations", "OBSERVATION", 63, 77], ["vascular", "ANATOMY", 112, 120], ["damage", "OBSERVATION", 121, 127]]], ["Vascular injury may be due to the direct damage of endothelial cells by the virus or may represents an epiphenomenon of a dysregulated host inflammatory responses triggered by the infection 2 .", [["Vascular", "ANATOMY", 0, 8], ["endothelial cells", "ANATOMY", 51, 68], ["Vascular injury", "DISEASE", 0, 15], ["infection", "DISEASE", 180, 189], ["Vascular", "MULTI-TISSUE_STRUCTURE", 0, 8], ["endothelial cells", "CELL", 51, 68], ["endothelial cells", "CELL_TYPE", 51, 68], ["Vascular injury", "PROBLEM", 0, 15], ["the direct damage of endothelial cells", "PROBLEM", 30, 68], ["the virus", "PROBLEM", 72, 81], ["a dysregulated host inflammatory responses", "PROBLEM", 120, 162], ["the infection", "PROBLEM", 176, 189], ["injury", "OBSERVATION", 9, 15], ["may be due to", "UNCERTAINTY", 16, 29], ["endothelial cells", "OBSERVATION", 51, 68], ["may represents", "UNCERTAINTY", 85, 99], ["dysregulated", "OBSERVATION_MODIFIER", 122, 134], ["host", "OBSERVATION_MODIFIER", 135, 139], ["inflammatory", "OBSERVATION_MODIFIER", 140, 152], ["infection", "OBSERVATION", 180, 189]]], ["Here, we describe an unprecedented case of leukocytoclastic vasculitis presenting with a hemorrhagic bullous eruption in a patient affected by COVID-19.", [["leukocytoclastic vasculitis", "DISEASE", 43, 70], ["hemorrhagic bullous eruption", "DISEASE", 89, 117], ["patient", "ORGANISM", 123, 130], ["patient", "SPECIES", 123, 130], ["leukocytoclastic vasculitis", "PROBLEM", 43, 70], ["a hemorrhagic bullous eruption", "PROBLEM", 87, 117], ["COVID", "TEST", 143, 148], ["leukocytoclastic", "OBSERVATION_MODIFIER", 43, 59], ["vasculitis", "OBSERVATION", 60, 70], ["hemorrhagic", "OBSERVATION_MODIFIER", 89, 100], ["bullous", "OBSERVATION_MODIFIER", 101, 108], ["eruption", "OBSERVATION", 109, 117]]]], "PMC7252060": [["In response to the ongoing coronavirus disease 2019 (COVID-19) pandemic, several countries including the USA, the UK, and Sweden initially relied on recommendations for \u2018responsible behaviour\u2019 of their citizens in reducing the spread of infection.", [["coronavirus disease", "DISEASE", 27, 46], ["infection", "DISEASE", 237, 246], ["the ongoing coronavirus disease", "PROBLEM", 15, 46], ["COVID", "TEST", 53, 58], ["pandemic", "PROBLEM", 63, 71], ["infection", "PROBLEM", 237, 246], ["coronavirus disease", "OBSERVATION", 27, 46], ["infection", "OBSERVATION", 237, 246]]], ["For these social distancing recommendations to make an impact on the COVID-19 spread rate, they had to be adhered to by the absolute majority\u2014as much as 90%\u2014of the population.1", [["the COVID", "TREATMENT", 65, 74]]]], "a6946039ab0f28efa8184f33fcbb4941222e3c94": [["INTRODUCTIONThree genetic and serologic groups of coronaviruses have been described.", [["coronaviruses", "ORGANISM", 50, 63], ["coronaviruses", "PROBLEM", 50, 63]]], ["Group 1 human coronavirus HCoV-229E utilizes aminopeptidase N (APN; CD13) as its cellular receptor, 1, 2 whereas SARS-CoV, a group 2 virus, uses angiotensin-converting enzyme 2 (ACE2).", [["cellular", "ANATOMY", 81, 89], ["HCoV-229E", "CHEMICAL", 26, 35], ["angiotensin", "CHEMICAL", 145, 156], ["human", "ORGANISM", 8, 13], ["aminopeptidase N", "GENE_OR_GENE_PRODUCT", 45, 61], ["APN", "GENE_OR_GENE_PRODUCT", 63, 66], ["CD13", "GENE_OR_GENE_PRODUCT", 68, 72], ["cellular", "CELL", 81, 89], ["SARS-CoV", "ORGANISM", 113, 121], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 145, 176], ["ACE2", "GENE_OR_GENE_PRODUCT", 178, 182], ["aminopeptidase N", "PROTEIN", 45, 61], ["APN", "PROTEIN", 63, 66], ["CD13", "PROTEIN", 68, 72], ["cellular receptor", "PROTEIN", 81, 98], ["angiotensin-converting enzyme 2", "PROTEIN", 145, 176], ["ACE2", "PROTEIN", 178, 182], ["human", "SPECIES", 8, 13], ["coronavirus HCoV", "SPECIES", 14, 30], ["human coronavirus HCoV-229E", "SPECIES", 8, 35], ["SARS-CoV", "SPECIES", 113, 121], ["Group 1 human coronavirus HCoV", "TEST", 0, 30], ["aminopeptidase N (APN", "TREATMENT", 45, 66], ["CD13", "TEST", 68, 72], ["its cellular receptor", "TEST", 77, 98], ["a group 2 virus", "TREATMENT", 123, 138], ["angiotensin", "TREATMENT", 145, 156]]], ["3, 4 A recently identified novel group 1 coronavirus, HCoV-NL63, utilizes the SARS-CoV receptor ACE2, 5 despite its close similarity to other group 1 coronaviruses.INTRODUCTIONSome coronavirus S proteins are cleaved into 2 domains by a furin-like protease in virus-producing cells.", [["cells", "ANATOMY", 275, 280], ["coronavirus", "ORGANISM", 41, 52], ["HCoV-NL63", "ORGANISM", 54, 63], ["ACE2", "GENE_OR_GENE_PRODUCT", 96, 100], ["5", "ORGANISM", 102, 103], ["furin", "GENE_OR_GENE_PRODUCT", 236, 241], ["cells", "CELL", 275, 280], ["HCoV", "PROTEIN", 54, 58], ["NL63", "PROTEIN", 59, 63], ["SARS-CoV receptor", "PROTEIN", 78, 95], ["ACE2", "PROTEIN", 96, 100], ["INTRODUCTIONSome coronavirus S proteins", "PROTEIN", 164, 203], ["furin-like protease", "PROTEIN", 236, 255], ["virus-producing cells", "CELL_TYPE", 259, 280], ["SARS-CoV", "SPECIES", 78, 86], ["INTRODUCTIONSome coronavirus", "SPECIES", 164, 192], ["HCoV", "TEST", 54, 58], ["the SARS-CoV receptor ACE2", "TREATMENT", 74, 100], ["INTRODUCTIONSome coronavirus S proteins", "PROBLEM", 164, 203], ["a furin-like protease", "TREATMENT", 234, 255]]], ["The resulting S1 domain mediates receptor binding, 6, 7 and the Cterminal S2 domain mediates fusion between viral and cellular membranes.", [["cellular membranes", "ANATOMY", 118, 136], ["Cterminal S2", "GENE_OR_GENE_PRODUCT", 64, 76], ["cellular membranes", "CELLULAR_COMPONENT", 118, 136], ["S1 domain", "PROTEIN", 14, 23], ["Cterminal S2 domain", "PROTEIN", 64, 83], ["The resulting S1 domain mediates receptor binding", "PROBLEM", 0, 49], ["the Cterminal S2 domain mediates fusion", "TREATMENT", 60, 99], ["viral and cellular membranes", "PROBLEM", 108, 136], ["S1", "ANATOMY_MODIFIER", 14, 16], ["receptor binding", "OBSERVATION", 33, 49], ["Cterminal S2", "ANATOMY", 64, 76], ["fusion", "OBSERVATION", 93, 99], ["viral", "OBSERVATION", 108, 113], ["cellular membranes", "OBSERVATION", 118, 136]]], ["This producer-cell processing of fusion protein is essential for the infection of HIV-1 and influenza virus.", [["cell", "ANATOMY", 14, 18], ["infection", "DISEASE", 69, 78], ["cell", "CELL", 14, 18], ["HIV-1", "ORGANISM", 82, 87], ["influenza virus", "ORGANISM", 92, 107], ["fusion protein", "PROTEIN", 33, 47], ["HIV-1", "SPECIES", 82, 87], ["influenza virus", "SPECIES", 92, 107], ["HIV-1", "SPECIES", 82, 87], ["fusion protein", "PROBLEM", 33, 47], ["the infection of HIV", "PROBLEM", 65, 85], ["influenza virus", "PROBLEM", 92, 107], ["fusion protein", "OBSERVATION", 33, 47], ["infection", "OBSERVATION", 69, 78]]], ["8 Although the S1 and S2 domains can be identified by their similarity with other S proteins, SARS-CoV and HCoV-NL63 S proteins are not processed in the producer cells.INTRODUCTIONCathepsins are a diverse group of endosomal and lysosomal proteases.", [["cells", "ANATOMY", 162, 167], ["endosomal", "ANATOMY", 214, 223], ["lysosomal", "ANATOMY", 228, 237], ["S1", "GENE_OR_GENE_PRODUCT", 15, 17], ["S2", "GENE_OR_GENE_PRODUCT", 22, 24], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 94, 102], ["HCoV-NL63 S", "GENE_OR_GENE_PRODUCT", 107, 118], ["cells", "CELL", 162, 167], ["endosomal", "CELLULAR_COMPONENT", 214, 223], ["lysosomal", "CELLULAR_COMPONENT", 228, 237], ["S1 and S2 domains", "PROTEIN", 15, 32], ["S proteins", "PROTEIN", 82, 92], ["SARS-CoV and HCoV-NL63 S proteins", "PROTEIN", 94, 127], ["producer cells", "CELL_TYPE", 153, 167], ["endosomal and lysosomal proteases", "PROTEIN", 214, 247], ["SARS-CoV", "SPECIES", 94, 102], ["the S1 and S2 domains", "PROBLEM", 11, 32], ["other S proteins", "TEST", 76, 92], ["SARS", "TEST", 94, 98], ["CoV", "TEST", 99, 102], ["HCoV", "TEST", 107, 111], ["NL63 S proteins", "TEST", 112, 127], ["INTRODUCTIONCathepsins", "TREATMENT", 168, 190], ["endosomal and lysosomal proteases", "TREATMENT", 214, 247], ["S1", "ANATOMY", 15, 17], ["S2", "ANATOMY", 22, 24], ["producer cells", "OBSERVATION", 153, 167], ["lysosomal proteases", "OBSERVATION", 228, 247]]], ["The role of cathepsins in reovirus infection is well established.", [["reovirus infection", "DISEASE", 26, 44], ["cathepsins", "GENE_OR_GENE_PRODUCT", 12, 22], ["reovirus", "ORGANISM", 26, 34], ["cathepsins", "PROTEIN", 12, 22], ["cathepsins", "TREATMENT", 12, 22], ["reovirus infection", "PROBLEM", 26, 44], ["cathepsins", "OBSERVATION", 12, 22], ["reovirus", "OBSERVATION_MODIFIER", 26, 34], ["infection", "OBSERVATION", 35, 44]]], ["9-12 After receptor-mediated endocytosis, degradation of outer capsid protein \u03c33 by cathepsins is essential for reovirus infection.", [["9-12", "CHEMICAL", 0, 4], ["reovirus infection", "DISEASE", 112, 130], ["\u03c33", "GENE_OR_GENE_PRODUCT", 78, 80], ["cathepsins", "GENE_OR_GENE_PRODUCT", 84, 94], ["reovirus", "ORGANISM", 112, 120], ["outer capsid protein \u03c33", "PROTEIN", 57, 80], ["cathepsins", "PROTEIN", 84, 94], ["receptor-mediated endocytosis", "TREATMENT", 11, 40], ["outer capsid protein \u03c33", "TREATMENT", 57, 80], ["cathepsins", "PROBLEM", 84, 94], ["reovirus infection", "PROBLEM", 112, 130], ["endocytosis", "OBSERVATION", 29, 40], ["outer", "ANATOMY_MODIFIER", 57, 62], ["capsid protein", "OBSERVATION", 63, 77], ["essential for", "UNCERTAINTY", 98, 111], ["reovirus", "OBSERVATION_MODIFIER", 112, 120], ["infection", "OBSERVATION", 121, 130]]], ["Recently, it has been demonstrated that infection mediated by the GP protein of the Zaire Ebola virus depends on cathepsin B. 13 Here we show that cathepsins play an important role in SARS-CoV infection.", [["infection", "DISEASE", 40, 49], ["Ebola", "DISEASE", 90, 95], ["SARS-CoV infection", "DISEASE", 184, 202], ["GP", "GENE_OR_GENE_PRODUCT", 66, 68], ["Zaire Ebola virus", "ORGANISM", 84, 101], ["cathepsins", "GENE_OR_GENE_PRODUCT", 147, 157], ["SARS-CoV", "ORGANISM", 184, 192], ["GP protein", "PROTEIN", 66, 76], ["cathepsin B. 13", "PROTEIN", 113, 128], ["cathepsins", "PROTEIN", 147, 157], ["Zaire Ebola virus", "SPECIES", 84, 101], ["Zaire Ebola virus", "SPECIES", 84, 101], ["SARS-CoV", "SPECIES", 184, 192], ["infection", "PROBLEM", 40, 49], ["the Zaire Ebola virus", "PROBLEM", 80, 101], ["cathepsin B.", "TREATMENT", 113, 125], ["cathepsins", "TREATMENT", 147, 157], ["SARS", "PROBLEM", 184, 188], ["CoV infection", "PROBLEM", 189, 202], ["infection", "OBSERVATION", 40, 49], ["CoV", "OBSERVATION_MODIFIER", 189, 192], ["infection", "OBSERVATION", 193, 202]]], ["In contrast, HCoV-NL63 infection is not dependent on cathepsin activities.", [["infection", "DISEASE", 23, 32], ["HCoV", "GENE_OR_GENE_PRODUCT", 13, 17], ["cathepsin", "GENE_OR_GENE_PRODUCT", 53, 62], ["cathepsin", "PROTEIN", 53, 62], ["HCoV", "SPECIES", 13, 17], ["HCoV", "TEST", 13, 17], ["NL63 infection", "PROBLEM", 18, 32], ["cathepsin activities", "TREATMENT", 53, 73], ["infection", "OBSERVATION", 23, 32], ["not", "UNCERTAINTY", 36, 39], ["dependent", "OBSERVATION_MODIFIER", 40, 49]]], ["Thus variations in cellular proteases can serve as an additional determinant of viral tropism.RESULTSInhibitors for several classes of proteases were assayed for their ability to modulate SARS-CoV infection.", [["cellular", "ANATOMY", 19, 27], ["SARS-CoV infection", "DISEASE", 188, 206], ["cellular", "CELL", 19, 27], ["SARS-CoV", "ORGANISM", 188, 196], ["cellular proteases", "PROTEIN", 19, 37], ["proteases", "PROTEIN", 135, 144], ["SARS-CoV", "SPECIES", 188, 196], ["variations in cellular proteases", "PROBLEM", 5, 37], ["viral tropism", "PROBLEM", 80, 93], ["RESULTSInhibitors", "TEST", 94, 111], ["proteases", "TREATMENT", 135, 144], ["CoV infection", "PROBLEM", 193, 206], ["cellular proteases", "OBSERVATION", 19, 37], ["viral tropism", "OBSERVATION", 80, 93], ["CoV", "OBSERVATION_MODIFIER", 193, 196], ["infection", "OBSERVATION", 197, 206]]], ["HIV-1 is included as a control.", [["HIV-1", "ORGANISM", 0, 5], ["HIV-1", "SPECIES", 0, 5], ["HIV-1", "SPECIES", 0, 5], ["HIV", "PROBLEM", 0, 3]]], ["Murine leukemia viruses carrying the gene for green fluorescent protein (GFP) were pseudotyped with the SARS-CoV S protein or HIV-1 gp160 (SARS/MLV and HIV-1/MLV, respectively).", [["leukemia", "ANATOMY", 7, 15], ["Murine leukemia viruses", "DISEASE", 0, 23], ["Murine leukemia viruses", "ORGANISM", 0, 23], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 46, 71], ["GFP", "GENE_OR_GENE_PRODUCT", 73, 76], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 104, 114], ["HIV-1 gp160", "ORGANISM", 126, 137], ["SARS/MLV", "ORGANISM", 139, 147], ["HIV-1", "ORGANISM", 152, 157], ["MLV", "ORGANISM", 158, 161], ["green fluorescent protein", "PROTEIN", 46, 71], ["GFP", "PROTEIN", 73, 76], ["SARS-CoV S protein", "PROTEIN", 104, 122], ["Murine", "SPECIES", 0, 6], ["HIV-1", "SPECIES", 126, 131], ["HIV", "SPECIES", 152, 155], ["Murine leukemia viruses", "SPECIES", 0, 23], ["SARS-CoV", "SPECIES", 104, 112], ["HIV-1", "SPECIES", 126, 131], ["HIV-1/MLV", "SPECIES", 152, 161], ["Murine leukemia viruses", "PROBLEM", 0, 23], ["green fluorescent protein (GFP", "TEST", 46, 76], ["pseudotyped", "PROBLEM", 83, 94], ["the SARS", "TEST", 100, 108], ["CoV S protein", "TEST", 109, 122], ["HIV", "TEST", 126, 129], ["SARS", "TEST", 139, 143], ["MLV", "TEST", 144, 147], ["HIV", "TEST", 152, 155], ["leukemia viruses", "OBSERVATION", 7, 23]]], ["293T cells expressing ACE2 or CD4/CXCR4 were incubated with these pseudotyped viruses in the presence of the aspartic protease inhibitor pepstatin A, serine protease inhibitor AEBSF, cysteine protease inhibitor E64d, and metalloprotease inhibitor phosphoramidon.", [["293T cells", "ANATOMY", 0, 10], ["pepstatin A", "CHEMICAL", 137, 148], ["AEBSF", "CHEMICAL", 176, 181], ["phosphoramidon", "CHEMICAL", 247, 261], ["pepstatin A", "CHEMICAL", 137, 148], ["serine", "CHEMICAL", 150, 156], ["AEBSF", "CHEMICAL", 176, 181], ["cysteine", "CHEMICAL", 183, 191], ["phosphoramidon", "CHEMICAL", 247, 261], ["293T cells", "CELL", 0, 10], ["ACE2", "GENE_OR_GENE_PRODUCT", 22, 26], ["CD4", "GENE_OR_GENE_PRODUCT", 30, 33], ["CXCR4", "GENE_OR_GENE_PRODUCT", 34, 39], ["pepstatin A", "SIMPLE_CHEMICAL", 137, 148], ["serine", "AMINO_ACID", 150, 156], ["AEBSF", "SIMPLE_CHEMICAL", 176, 181], ["cysteine", "AMINO_ACID", 183, 191], ["E64d", "SIMPLE_CHEMICAL", 211, 215], ["phosphoramidon", "SIMPLE_CHEMICAL", 247, 261], ["293T cells", "CELL_LINE", 0, 10], ["ACE2", "PROTEIN", 22, 26], ["CD4", "PROTEIN", 30, 33], ["CXCR4", "PROTEIN", 34, 39], ["aspartic protease", "PROTEIN", 109, 126], ["ACE2", "TEST", 22, 26], ["CD4/CXCR4", "TREATMENT", 30, 39], ["these pseudotyped viruses", "PROBLEM", 60, 85], ["the aspartic protease inhibitor pepstatin", "TREATMENT", 105, 146], ["serine protease inhibitor AEBSF", "TREATMENT", 150, 181], ["cysteine protease inhibitor E64d", "TREATMENT", 183, 215], ["metalloprotease inhibitor phosphoramidon", "TREATMENT", 221, 261], ["pseudotyped viruses", "OBSERVATION", 66, 85]]], ["As shown in Fig. 1A , only E64d, a general inhibitor of cysteine proteases, blocked SARS/MLV infection.", [["E64d", "CHEMICAL", 27, 31], ["SARS/MLV infection", "DISEASE", 84, 102], ["cysteine", "CHEMICAL", 56, 64], ["E64d", "SIMPLE_CHEMICAL", 27, 31], ["cysteine", "AMINO_ACID", 56, 64], ["MLV", "ORGANISM", 89, 92], ["cysteine proteases", "PROTEIN", 56, 74], ["a general inhibitor of cysteine proteases", "TREATMENT", 33, 74], ["blocked SARS", "PROBLEM", 76, 88], ["MLV infection", "PROBLEM", 89, 102], ["MLV", "ANATOMY", 89, 92], ["infection", "OBSERVATION", 93, 102]]], ["Because SARS-CoV infection is sensitive to NH 4 Cl, an inhibitor of lysosomal acidification, 14 and roles for the lysosomal cysteine protease cathepsins in reovirus infection have been described, [9] [10] [11] [12] The ability of cathepsin inhibitors to block infection was then examined using replication-competent SARS-CoV or HCoV-NL63, which also utilizes ACE2 as its receptor.", [["lysosomal", "ANATOMY", 68, 77], ["lysosomal", "ANATOMY", 114, 123], ["SARS-CoV infection", "DISEASE", 8, 26], ["NH 4 Cl", "CHEMICAL", 43, 50], ["reovirus infection", "DISEASE", 156, 174], ["infection", "DISEASE", 260, 269], ["NH 4 Cl", "CHEMICAL", 43, 50], ["cysteine", "CHEMICAL", 124, 132], ["SARS-CoV", "ORGANISM", 8, 16], ["NH 4 Cl", "SIMPLE_CHEMICAL", 43, 50], ["lysosomal", "CELLULAR_COMPONENT", 68, 77], ["cathepsins", "GENE_OR_GENE_PRODUCT", 142, 152], ["reovirus", "ORGANISM", 156, 164], ["[9] [10] [11] [12]", "SIMPLE_CHEMICAL", 196, 214], ["cathepsin", "GENE_OR_GENE_PRODUCT", 230, 239], ["SARS-CoV", "ORGANISM", 316, 324], ["HCoV-NL63", "CELL", 328, 337], ["ACE2", "GENE_OR_GENE_PRODUCT", 359, 363], ["lysosomal cysteine protease cathepsins", "PROTEIN", 114, 152], ["NL63", "PROTEIN", 333, 337], ["ACE2", "PROTEIN", 359, 363], ["SARS-CoV", "SPECIES", 8, 16], ["SARS-CoV", "SPECIES", 316, 324], ["SARS", "PROBLEM", 8, 12], ["CoV infection", "PROBLEM", 13, 26], ["lysosomal acidification", "PROBLEM", 68, 91], ["the lysosomal cysteine protease cathepsins", "TREATMENT", 110, 152], ["reovirus infection", "PROBLEM", 156, 174], ["cathepsin inhibitors", "TREATMENT", 230, 250], ["block infection", "PROBLEM", 254, 269], ["replication", "TEST", 294, 305], ["HCoV", "TEST", 328, 332], ["infection", "OBSERVATION", 17, 26], ["infection", "OBSERVATION", 260, 269]]], ["Sindbis virus and vesicular stomatitis virus (VSV) were included as controls.", [["vesicular stomatitis", "DISEASE", 18, 38], ["Sindbis virus", "ORGANISM", 0, 13], ["vesicular stomatitis virus", "ORGANISM", 18, 44], ["VSV", "ORGANISM", 46, 49], ["Sindbis virus", "SPECIES", 0, 13], ["vesicular stomatitis virus", "SPECIES", 18, 44], ["Sindbis virus", "SPECIES", 0, 13], ["stomatitis virus", "SPECIES", 28, 44], ["VSV", "SPECIES", 46, 49], ["Sindbis virus", "PROBLEM", 0, 13], ["vesicular stomatitis virus", "PROBLEM", 18, 44], ["vesicular stomatitis virus", "OBSERVATION", 18, 44]]], ["Infection was assessed within 8 and 24 hours of incubation with SARS-CoV and HCoV-NL63, respectively, thereby minimizing any potential effects of inhibitors on post-entry steps in viral replication.", [["HCoV-NL63", "CELL", 77, 86], ["SARS-CoV", "SPECIES", 64, 72], ["Infection", "PROBLEM", 0, 9], ["SARS", "TEST", 64, 68], ["CoV", "TEST", 69, 72], ["HCoV", "TEST", 77, 81], ["inhibitors", "TREATMENT", 146, 156], ["viral replication", "TREATMENT", 180, 197], ["viral replication", "OBSERVATION", 180, 197]]], ["As shown in Fig. 2, SARS-CoV infection was effectively blocked by cathepsin L inhibitor and less significantly by cathepsin B inhibitor.", [["SARS", "DISEASE", 20, 24], ["infection", "DISEASE", 29, 38], ["SARS-CoV", "ORGANISM", 20, 28], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 66, 77], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 114, 125], ["cathepsin B", "PROTEIN", 114, 125], ["SARS-CoV", "SPECIES", 20, 28], ["SARS", "PROBLEM", 20, 24], ["CoV infection", "PROBLEM", 25, 38], ["cathepsin L inhibitor", "TREATMENT", 66, 87], ["cathepsin B inhibitor", "TREATMENT", 114, 135], ["Fig", "OBSERVATION", 12, 15], ["CoV", "OBSERVATION_MODIFIER", 25, 28], ["infection", "OBSERVATION", 29, 38]]], ["NeitherThis difference between HCoV-NL63 and SARS-CoV was confirmed using pseudotyped viruses.", [["SARS", "DISEASE", 45, 49], ["HCoV-NL63", "GENE_OR_GENE_PRODUCT", 31, 40], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 45, 53], ["pseudotyped", "ORGANISM", 74, 85], ["HCoV", "PROTEIN", 31, 35], ["HCoV", "SPECIES", 31, 35], ["SARS-CoV", "SPECIES", 45, 53], ["HCoV", "TEST", 31, 35], ["SARS", "PROBLEM", 45, 49], ["CoV", "PROBLEM", 50, 53], ["pseudotyped viruses", "PROBLEM", 74, 93], ["pseudotyped viruses", "OBSERVATION", 74, 93]]], ["Inhibitors of cathepsin B, L, K, and S-the only available specific cathepsin inhibitors-were assessed.", [["cathepsin B", "GENE_OR_GENE_PRODUCT", 14, 25], ["L, K", "GENE_OR_GENE_PRODUCT", 27, 31], ["cathepsin", "GENE_OR_GENE_PRODUCT", 67, 76], ["cathepsin B", "PROTEIN", 14, 25], ["L, K, and S", "PROTEIN", 27, 38], ["Inhibitors", "TEST", 0, 10], ["cathepsin B", "TEST", 14, 25], ["K", "TEST", 30, 31], ["specific cathepsin inhibitors", "TREATMENT", 58, 87]]], ["None of these inhibitors had a detectable effect on the infection of MLV pseudotyped with the HCoV-NL63 S protein (NL63/MLV), or with the VSV G protein (VSV-G/MLV), whereas cathepsin L and S inhibitors efficiently blocked SARS/MLV entry (Fig. 3A) .", [["infection", "DISEASE", 56, 65], ["MLV", "ORGANISM", 69, 72], ["HCoV-NL63 S", "GENE_OR_GENE_PRODUCT", 94, 105], ["VSV G protein", "GENE_OR_GENE_PRODUCT", 138, 151], ["VSV-G/MLV", "ORGANISM", 153, 162], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 173, 184], ["MLV", "ORGANISM", 227, 230], ["HCoV", "PROTEIN", 94, 98], ["NL63 S protein", "PROTEIN", 99, 113], ["NL63", "PROTEIN", 115, 119], ["VSV G protein", "PROTEIN", 138, 151], ["VSV", "PROTEIN", 153, 156], ["cathepsin L", "PROTEIN", 173, 184], ["MLV", "SPECIES", 69, 72], ["VSV", "SPECIES", 138, 141], ["the infection of MLV pseudotyped", "PROBLEM", 52, 84], ["the HCoV", "TEST", 90, 98], ["S protein", "TEST", 104, 113], ["the VSV G protein", "TEST", 134, 151], ["VSV", "TEST", 153, 156], ["cathepsin L and S inhibitors", "TREATMENT", 173, 201], ["SARS", "PROBLEM", 222, 226], ["infection", "OBSERVATION", 56, 65]]], ["None of the protease inhibitors tested in Fig. 1A had any effect on NL63/MLV infection (data not shown), nor did E64d, which again potently inhibited SARS/MLV (Fig. 3B) .", [["MLV infection", "DISEASE", 73, 86], ["NL63", "GENE_OR_GENE_PRODUCT", 68, 72], ["MLV", "ORGANISM", 73, 76], ["MLV", "ORGANISM", 155, 158], ["Fig. 3B", "ORGANISM", 160, 167], ["the protease inhibitors", "TREATMENT", 8, 31], ["NL63/MLV infection", "PROBLEM", 68, 86], ["SARS", "PROBLEM", 150, 154], ["MLV", "ANATOMY", 73, 76], ["infection", "OBSERVATION", 77, 86]]], ["Because cathepsin inhibitors can cross-react, the roles of specific cathepsins were studied by introducing exogenous cathepsins into 293T cells.", [["293T cells", "ANATOMY", 133, 143], ["cathepsin", "GENE_OR_GENE_PRODUCT", 8, 17], ["cathepsins", "GENE_OR_GENE_PRODUCT", 68, 78], ["cathepsins", "GENE_OR_GENE_PRODUCT", 117, 127], ["293T cells", "CELL", 133, 143], ["cathepsins", "PROTEIN", 68, 78], ["cathepsins", "PROTEIN", 117, 127], ["293T cells", "CELL_LINE", 133, 143], ["cathepsin inhibitors", "TREATMENT", 8, 28], ["specific cathepsins", "TREATMENT", 59, 78], ["293T cells", "OBSERVATION", 133, 143]]], ["To ensure comparable ACE2 expression levels in cells transfected with various cathepsins, varying amounts of ACE2-expressing plasmid were used in transfection together with fixed amount of cathepsin plasmids.", [["cells", "ANATOMY", 47, 52], ["plasmid", "ANATOMY", 125, 132], ["ACE2", "GENE_OR_GENE_PRODUCT", 21, 25], ["cells", "CELL", 47, 52], ["cathepsins", "GENE_OR_GENE_PRODUCT", 78, 88], ["ACE2", "GENE_OR_GENE_PRODUCT", 109, 113], ["cathepsin", "GENE_OR_GENE_PRODUCT", 189, 198], ["ACE2", "PROTEIN", 21, 25], ["cathepsins", "PROTEIN", 78, 88], ["ACE2", "PROTEIN", 109, 113], ["cathepsin plasmids", "DNA", 189, 207], ["various cathepsins", "TREATMENT", 70, 88], ["ACE2-expressing plasmid", "TREATMENT", 109, 132], ["cathepsin plasmids", "TREATMENT", 189, 207], ["cathepsin plasmids", "OBSERVATION", 189, 207]]], ["Also, ACE2 cell-surface expression was assessed by flow cytometry in each experiment.", [["cell", "ANATOMY", 11, 15], ["surface", "ANATOMY", 16, 23], ["ACE2", "GENE_OR_GENE_PRODUCT", 6, 10], ["ACE2", "PROTEIN", 6, 10], ["ACE2 cell-surface expression", "TREATMENT", 6, 34], ["flow cytometry", "TEST", 51, 65], ["ACE2 cell", "OBSERVATION", 6, 15]]], ["As shown in Fig. 4A , cathepsin L markedly increased infection of SARS/MLV but had no effect on NL63/MLV or VSV-G/MLV.", [["infection", "DISEASE", 53, 62], ["SARS", "DISEASE", 66, 70], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 22, 33], ["MLV", "ORGANISM", 71, 74], ["NL63", "GENE_OR_GENE_PRODUCT", 96, 100], ["MLV", "ORGANISM", 101, 104], ["VSV-G/MLV", "ORGANISM", 108, 117], ["cathepsin L", "PROTEIN", 22, 33], ["MLV", "SPECIES", 101, 104], ["VSV", "SPECIES", 108, 111], ["cathepsin L markedly increased infection of SARS/MLV", "PROBLEM", 22, 74], ["NL63", "TEST", 96, 100], ["MLV", "PROBLEM", 101, 104], ["VSV", "PROBLEM", 108, 111], ["markedly", "OBSERVATION_MODIFIER", 34, 42], ["increased", "OBSERVATION_MODIFIER", 43, 52], ["infection", "OBSERVATION", 53, 62], ["SARS", "OBSERVATION", 66, 70], ["MLV", "ANATOMY", 71, 74], ["no", "UNCERTAINTY", 83, 85], ["MLV", "ANATOMY", 114, 117]]], ["Cathepsin S also modestly enhanced SARS/MLV infection, but, surprisingly, reduced NL63/MLV infection.", [["SARS/MLV infection", "DISEASE", 35, 53], ["MLV infection", "DISEASE", 87, 100], ["Cathepsin S", "GENE_OR_GENE_PRODUCT", 0, 11], ["MLV", "ORGANISM", 40, 43], ["NL63", "GENE_OR_GENE_PRODUCT", 82, 86], ["MLV", "ORGANISM", 87, 90], ["MLV", "SPECIES", 87, 90], ["Cathepsin S", "TEST", 0, 11], ["modestly enhanced SARS/MLV infection", "PROBLEM", 17, 53], ["reduced NL63/MLV infection", "PROBLEM", 74, 100], ["modestly", "OBSERVATION_MODIFIER", 17, 25], ["enhanced", "OBSERVATION_MODIFIER", 26, 34], ["SARS", "OBSERVATION", 35, 39], ["MLV infection", "OBSERVATION", 40, 53], ["reduced", "OBSERVATION_MODIFIER", 74, 81], ["MLV infection", "OBSERVATION", 87, 100]]], ["In parallel, these cathepsins were immunoprecipitated from aliquots of the same cells that were metabolically labeled, and analyzed by SDS-PAGE.", [["cells", "ANATOMY", 80, 85], ["cathepsins", "GENE_OR_GENE_PRODUCT", 19, 29], ["cells", "CELL", 80, 85], ["cathepsins", "PROTEIN", 19, 29], ["these cathepsins", "TREATMENT", 13, 29], ["the same cells", "TREATMENT", 71, 85]]], ["Figure 4B shows that exogenous cathepsin L expression was lower than that of cathepsin B or S, despite its greater effect on SARS-CoV infection.", [["SARS-CoV infection", "DISEASE", 125, 143], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 31, 42], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 77, 88], ["SARS-CoV", "ORGANISM", 125, 133], ["cathepsin L", "PROTEIN", 31, 42], ["cathepsin B", "PROTEIN", 77, 88], ["SARS-CoV", "SPECIES", 125, 133], ["Figure 4B", "TEST", 0, 9], ["exogenous cathepsin L expression", "PROBLEM", 21, 53], ["cathepsin B", "TREATMENT", 77, 88], ["SARS", "PROBLEM", 125, 129], ["CoV infection", "PROBLEM", 130, 143], ["exogenous", "OBSERVATION_MODIFIER", 21, 30], ["cathepsin", "OBSERVATION", 31, 40], ["greater", "OBSERVATION_MODIFIER", 107, 114], ["SARS", "OBSERVATION", 125, 129], ["CoV", "OBSERVATION_MODIFIER", 130, 133], ["infection", "OBSERVATION", 134, 143]]], ["Similarly, as shown in Fig. 4C , introduction of cathepsin L into mouse embryonic fibroblasts derived from mice lacking cathepsin L resulted in enhanced infection by SARS/MLV and MLV pseudotyped with Marburg virus or Ebola virus GP proteins, while no enhancement of infection was observed with NL63/MLV or VSV-G/MLV.", [["embryonic fibroblasts", "ANATOMY", 72, 93], ["infection", "DISEASE", 153, 162], ["infection", "DISEASE", 266, 275], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 49, 60], ["mouse", "ORGANISM", 66, 71], ["embryonic fibroblasts", "CELL", 72, 93], ["mice", "ORGANISM", 107, 111], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 120, 131], ["SARS/MLV", "ORGANISM", 166, 174], ["MLV pseudotyped", "ORGANISM", 179, 194], ["Marburg virus", "ORGANISM", 200, 213], ["Ebola virus GP", "ORGANISM", 217, 231], ["MLV", "ORGANISM", 299, 302], ["VSV-G/MLV", "ORGANISM", 306, 315], ["cathepsin L", "PROTEIN", 49, 60], ["mouse embryonic fibroblasts", "CELL_TYPE", 66, 93], ["cathepsin L", "PROTEIN", 120, 131], ["Ebola virus GP proteins", "PROTEIN", 217, 240], ["mouse", "SPECIES", 66, 71], ["mice", "SPECIES", 107, 111], ["Marburg virus", "SPECIES", 200, 213], ["Ebola virus", "SPECIES", 217, 228], ["mouse", "SPECIES", 66, 71], ["mice", "SPECIES", 107, 111], ["MLV", "SPECIES", 179, 182], ["Marburg virus", "SPECIES", 200, 213], ["Ebola virus", "SPECIES", 217, 228], ["MLV", "SPECIES", 299, 302], ["VSV", "SPECIES", 306, 309], ["cathepsin L into mouse embryonic fibroblasts", "TREATMENT", 49, 93], ["mice lacking cathepsin L", "TREATMENT", 107, 131], ["enhanced infection", "PROBLEM", 144, 162], ["SARS/MLV", "PROBLEM", 166, 174], ["MLV pseudotyped", "PROBLEM", 179, 194], ["Marburg virus", "PROBLEM", 200, 213], ["Ebola virus GP proteins", "PROBLEM", 217, 240], ["enhancement of infection", "PROBLEM", 251, 275], ["NL63", "TEST", 294, 298], ["VSV", "TEST", 306, 309], ["infection", "OBSERVATION", 153, 162], ["MLV", "ANATOMY", 171, 174], ["infection", "OBSERVATION", 266, 275], ["MLV", "ANATOMY", 312, 315]]], ["Collectively, these data show that cathepsins L and S contribute to SARS-CoV infection but not to that of HCoV-NL63.", [["SARS-CoV infection", "DISEASE", 68, 86], ["cathepsins L", "GENE_OR_GENE_PRODUCT", 35, 47], ["SARS-CoV", "ORGANISM", 68, 76], ["HCoV-NL63", "GENE_OR_GENE_PRODUCT", 106, 115], ["cathepsins L and S", "PROTEIN", 35, 53], ["HCoV", "PROTEIN", 106, 110], ["NL63", "DNA", 111, 115], ["SARS-CoV", "SPECIES", 68, 76], ["these data", "TEST", 14, 24], ["cathepsins L and S", "PROBLEM", 35, 53], ["SARS", "PROBLEM", 68, 72], ["CoV infection", "PROBLEM", 73, 86], ["HCoV", "TEST", 106, 110], ["SARS", "OBSERVATION", 68, 72], ["CoV", "OBSERVATION_MODIFIER", 73, 76], ["infection", "OBSERVATION", 77, 86]]]], "PMC7326017": [["IntroductionPorcine deltacoronavirus (PDCoV), a newly emerging swine enteropathogenic coronavirus, belongs to the genus Deltacoronavirus in the family Coronaviridae of the order Nidovirales (Wang et al., 2019).", [["deltacoronavirus", "CHEMICAL", 20, 36], ["PDCoV", "CHEMICAL", 38, 43], ["swine enteropathogenic coronavirus", "DISEASE", 63, 97], ["deltacoronavirus", "GENE_OR_GENE_PRODUCT", 20, 36], ["PDCoV", "GENE_OR_GENE_PRODUCT", 38, 43], ["swine enteropathogenic coronavirus", "ORGANISM", 63, 97], ["swine enteropathogenic coronavirus", "SPECIES", 63, 97], ["swine enteropathogenic coronavirus", "SPECIES", 63, 97], ["IntroductionPorcine deltacoronavirus", "PROBLEM", 0, 36], ["a newly emerging swine enteropathogenic coronavirus", "PROBLEM", 46, 97], ["enteropathogenic coronavirus", "OBSERVATION", 69, 97]]], ["PDCoV was first detected in Hong Kong in 2012 (Woo et al., 2012), and this was followed by outbreaks in multiple states of the United States in 2014 (Wang et al., 2014a,b).", [["PDCoV", "SPECIES", 0, 5]]], ["PDCoV infection causes typical clinical symptoms characterized by acute diarrhea and vomiting\u2014even mortality\u2014in piglets, leading to economic losses for the swine industry (Jung et al., 2015; Ma et al., 2015; Zhang, 2016).", [["PDCoV infection", "DISEASE", 0, 15], ["diarrhea", "DISEASE", 72, 80], ["piglets", "ORGANISM", 112, 119], ["piglets", "SPECIES", 112, 119], ["PDCoV", "SPECIES", 0, 5], ["swine", "SPECIES", 156, 161], ["PDCoV infection", "PROBLEM", 0, 15], ["typical clinical symptoms", "PROBLEM", 23, 48], ["acute diarrhea", "PROBLEM", 66, 80], ["vomiting\u2014even mortality\u2014in piglets", "PROBLEM", 85, 119], ["economic losses", "PROBLEM", 132, 147], ["infection", "OBSERVATION", 6, 15], ["acute", "OBSERVATION_MODIFIER", 66, 71], ["diarrhea", "OBSERVATION", 72, 80]]], ["In addition, recent studies have demonstrated that chicken and calves are also susceptible to PDCoV infection (Jung et al., 2017; Liang et al., 2019) and that PDCoV possesses the potential to infect humans (Li et al., 2018), which has sparked growing interest in studying this emerging coronavirus.IntroductionInterferon (IFN) and the IFN-induced cellular antiviral response are important components of the innate immune response that constitutes the first line of defense against viral infection (Randall and Goodbourn, 2008).", [["cellular", "ANATOMY", 347, 355], ["infection", "DISEASE", 100, 109], ["PDCoV", "CHEMICAL", 159, 164], ["coronavirus", "DISEASE", 286, 297], ["IFN", "CHEMICAL", 335, 338], ["viral infection", "DISEASE", 481, 496], ["chicken", "ORGANISM", 51, 58], ["calves", "ORGANISM", 63, 69], ["PDCoV", "GENE_OR_GENE_PRODUCT", 159, 164], ["humans", "ORGANISM", 199, 205], ["coronavirus", "ORGANISM", 286, 297], ["Interferon", "GENE_OR_GENE_PRODUCT", 310, 320], ["IFN", "GENE_OR_GENE_PRODUCT", 322, 325], ["IFN", "GENE_OR_GENE_PRODUCT", 335, 338], ["cellular", "CELL", 347, 355], ["Interferon", "PROTEIN", 310, 320], ["IFN", "PROTEIN", 322, 325], ["IFN", "PROTEIN", 335, 338], ["chicken", "SPECIES", 51, 58], ["calves", "SPECIES", 63, 69], ["humans", "SPECIES", 199, 205], ["chicken", "SPECIES", 51, 58], ["calves", "SPECIES", 63, 69], ["PDCoV", "SPECIES", 94, 99], ["humans", "SPECIES", 199, 205], ["recent studies", "TEST", 13, 27], ["PDCoV infection", "PROBLEM", 94, 109], ["IntroductionInterferon (IFN)", "TREATMENT", 298, 326], ["the IFN-induced cellular antiviral response", "TREATMENT", 331, 374], ["viral infection", "PROBLEM", 481, 496], ["infection", "OBSERVATION", 100, 109], ["cellular antiviral response", "OBSERVATION", 347, 374], ["viral", "OBSERVATION_MODIFIER", 481, 486], ["infection", "OBSERVATION", 487, 496]]], ["RNA virus infection produces a double-strand RNA (dsRNA) replication intermediate, which represents pathogen-associated molecular patterns (PAMPs).", [["infection", "DISEASE", 10, 19], ["pathogen-associated molecular patterns", "GENE_OR_GENE_PRODUCT", 100, 138], ["double-strand RNA", "RNA", 31, 48], ["pathogen-associated molecular patterns", "PROTEIN", 100, 138], ["PAMPs", "PROTEIN", 140, 145], ["RNA virus infection", "PROBLEM", 0, 19], ["a double-strand RNA (dsRNA", "TREATMENT", 29, 55], ["pathogen", "PROBLEM", 100, 108], ["virus infection", "OBSERVATION", 4, 19], ["double-strand RNA", "OBSERVATION_MODIFIER", 31, 48], ["intermediate", "OBSERVATION_MODIFIER", 69, 81], ["pathogen", "OBSERVATION_MODIFIER", 100, 108], ["molecular patterns", "OBSERVATION", 120, 138]]], ["Upon binding to cytoplasmic viral PAMPs, host pattern-recognition receptors in the cytoplasm, such as retinoic acid-induced gene I (RIG-I) and melanoma differentiation gene 5 (MDA5), are activated, facilitating the aggregation of mitochondrial signaling adapter (MAVS), and recruitment of TANK binding kinase 1 (TBK1)/I-kappa B kinase \u03b5 (IKK\u03b5) (Kawai and Akira, 2009; Belgnaoui et al., 2011).", [["cytoplasmic", "ANATOMY", 16, 27], ["cytoplasm", "ANATOMY", 83, 92], ["mitochondrial", "ANATOMY", 230, 243], ["cytoplasmic", "ORGANISM_SUBSTANCE", 16, 27], ["pattern-recognition receptors", "GENE_OR_GENE_PRODUCT", 46, 75], ["cytoplasm", "ORGANISM_SUBSTANCE", 83, 92], ["retinoic acid-induced gene I", "GENE_OR_GENE_PRODUCT", 102, 130], ["RIG-I", "GENE_OR_GENE_PRODUCT", 132, 137], ["melanoma differentiation gene 5", "GENE_OR_GENE_PRODUCT", 143, 174], ["MDA5", "GENE_OR_GENE_PRODUCT", 176, 180], ["mitochondrial", "CELLULAR_COMPONENT", 230, 243], ["MAVS", "GENE_OR_GENE_PRODUCT", 263, 267], ["TANK binding kinase 1", "GENE_OR_GENE_PRODUCT", 289, 310], ["TBK1", "GENE_OR_GENE_PRODUCT", 312, 316], ["I-kappa B kinase \u03b5", "GENE_OR_GENE_PRODUCT", 318, 336], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 338, 342], ["cytoplasmic viral PAMPs", "PROTEIN", 16, 39], ["host pattern-recognition receptors", "PROTEIN", 41, 75], ["retinoic acid-induced gene I", "DNA", 102, 130], ["RIG-I", "DNA", 132, 137], ["melanoma differentiation gene 5", "DNA", 143, 174], ["MDA5", "DNA", 176, 180], ["mitochondrial signaling adapter", "PROTEIN", 230, 261], ["MAVS", "PROTEIN", 263, 267], ["TANK binding kinase 1", "PROTEIN", 289, 310], ["TBK1", "PROTEIN", 312, 316], ["I-kappa B kinase \u03b5", "PROTEIN", 318, 336], ["IKK\u03b5", "PROTEIN", 338, 342], ["cytoplasmic viral PAMPs", "TEST", 16, 39], ["the cytoplasm", "PROBLEM", 79, 92], ["retinoic acid-induced gene I (RIG-I) and melanoma differentiation gene", "PROBLEM", 102, 172], ["TANK binding kinase", "TEST", 289, 308], ["TBK1", "TEST", 312, 316], ["kappa B kinase", "TEST", 320, 334], ["Kawai", "TEST", 345, 350], ["viral PAMPs", "OBSERVATION", 28, 39], ["melanoma", "OBSERVATION", 143, 151]]], ["This event leads to the activation of transcription factors interferon regulation factor 3 (IRF3) and nuclear factor \u03baB (NF-\u03baB) and subsequent production of type I IFNs (Fitzgerald et al., 2003; Fang R. et al., 2017).", [["interferon regulation factor 3", "GENE_OR_GENE_PRODUCT", 60, 90], ["IRF3", "GENE_OR_GENE_PRODUCT", 92, 96], ["nuclear factor \u03baB", "GENE_OR_GENE_PRODUCT", 102, 119], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 121, 126], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 157, 168], ["transcription factors", "PROTEIN", 38, 59], ["interferon regulation factor 3", "PROTEIN", 60, 90], ["IRF3", "PROTEIN", 92, 96], ["nuclear factor \u03baB", "PROTEIN", 102, 119], ["NF-\u03baB", "PROTEIN", 121, 126], ["type I IFNs", "PROTEIN", 157, 168], ["transcription factors interferon regulation factor", "TREATMENT", 38, 88], ["nuclear factor \u03baB", "TEST", 102, 119], ["NF", "TEST", 121, 123], ["type I IFNs", "PROBLEM", 157, 168]]], ["The secreted type I IFNs bind to receptors, leading to the activation of the Janus kinase (JAK)/signal transducers, and activators of transcription (STAT) signaling pathway and the production of hundreds of IFN-stimulated genes (Stark et al., 1998).", [["type I IFNs", "GENE_OR_GENE_PRODUCT", 13, 24], ["Janus kinase", "GENE_OR_GENE_PRODUCT", 77, 89], ["JAK", "GENE_OR_GENE_PRODUCT", 91, 94], ["signal transducers, and activators of transcription", "GENE_OR_GENE_PRODUCT", 96, 147], ["STAT", "GENE_OR_GENE_PRODUCT", 149, 153], ["IFN", "GENE_OR_GENE_PRODUCT", 207, 210], ["type I IFNs", "PROTEIN", 13, 24], ["Janus kinase", "PROTEIN", 77, 89], ["JAK", "PROTEIN", 91, 94], ["signal transducers", "PROTEIN", 96, 114], ["STAT", "PROTEIN", 149, 153], ["IFN-stimulated genes", "DNA", 207, 227], ["The secreted type I IFNs bind to receptors", "PROBLEM", 0, 42], ["signal transducers", "TEST", 96, 114], ["Janus kinase", "ANATOMY", 77, 89]]], ["Due to the deleterious effects of this response on viral replication, many viruses, including coronaviruses (CoVs), have developed various strategies to counteract IFN production and signaling transduction.", [["CoVs", "GENE_OR_GENE_PRODUCT", 109, 113], ["IFN", "GENE_OR_GENE_PRODUCT", 164, 167], ["IFN", "PROTEIN", 164, 167], ["viral replication", "TREATMENT", 51, 68], ["many viruses", "PROBLEM", 70, 82], ["coronaviruses", "PROBLEM", 94, 107], ["various strategies", "TREATMENT", 131, 149], ["IFN production", "PROBLEM", 164, 178], ["signaling transduction", "TREATMENT", 183, 205], ["deleterious", "OBSERVATION", 11, 22], ["viral replication", "OBSERVATION", 51, 68], ["viruses", "OBSERVATION", 75, 82]]], ["Some CoVs, including porcine epidemic diarrhea virus (PEDV), severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and mouse hepatitis virus (MHV), antagonize IFN production.", [["porcine epidemic diarrhea virus", "DISEASE", 21, 52], ["acute respiratory syndrome coronavirus", "DISEASE", 68, 106], ["SARS-CoV)", "DISEASE", 108, 117], ["Middle East respiratory syndrome coronavirus", "DISEASE", 119, 163], ["mouse hepatitis virus", "DISEASE", 180, 201], ["CoVs", "GENE_OR_GENE_PRODUCT", 5, 9], ["porcine epidemic diarrhea virus", "ORGANISM", 21, 52], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 61, 106], ["SARS-CoV", "ORGANISM", 108, 116], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 119, 163], ["MERS-CoV", "ORGANISM", 165, 173], ["mouse hepatitis virus", "ORGANISM", 180, 201], ["MHV", "ORGANISM", 203, 206], ["IFN", "GENE_OR_GENE_PRODUCT", 220, 223], ["IFN", "PROTEIN", 220, 223], ["porcine epidemic diarrhea virus", "SPECIES", 21, 52], ["MERS-CoV", "SPECIES", 165, 173], ["mouse", "SPECIES", 180, 185], ["hepatitis virus", "SPECIES", 186, 201], ["porcine epidemic diarrhea virus", "SPECIES", 21, 52], ["PEDV", "SPECIES", 54, 58], ["severe acute respiratory syndrome coronavirus", "SPECIES", 61, 106], ["SARS-CoV", "SPECIES", 108, 116], ["Middle East respiratory syndrome coronavirus", "SPECIES", 119, 163], ["MERS-CoV", "SPECIES", 165, 173], ["mouse hepatitis virus", "SPECIES", 180, 201], ["MHV", "SPECIES", 203, 206], ["Some CoVs", "PROBLEM", 0, 9], ["porcine epidemic diarrhea virus", "PROBLEM", 21, 52], ["PEDV", "PROBLEM", 54, 58], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 61, 106], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 119, 163], ["mouse hepatitis virus", "PROBLEM", 180, 201], ["antagonize IFN production", "PROBLEM", 209, 234], ["CoVs", "OBSERVATION", 5, 9], ["porcine", "OBSERVATION_MODIFIER", 21, 28], ["epidemic", "OBSERVATION_MODIFIER", 29, 37], ["severe", "OBSERVATION_MODIFIER", 61, 67], ["acute", "OBSERVATION_MODIFIER", 68, 73], ["respiratory syndrome coronavirus", "OBSERVATION", 74, 106], ["Middle", "ANATOMY_MODIFIER", 119, 125], ["respiratory syndrome", "OBSERVATION", 131, 151], ["hepatitis virus", "OBSERVATION", 186, 201]]], ["Detailed inhibitory mechanisms have been revealed and multiple viral proteins involved in the inhibition process have been identified (Vijay and Perlman, 2016; Zhang and Yoo, 2016; Deng et al., 2017; Case et al., 2018).", [["viral proteins", "PROTEIN", 63, 77], ["multiple viral proteins", "PROBLEM", 54, 77]]], ["As an emerging CoV, PDCoV has also been reported to suppress type I IFN production (Luo et al., 2016).", [["PDCoV", "CHEMICAL", 20, 25], ["CoV", "ORGANISM", 15, 18], ["PDCoV", "GENE_OR_GENE_PRODUCT", 20, 25], ["type I IFN", "GENE_OR_GENE_PRODUCT", 61, 71], ["PDCoV", "PROTEIN", 20, 25], ["IFN", "PROTEIN", 68, 71], ["type I IFN production", "PROBLEM", 61, 82]]], ["However, the molecular mechanisms used by PDCoV to antagonize IFN production remain largely unknown.IntroductionAccessory proteins are unique proteins encoded by CoVs; however, their number and sequence vary amongst the numerous species of CoVs.", [["PDCoV", "CHEMICAL", 42, 47], ["PDCoV", "SIMPLE_CHEMICAL", 42, 47], ["IFN", "GENE_OR_GENE_PRODUCT", 62, 65], ["CoVs", "GENE_OR_GENE_PRODUCT", 162, 166], ["CoVs", "GENE_OR_GENE_PRODUCT", 240, 244], ["IFN", "PROTEIN", 62, 65], ["Accessory proteins", "PROTEIN", 112, 130], ["CoVs", "PROTEIN", 162, 166], ["CoVs", "PROTEIN", 240, 244], ["the molecular mechanisms", "PROBLEM", 9, 33], ["PDCoV", "TREATMENT", 42, 47], ["antagonize IFN production", "TREATMENT", 51, 76]]], ["For example, SARS-CoV encodes the largest number of accessory proteins, containing ORFs 3a, 3b, 6, 7a, 7b, 8a, 8b, and 9b, whereas only one accessory protein, ORF3, has been identified in PEDV (Liu et al., 2014).", [["SARS", "DISEASE", 13, 17], ["SARS-CoV", "ORGANISM", 13, 21], ["b", "GENE_OR_GENE_PRODUCT", 93, 94], ["7a", "GENE_OR_GENE_PRODUCT", 99, 101], ["7b", "GENE_OR_GENE_PRODUCT", 103, 105], ["8a", "GENE_OR_GENE_PRODUCT", 107, 109], ["8", "GENE_OR_GENE_PRODUCT", 111, 112], ["b", "GENE_OR_GENE_PRODUCT", 112, 113], ["9b", "GENE_OR_GENE_PRODUCT", 119, 121], ["ORF3", "GENE_OR_GENE_PRODUCT", 159, 163], ["accessory proteins", "PROTEIN", 52, 70], ["ORFs 3a, 3b, 6, 7a, 7b, 8a, 8b, and 9b", "PROTEIN", 83, 121], ["accessory protein", "PROTEIN", 140, 157], ["ORF3", "PROTEIN", 159, 163], ["SARS-CoV", "SPECIES", 13, 21], ["PEDV", "SPECIES", 188, 192], ["SARS", "PROBLEM", 13, 17], ["accessory proteins", "PROBLEM", 52, 70], ["ORFs", "TEST", 83, 87], ["ORF3", "TEST", 159, 163], ["largest", "OBSERVATION_MODIFIER", 34, 41], ["number", "OBSERVATION_MODIFIER", 42, 48], ["accessory proteins", "OBSERVATION", 52, 70], ["accessory protein", "OBSERVATION", 140, 157]]], ["Accessory proteins of CoVs are generally not essential for normal viral replication in vitro (Tan et al., 2006).", [["CoVs", "GENE_OR_GENE_PRODUCT", 22, 26], ["Accessory proteins", "PROTEIN", 0, 18], ["CoVs", "PROTEIN", 22, 26], ["Accessory proteins of CoVs", "PROBLEM", 0, 26], ["CoVs", "OBSERVATION", 22, 26], ["viral replication", "OBSERVATION", 66, 83]]], ["However, extensive evidence indicates that many accessory proteins are closely associated with viral pathogenicity, optimal replication, and immune regulation, especially in relation to the regulation of IFN signaling.", [["IFN", "GENE_OR_GENE_PRODUCT", 204, 207], ["accessory proteins", "PROTEIN", 48, 66], ["IFN", "PROTEIN", 204, 207], ["many accessory proteins", "PROBLEM", 43, 66], ["viral pathogenicity", "PROBLEM", 95, 114], ["immune regulation", "PROBLEM", 141, 158], ["IFN signaling", "PROBLEM", 204, 217], ["viral", "OBSERVATION_MODIFIER", 95, 100], ["pathogenicity", "OBSERVATION", 101, 114]]], ["For example, at least four accessory proteins (ORFs 3b, 6, 8b, and 9b) encoded by SARS-CoV were identified as type I IFN antagonist (Frieman et al., 2007; Liu et al., 2014; Wong et al., 2018).", [["ORFs 3b", "GENE_OR_GENE_PRODUCT", 47, 54], ["8", "GENE_OR_GENE_PRODUCT", 59, 60], ["b", "GENE_OR_GENE_PRODUCT", 60, 61], ["9b", "GENE_OR_GENE_PRODUCT", 67, 69], ["SARS-CoV", "ORGANISM", 82, 90], ["type I IFN", "GENE_OR_GENE_PRODUCT", 110, 120], ["accessory proteins", "PROTEIN", 27, 45], ["ORFs 3b, 6, 8b, and 9b", "PROTEIN", 47, 69], ["SARS-CoV", "SPECIES", 82, 90], ["ORFs", "TEST", 47, 51]]], ["MERS-CoV ORF4a and ORF4b, MHV accessory protein ns2, transmissible gastroenteritis virus (TGEV) protein 7, and feline infectious peritonitis virus (FIPV) protein 7a have also been demonstrated to inhibit IFN responses (Zhao et al., 2012; Cruz et al., 2013; Niemeyer et al., 2013; Dedeurwaerder et al., 2014; Comar et al., 2019).", [["transmissible gastroenteritis", "DISEASE", 53, 82], ["infectious peritonitis", "DISEASE", 118, 140], ["MERS-CoV ORF4a", "GENE_OR_GENE_PRODUCT", 0, 14], ["ORF4b", "GENE_OR_GENE_PRODUCT", 19, 24], ["MHV", "ORGANISM", 26, 29], ["ns2", "GENE_OR_GENE_PRODUCT", 48, 51], ["transmissible gastroenteritis virus", "ORGANISM", 53, 88], ["(TGEV) protein 7", "GENE_OR_GENE_PRODUCT", 89, 105], ["feline infectious peritonitis virus", "ORGANISM", 111, 146], ["(FIPV) protein 7a", "GENE_OR_GENE_PRODUCT", 147, 164], ["IFN", "GENE_OR_GENE_PRODUCT", 204, 207], ["MERS-CoV ORF4a", "PROTEIN", 0, 14], ["ORF4b", "DNA", 19, 24], ["MHV accessory protein ns2", "PROTEIN", 26, 51], ["transmissible gastroenteritis virus (TGEV) protein 7", "PROTEIN", 53, 105], ["feline infectious peritonitis virus (FIPV) protein 7a", "PROTEIN", 111, 164], ["IFN", "PROTEIN", 204, 207], ["transmissible gastroenteritis virus", "SPECIES", 53, 88], ["feline infectious peritonitis virus", "SPECIES", 111, 146], ["MERS-CoV", "SPECIES", 0, 8], ["MHV", "SPECIES", 26, 29], ["transmissible gastroenteritis virus", "SPECIES", 53, 88], ["TGEV", "SPECIES", 90, 94], ["feline infectious peritonitis virus", "SPECIES", 111, 146], ["FIPV", "SPECIES", 148, 152], ["ORF4b", "TEST", 19, 24], ["MHV accessory protein ns2", "TREATMENT", 26, 51], ["transmissible gastroenteritis virus", "PROBLEM", 53, 88], ["TGEV) protein", "TEST", 90, 103], ["feline infectious peritonitis virus", "PROBLEM", 111, 146], ["infectious", "OBSERVATION_MODIFIER", 118, 128], ["peritonitis", "OBSERVATION", 129, 140]]], ["PDCoV encodes at least three accessory proteins, NS6, NS7, and NS7a (Fang et al., 2016; Fang P. et al., 2017).", [["PDCoV", "GENE_OR_GENE_PRODUCT", 0, 5], ["NS6", "GENE_OR_GENE_PRODUCT", 49, 52], ["NS7", "GENE_OR_GENE_PRODUCT", 54, 57], ["NS7a", "GENE_OR_GENE_PRODUCT", 63, 67], ["PDCoV", "PROTEIN", 0, 5], ["accessory proteins", "PROTEIN", 29, 47], ["NS6", "PROTEIN", 49, 52], ["NS7", "PROTEIN", 54, 57], ["NS7a", "PROTEIN", 63, 67], ["NS6", "TREATMENT", 49, 52], ["NS7", "TREATMENT", 54, 57]]], ["PDCoV NS6 inhibits IFN-\u03b2 production by interacting with RIG-I and MDA5 to attenuate their association with double-stranded RNA (Fang et al., 2018).", [["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 19, 24], ["RIG-I", "GENE_OR_GENE_PRODUCT", 56, 61], ["MDA5", "GENE_OR_GENE_PRODUCT", 66, 70], ["NS6", "PROTEIN", 6, 9], ["IFN", "PROTEIN", 19, 22], ["\u03b2", "PROTEIN", 23, 24], ["RIG-I", "PROTEIN", 56, 61], ["MDA5", "PROTEIN", 66, 70], ["PDCoV", "SPECIES", 0, 5], ["PDCoV", "TREATMENT", 0, 5]]], ["Currently, the role of other accessory proteins encoded by PDCoV in the regulation of the IFN signaling pathway remains unclear.IntroductionIn this study, we demonstrated that PDCoV NS7a also antagonizes IFN-\u03b2 production in vitro.", [["PDCoV", "GENE_OR_GENE_PRODUCT", 59, 64], ["IFN", "GENE_OR_GENE_PRODUCT", 90, 93], ["PDCoV NS7a", "GENE_OR_GENE_PRODUCT", 176, 186], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 204, 209], ["accessory proteins", "PROTEIN", 29, 47], ["PDCoV", "PROTEIN", 59, 64], ["IFN", "PROTEIN", 90, 93], ["PDCoV NS7a", "PROTEIN", 176, 186], ["IFN", "PROTEIN", 204, 207], ["\u03b2", "PROTEIN", 208, 209], ["PDCoV", "SPECIES", 176, 181], ["the IFN signaling pathway", "PROBLEM", 86, 111], ["this study", "TEST", 143, 153], ["PDCoV NS7a", "TREATMENT", 176, 186], ["IFN", "PROBLEM", 204, 207]]], ["Mechanistically, PDCoV NS7a specifically targets the key kinase IKK\u03b5 to disrupt its interaction with both TRAF3 and IRF3, thereby blocking the production of IFN-\u03b2.Viruses, Cells, and Reagents ::: Materials and MethodsPDCoV strain CHN-HN-2014 (GenBank accession number KT336560) was isolated in China in 2014 from a piglet with severe diarrhea (Dong et al., 2016).", [["Cells", "ANATOMY", 172, 177], ["piglet", "ANATOMY", 315, 321], ["CHN-HN-2014", "CHEMICAL", 230, 241], ["diarrhea", "DISEASE", 334, 342], ["PDCoV NS7a", "GENE_OR_GENE_PRODUCT", 17, 27], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 64, 68], ["TRAF3", "GENE_OR_GENE_PRODUCT", 106, 111], ["IRF3", "GENE_OR_GENE_PRODUCT", 116, 120], ["Cells", "CELL", 172, 177], ["piglet", "ORGANISM", 315, 321], ["PDCoV NS7a", "PROTEIN", 17, 27], ["IKK\u03b5", "PROTEIN", 64, 68], ["TRAF3", "PROTEIN", 106, 111], ["IRF3", "PROTEIN", 116, 120], ["IFN", "PROTEIN", 157, 160], ["piglet", "SPECIES", 315, 321], ["MethodsPDCoV strain CHN-HN-2014 (GenBank accession number KT336560", "SPECIES", 210, 276], ["PDCoV NS7a", "TREATMENT", 17, 27], ["IRF3", "TREATMENT", 116, 120], ["IFN", "PROBLEM", 157, 160], ["severe diarrhea", "PROBLEM", 327, 342], ["severe", "OBSERVATION_MODIFIER", 327, 333], ["diarrhea", "OBSERVATION", 334, 342]]], ["Vesicular stomatitis virus-expressing green fluorescent protein (VSV-GFP) was generously gifted by Dr. Zhigao Bu at Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences.", [["Zhigao Bu", "CHEMICAL", 103, 112], ["Vesicular stomatitis virus", "ORGANISM", 0, 26], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 38, 63], ["VSV", "ORGANISM", 65, 68], ["GFP", "GENE_OR_GENE_PRODUCT", 69, 72], ["green fluorescent protein", "PROTEIN", 38, 63], ["VSV", "PROTEIN", 65, 68], ["GFP", "PROTEIN", 69, 72], ["Vesicular stomatitis virus", "SPECIES", 0, 26], ["Vesicular stomatitis virus", "SPECIES", 0, 26], ["Vesicular stomatitis virus", "PROBLEM", 0, 26], ["stomatitis virus", "OBSERVATION", 10, 26]]], ["Sendai virus (SeV) was obtained from the Center of Virus Resource and Information, Wuhan Institute of Virology, Chinese Academy of Sciences.", [["Sendai virus", "ORGANISM", 0, 12], ["SeV", "ORGANISM", 14, 17], ["Sendai virus", "SPECIES", 0, 12], ["Sendai virus", "SPECIES", 0, 12], ["SeV", "SPECIES", 14, 17], ["Sendai virus", "PROBLEM", 0, 12]]], ["Human embryonic kidney cells (HEK-293T), and porcine intestinal epithelial cells (IPI-2I) were obtained from the China Center for Type Culture Collection.", [["embryonic kidney cells", "ANATOMY", 6, 28], ["HEK-293T", "ANATOMY", 30, 38], ["intestinal epithelial cells", "ANATOMY", 53, 80], ["IPI-2I", "ANATOMY", 82, 88], ["Human", "ORGANISM", 0, 5], ["embryonic kidney cells", "CELL", 6, 28], ["HEK-293T", "CELL", 30, 38], ["porcine", "ORGANISM", 45, 52], ["intestinal epithelial cells", "CELL", 53, 80], ["IPI-2I", "CELL", 82, 88], ["Human embryonic kidney cells", "CELL_LINE", 0, 28], ["HEK-293T", "CELL_LINE", 30, 38], ["porcine intestinal epithelial cells", "CELL_TYPE", 45, 80], ["IPI-2I", "CELL_LINE", 82, 88], ["Human", "SPECIES", 0, 5], ["porcine", "SPECIES", 45, 52], ["Human", "SPECIES", 0, 5], ["porcine", "SPECIES", 45, 52], ["Human embryonic kidney cells", "TEST", 0, 28], ["HEK", "TEST", 30, 33], ["porcine intestinal epithelial cells", "PROBLEM", 45, 80], ["Type Culture Collection", "PROBLEM", 130, 153], ["kidney", "ANATOMY", 16, 22], ["intestinal", "ANATOMY", 53, 63], ["epithelial cells", "OBSERVATION", 64, 80]]], ["Porcine kidney epithelial cells (LLC-PK1) were obtained from American Type Culture Collection.", [["kidney epithelial cells", "ANATOMY", 8, 31], ["LLC-PK1", "ANATOMY", 33, 40], ["Porcine", "ORGANISM", 0, 7], ["kidney epithelial cells", "CELL", 8, 31], ["LLC-PK1", "CELL", 33, 40], ["Porcine kidney epithelial cells", "CELL_TYPE", 0, 31], ["PK1", "CELL_LINE", 37, 40], ["Porcine", "SPECIES", 0, 7], ["Porcine kidney epithelial cells", "TEST", 0, 31], ["kidney", "ANATOMY", 8, 14], ["epithelial cells", "OBSERVATION", 15, 31]]], ["They were cultured and maintained at 37\u00b0C and 5% CO2 in Dulbecco's Modified Eagle's medium (Invitrogen, NY, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (PAN-biotech, Bavaria, Germany).", [["fetal bovine serum", "ANATOMY", 152, 170], ["FBS", "ANATOMY", 172, 175], ["CO2", "CHEMICAL", 49, 52], ["CO2", "CHEMICAL", 49, 52], ["CO2", "SIMPLE_CHEMICAL", 49, 52], ["bovine", "ORGANISM", 158, 164], ["serum", "ORGANISM_SUBSTANCE", 165, 170], ["FBS", "ORGANISM_SUBSTANCE", 172, 175], ["bovine", "SPECIES", 158, 164], ["bovine", "SPECIES", 158, 164], ["fetal bovine serum", "TEST", 152, 170], ["FBS", "TEST", 172, 175]]], ["Antibodies against p-IRF3, p65, Lamin A/C, and \u03b2-actin were purchased from ABclonal (Wuhan, China).", [["p-IRF3", "GENE_OR_GENE_PRODUCT", 19, 25], ["p65", "GENE_OR_GENE_PRODUCT", 27, 30], ["Lamin A", "GENE_OR_GENE_PRODUCT", 32, 39], ["C", "GENE_OR_GENE_PRODUCT", 40, 41], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 47, 54], ["p", "PROTEIN", 19, 20], ["IRF3", "PROTEIN", 21, 25], ["p65", "PROTEIN", 27, 30], ["Lamin A", "PROTEIN", 32, 39], ["C", "PROTEIN", 40, 41], ["\u03b2-actin", "PROTEIN", 47, 54], ["Antibodies", "TEST", 0, 10], ["Lamin A/C", "TREATMENT", 32, 41], ["\u03b2-actin", "TREATMENT", 47, 54]]], ["Rabbit anti-p-p65, anti-IRF3, and TNF receptor-associated factor 3 (TRAF3) were purchased from Cell Signaling Technology (Danvers, MA, USA).", [["Cell", "ANATOMY", 95, 99], ["Rabbit", "ORGANISM", 0, 6], ["anti-p-p65", "GENE_OR_GENE_PRODUCT", 7, 17], ["anti-IRF3", "GENE_OR_GENE_PRODUCT", 19, 28], ["TNF receptor-associated factor 3", "GENE_OR_GENE_PRODUCT", 34, 66], ["TRAF3", "GENE_OR_GENE_PRODUCT", 68, 73], ["Cell", "CELL", 95, 99], ["anti-p", "PROTEIN", 7, 13], ["p65", "PROTEIN", 14, 17], ["anti-IRF3", "PROTEIN", 19, 28], ["TNF receptor-associated factor 3", "PROTEIN", 34, 66], ["TRAF3", "PROTEIN", 68, 73], ["Rabbit", "SPECIES", 0, 6], ["Rabbit", "SPECIES", 0, 6], ["Rabbit anti-p", "TEST", 0, 13], ["anti-IRF3", "TEST", 19, 28], ["TNF receptor", "TEST", 34, 46]]], ["Mouse anti-Flag, anti-GFP, -Myc, or -hemagglutinin (HA) antibodies were purchased from Medical and Biological Laboratories (Nagoya, Japan).", [["Mouse", "ORGANISM", 0, 5], ["anti-Flag", "GENE_OR_GENE_PRODUCT", 6, 15], ["anti-GFP, -Myc", "GENE_OR_GENE_PRODUCT", 17, 31], ["-hemagglutinin", "GENE_OR_GENE_PRODUCT", 36, 50], ["HA", "GENE_OR_GENE_PRODUCT", 52, 54], ["Mouse anti-Flag, anti-GFP, -Myc, or -hemagglutinin (HA) antibodies", "PROTEIN", 0, 66], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["Mouse anti-Flag", "TREATMENT", 0, 15], ["anti-GFP", "TREATMENT", 17, 25], ["Myc", "PROBLEM", 28, 31], ["-hemagglutinin (HA) antibodies", "PROBLEM", 36, 66]]], ["Mouse anti-Hsp90 were purchased from BD Transduction Labs (NJ, NY, USA).", [["Mouse", "ORGANISM", 0, 5], ["anti-Hsp90", "GENE_OR_GENE_PRODUCT", 6, 16], ["Mouse anti-Hsp90", "PROTEIN", 0, 16], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["Mouse anti-Hsp90", "TREATMENT", 0, 16]]], ["Horseradish peroxidase (HRP)-conjugated secondary antibodies and 4\u2032, 6-diamidino-2-phenylindole (DAPI) were purchased from Beyotime (Shanghai, China).", [["4\u2032, 6-diamidino-2-phenylindole", "CHEMICAL", 65, 95], ["DAPI", "CHEMICAL", 97, 101], ["4\u2032, 6-diamidino-2-phenylindole", "CHEMICAL", 65, 95], ["DAPI", "CHEMICAL", 97, 101], ["Horseradish peroxidase", "SIMPLE_CHEMICAL", 0, 22], ["HRP", "SIMPLE_CHEMICAL", 24, 27], ["4\u2032, 6-diamidino-2-phenylindole", "SIMPLE_CHEMICAL", 65, 95], ["DAPI", "SIMPLE_CHEMICAL", 97, 101], ["Horseradish peroxidase", "PROTEIN", 0, 22], ["HRP", "PROTEIN", 24, 27], ["Horseradish", "SPECIES", 0, 11], ["Horseradish peroxidase", "TEST", 0, 22], ["HRP", "TEST", 24, 27], ["conjugated secondary antibodies", "TEST", 29, 60], ["diamidino", "TREATMENT", 71, 80], ["phenylindole (DAPI", "TREATMENT", 83, 101]]], ["Goat anti-mouse IgG LCS/HCS were purchased from Abbkine (California, USA).", [["Goat anti-mouse IgG LCS", "PROTEIN", 0, 23], ["Goat", "SPECIES", 0, 4], ["anti-mouse", "SPECIES", 5, 15], ["Goat", "SPECIES", 0, 4], ["Goat anti-mouse IgG LCS", "TEST", 0, 23], ["HCS", "PROBLEM", 24, 27]]], ["Alexa Fluor 594-conjugated donkey anti-mouse IgG and Alexa Fluor 488-conjugated donkey anti-rabbit IgG were obtained from Jackson ImmunoResearch (PA, USA).", [["Alexa Fluor 594", "CHEMICAL", 0, 15], ["Alexa Fluor 488", "CHEMICAL", 53, 68], ["Alexa Fluor 594", "SIMPLE_CHEMICAL", 0, 15], ["Alexa Fluor 488", "SIMPLE_CHEMICAL", 53, 68], ["Alexa Fluor 594-conjugated donkey anti-mouse IgG", "PROTEIN", 0, 48], ["Alexa Fluor 488-conjugated donkey anti-rabbit IgG", "PROTEIN", 53, 102], ["donkey", "SPECIES", 27, 33], ["anti-mouse", "SPECIES", 34, 44], ["donkey", "SPECIES", 80, 86], ["anti-rabbit", "SPECIES", 87, 98], ["anti-mouse", "SPECIES", 34, 44], ["Alexa", "SPECIES", 53, 58], ["anti-rabbit", "SPECIES", 87, 98], ["Alexa Fluor", "TEST", 0, 11], ["conjugated donkey anti-mouse IgG", "TEST", 16, 48], ["Alexa Fluor", "TEST", 53, 64], ["conjugated donkey anti-rabbit IgG", "TEST", 69, 102]]], ["NE-PER nuclear and cytoplasmic extraction reagents kit was purchased from Thermo Fisher Scientific (IL, USA).Plasmids and Dual-Luciferase Reporter Assay ::: Materials and MethodsThe NS7a gene from the PDCoV strain CHN-HN-2014 was amplified using primers NS7a-F and NS7a-R (Table 1) and then cloned into pCAGGS-Myc-N with an N-terminal Myc tag to yield pCAGGS-Myc-NS7a.", [["nuclear", "ANATOMY", 7, 14], ["cytoplasmic", "ANATOMY", 19, 30], ["NE", "CHEMICAL", 0, 2], ["NE", "SIMPLE_CHEMICAL", 0, 2], ["cytoplasmic", "ORGANISM_SUBSTANCE", 19, 30], ["NS7a", "GENE_OR_GENE_PRODUCT", 182, 186], ["PDCoV strain", "ORGANISM", 201, 213], ["CHN-HN-2014", "CELL", 214, 225], ["NS7a-F", "GENE_OR_GENE_PRODUCT", 254, 260], ["NS7a-R (Table 1", "GENE_OR_GENE_PRODUCT", 265, 280], ["pCAGGS-Myc", "GENE_OR_GENE_PRODUCT", 303, 313], ["Myc", "GENE_OR_GENE_PRODUCT", 335, 338], ["pCAGGS-Myc", "GENE_OR_GENE_PRODUCT", 352, 362], ["NE", "PROTEIN", 0, 2], ["NS7a gene", "DNA", 182, 191], ["PDCoV strain CHN-HN-2014", "DNA", 201, 225], ["NS7a", "DNA", 254, 258], ["F", "DNA", 259, 260], ["NS7a", "DNA", 265, 269], ["R", "DNA", 270, 271], ["Table 1", "DNA", 273, 280], ["pCAGGS", "DNA", 303, 309], ["Myc", "PROTEIN", 310, 313], ["N-terminal Myc tag", "PROTEIN", 324, 342], ["pCAGGS", "PROTEIN", 352, 358], ["Myc", "PROTEIN", 359, 362], ["NS7a", "PROTEIN", 363, 367], ["Methods", "TREATMENT", 171, 178]]], ["Expression plasmid pCAGGS-HA-NS7a was constructed as described previously (Fang P. et al., 2017).", [["pCAGGS-HA-NS7a", "GENE_OR_GENE_PRODUCT", 19, 33], ["Expression plasmid", "DNA", 0, 18], ["pCAGGS", "DNA", 19, 25], ["HA", "DNA", 26, 28], ["NS7a", "DNA", 29, 33], ["HA", "PROBLEM", 26, 28]]], ["Flag-tagged expression constructs encoding RIG-I, MDA5, MAVS, TBK1, IKK\u03b5, and IRF3 have been described previously (Ding et al., 2014; Fang et al., 2018).", [["Flag", "GENE_OR_GENE_PRODUCT", 0, 4], ["RIG-I", "GENE_OR_GENE_PRODUCT", 43, 48], ["MDA5", "GENE_OR_GENE_PRODUCT", 50, 54], ["MAVS", "GENE_OR_GENE_PRODUCT", 56, 60], ["TBK1", "GENE_OR_GENE_PRODUCT", 62, 66], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 68, 72], ["IRF3", "GENE_OR_GENE_PRODUCT", 78, 82], ["Flag-tagged expression constructs", "DNA", 0, 33], ["RIG-I", "PROTEIN", 43, 48], ["MDA5", "PROTEIN", 50, 54], ["MAVS", "PROTEIN", 56, 60], ["TBK1", "PROTEIN", 62, 66], ["IKK\u03b5", "PROTEIN", 68, 72], ["IRF3", "PROTEIN", 78, 82], ["TBK1", "PROBLEM", 62, 66], ["IRF3", "PROBLEM", 78, 82], ["IRF3", "OBSERVATION", 78, 82]]], ["The HA-tagged expression construct encoding IKK\u03b5, pCAGGS-HA-IKK\u03b5, was constructed by cloning the full-length cDNA of IKK\u03b5 into the pCAGGS-HA-N vector with primers IKK\u03b5-F and IKK\u03b5-R (Table 1).", [["HA", "GENE_OR_GENE_PRODUCT", 4, 6], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 44, 48], ["pCAGGS-HA-IKK\u03b5", "GENE_OR_GENE_PRODUCT", 50, 64], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 117, 121], ["pCAGGS", "GENE_OR_GENE_PRODUCT", 131, 137], ["IKK\u03b5-F", "GENE_OR_GENE_PRODUCT", 163, 169], ["IKK\u03b5-R", "GENE_OR_GENE_PRODUCT", 174, 180], ["HA-tagged expression construct", "DNA", 4, 34], ["IKK\u03b5", "PROTEIN", 44, 48], ["pCAGGS", "PROTEIN", 50, 56], ["HA", "PROTEIN", 57, 59], ["IKK\u03b5", "PROTEIN", 60, 64], ["full-length cDNA", "DNA", 97, 113], ["IKK\u03b5", "PROTEIN", 117, 121], ["pCAGGS-HA-N vector", "DNA", 131, 149], ["IKK", "PROTEIN", 163, 166], ["IKK\u03b5-R", "DNA", 174, 180], ["Table 1", "DNA", 182, 189], ["The HA", "PROBLEM", 0, 6], ["the pCAGGS", "TEST", 127, 137], ["HA", "PROBLEM", 138, 140], ["primers IKK", "TEST", 155, 166], ["IKK", "TEST", 174, 177]]], ["The Flag-tagged full-length IKK\u03b5 expression plasmid was used as the template to amplify two functional domains of IKK\u03b5, the kinase domain (KD) (IKK\u03b5 aa 1\u2013304) and scaffold dimerization domain (SDD) (IKK\u03b5 aa 383\u2013648), as reported previously (Fang R. et al., 2017), which were cloned into the pCAGGS-Flag/HA-N vector with an N-terminal Flag/HA tag using specific primers (Table 1).", [["Flag", "GENE_OR_GENE_PRODUCT", 4, 8], ["IKK", "GENE_OR_GENE_PRODUCT", 28, 31], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 114, 118], ["IKK\u03b5 aa 1\u2013304", "GENE_OR_GENE_PRODUCT", 144, 157], ["IKK\u03b5 aa 383\u2013648", "GENE_OR_GENE_PRODUCT", 199, 214], ["pCAGGS", "GENE_OR_GENE_PRODUCT", 291, 297], ["Flag", "GENE_OR_GENE_PRODUCT", 298, 302], ["Flag-tagged full-length IKK\u03b5 expression plasmid", "DNA", 4, 51], ["IKK\u03b5", "PROTEIN", 114, 118], ["kinase domain", "PROTEIN", 124, 137], ["KD", "PROTEIN", 139, 141], ["IKK\u03b5 aa 1\u2013304", "PROTEIN", 144, 157], ["scaffold dimerization domain", "PROTEIN", 163, 191], ["SDD", "PROTEIN", 193, 196], ["IKK", "PROTEIN", 199, 202], ["pCAGGS", "PROTEIN", 291, 297], ["Flag", "PROTEIN", 298, 302], ["HA", "PROTEIN", 303, 305], ["N-terminal Flag", "PROTEIN", 323, 338], ["HA tag", "PROTEIN", 339, 345], ["The Flag", "TEST", 0, 8], ["full-length IKK\u03b5 expression plasmid", "TREATMENT", 16, 51], ["the template", "TREATMENT", 64, 76], ["IKK\u03b5", "TEST", 114, 118], ["the kinase domain", "TEST", 120, 137], ["KD", "TEST", 139, 141], ["IKK", "TEST", 144, 147], ["aa", "TEST", 149, 151], ["scaffold dimerization domain", "TEST", 163, 191], ["SDD", "TEST", 193, 196], ["IKK\u03b5 aa", "TEST", 199, 206], ["Flag/HA-N vector", "TREATMENT", 298, 314], ["an N-terminal Flag/HA tag", "TREATMENT", 320, 345]]], ["The resulting expression plasmids were named pCAGGS-Flag/HA-KD and pCAGGS-Flag/HA-SDD.", [["plasmids", "ANATOMY", 25, 33], ["pCAGGS-Flag", "GENE_OR_GENE_PRODUCT", 45, 56], ["pCAGGS-Flag", "GENE_OR_GENE_PRODUCT", 67, 78], ["expression plasmids", "DNA", 14, 33], ["pCAGGS", "PROTEIN", 45, 51], ["Flag", "PROTEIN", 52, 56], ["HA", "PROTEIN", 57, 59], ["pCAGGS", "PROTEIN", 67, 73], ["Flag", "PROTEIN", 74, 78], ["HA", "PROTEIN", 79, 81], ["The resulting expression plasmids", "TREATMENT", 0, 33], ["HA", "PROBLEM", 57, 59], ["HA", "PROBLEM", 79, 81], ["SDD", "PROBLEM", 82, 85]]], ["All expression constructs were validated via DNA sequencing.", [["DNA", "CELLULAR_COMPONENT", 45, 48], ["All expression constructs", "TREATMENT", 0, 25], ["DNA sequencing", "TEST", 45, 59]]], ["For the luciferase reporter assay, cells cultured in 24-well plates were co-transfected with a luciferase reporter plasmid (IFN-\u03b2-Luc, NF-\u03baB-Luc, or IRF3-Luc) and pRL-TK (Promega, WI, USA), along with the indicated plasmids or empty vector for 24 h, and were then infected with SeV (10 hemagglutinating activity units/well).", [["cells", "ANATOMY", 35, 40], ["plasmids", "ANATOMY", 215, 223], ["luciferase", "GENE_OR_GENE_PRODUCT", 8, 18], ["cells", "CELL", 35, 40], ["luciferase", "GENE_OR_GENE_PRODUCT", 95, 105], ["IFN-\u03b2-Luc", "GENE_OR_GENE_PRODUCT", 124, 133], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 135, 140], ["Luc", "GENE_OR_GENE_PRODUCT", 141, 144], ["IRF3", "GENE_OR_GENE_PRODUCT", 149, 153], ["Luc", "GENE_OR_GENE_PRODUCT", 154, 157], ["Promega", "ORGANISM", 171, 178], ["SeV", "ORGANISM", 278, 281], ["luciferase", "PROTEIN", 8, 18], ["luciferase reporter plasmid", "DNA", 95, 122], ["IFN-\u03b2-Luc", "DNA", 124, 133], ["NF-\u03baB", "DNA", 135, 140], ["Luc", "DNA", 141, 144], ["IRF3", "DNA", 149, 153], ["Luc", "DNA", 154, 157], ["pRL", "DNA", 163, 166], ["TK", "DNA", 167, 169], ["plasmids", "DNA", 215, 223], ["SeV", "SPECIES", 278, 281], ["the luciferase reporter assay", "TEST", 4, 33], ["cells cultured", "TEST", 35, 49], ["a luciferase reporter plasmid", "TEST", 93, 122], ["IFN", "TEST", 124, 127], ["Luc", "TEST", 130, 133], ["NF", "TEST", 135, 137], ["B", "TEST", 139, 140], ["IRF3", "TEST", 149, 153], ["pRL", "TEST", 163, 166], ["empty vector", "TREATMENT", 227, 239], ["SeV (10 hemagglutinating activity units", "TREATMENT", 278, 317]]], ["At 12 h post-infection, the cells were lysed, and firefly luciferase and Renilla luciferase activities were detected through the dual-luciferase reporter assay system according to the protocol from the manufacturer (Promega).", [["cells", "ANATOMY", 28, 33], ["cells", "CELL", 28, 33], ["luciferase", "GENE_OR_GENE_PRODUCT", 58, 68], ["Renilla", "GENE_OR_GENE_PRODUCT", 73, 80], ["luciferase", "GENE_OR_GENE_PRODUCT", 81, 91], ["luciferase", "GENE_OR_GENE_PRODUCT", 134, 144], ["luciferase", "PROTEIN", 58, 68], ["luciferase", "PROTEIN", 81, 91], ["infection", "PROBLEM", 13, 22], ["the cells", "PROBLEM", 24, 33], ["firefly luciferase", "TEST", 50, 68], ["Renilla luciferase activities", "TEST", 73, 102], ["infection", "OBSERVATION", 13, 22]]], ["Representative data from three independently conducted experiments are shown as the relative firefly luciferase activities with normalization to the Renilla luciferase activities.RNA Extraction and Quantitative Real-Time RT-PCR ::: Materials and MethodsHEK-293T cells in 24-well plates were transfected with increasing amounts of NS7a expression plasmids or empty vector.", [["MethodsHEK-293T cells", "ANATOMY", 246, 267], ["plasmids", "ANATOMY", 346, 354], ["luciferase", "GENE_OR_GENE_PRODUCT", 101, 111], ["luciferase", "GENE_OR_GENE_PRODUCT", 157, 167], ["MethodsHEK-293T cells", "CELL", 246, 267], ["NS7a", "GENE_OR_GENE_PRODUCT", 330, 334], ["luciferase", "PROTEIN", 101, 111], ["luciferase", "PROTEIN", 157, 167], ["MethodsHEK-293T cells", "CELL_LINE", 246, 267], ["NS7a expression plasmids", "DNA", 330, 354], ["empty vector", "DNA", 358, 370], ["Representative data", "TEST", 0, 19], ["RNA Extraction", "TEST", 179, 193], ["Materials", "TEST", 232, 241], ["MethodsHEK", "TEST", 246, 256], ["NS7a expression plasmids", "TREATMENT", 330, 354], ["firefly luciferase", "OBSERVATION", 93, 111], ["Renilla luciferase", "OBSERVATION", 149, 167], ["increasing", "OBSERVATION_MODIFIER", 308, 318], ["amounts", "OBSERVATION_MODIFIER", 319, 326], ["empty vector", "OBSERVATION", 358, 370]]], ["After 24 h, the cells were left untreated or infected with SeV for 12 h.", [["cells", "ANATOMY", 16, 21], ["cells", "CELL", 16, 21], ["SeV", "ORGANISM", 59, 62], ["SeV", "SPECIES", 59, 62], ["the cells", "PROBLEM", 12, 21], ["left", "ANATOMY_MODIFIER", 27, 31], ["infected", "OBSERVATION", 45, 53]]], ["Total RNA was extracted from the cells using TRIzol reagent (Invitrogen), followed by first-strand cDNA synthesis by using avian myeloblastosis virus (AMV) reverse transcriptase (TaKaRa, Japan) with the indicated primers (Table 1).", [["cells", "ANATOMY", 33, 38], ["avian myeloblastosis", "DISEASE", 123, 143], ["cells", "CELL", 33, 38], ["avian myeloblastosis virus", "ORGANISM", 123, 149], ["AMV", "ORGANISM", 151, 154], ["avian myeloblastosis virus (AMV) reverse transcriptase", "PROTEIN", 123, 177], ["avian myeloblastosis virus", "SPECIES", 123, 149], ["avian myeloblastosis virus", "SPECIES", 123, 149], ["AMV", "SPECIES", 151, 154], ["Total RNA", "PROBLEM", 0, 9], ["TRIzol reagent", "TREATMENT", 45, 59], ["strand cDNA synthesis", "TREATMENT", 92, 113], ["avian myeloblastosis virus", "TREATMENT", 123, 149], ["transcriptase (TaKaRa, Japan)", "TREATMENT", 164, 193]]], ["The above cDNA (0.5 \u03bcl of the 20 \u03bcl RT reaction mixture) were used as templates and subjected to SYBR green PCR assays (Applied Biosystems) at least three times.", [["cDNA", "DNA", 10, 14], ["The above cDNA", "TREATMENT", 0, 14], ["the 20 \u03bcl RT reaction mixture", "TREATMENT", 26, 55], ["SYBR green PCR assays", "TEST", 97, 118]]], ["The results are expressed as the relative gene expression level with normalization to the expression level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH).Lentivirus Packaging ::: Materials and MethodsThe lentiviral expression plasmid pLvx-P2A-mCherry-IKK\u03b5-Flag was generated by cloning IKK\u03b5 with the Flag tag at the C-terminus into the lentiviral vector pLvx-P2A-mCherry, which was constructed via the introduction of the P2A sequence (GGAAGCGGAGCTACTAACTTCAGCCTGCTGAAGCAGGCTGGAGACGTGGAGGAGAACCCTGGACCT) into the N-terminal of mCherry in the lentiviral vector pLvx-mCherry (TaKaRa, Japan), as reported previously (Wang Y. et al., 2015).", [["glyceraldehyde-3-phosphate", "CHEMICAL", 110, 136], ["glyceraldehyde-3-phosphate", "CHEMICAL", 110, 136], ["glyceraldehyde-3-phosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 110, 150], ["GAPDH", "GENE_OR_GENE_PRODUCT", 152, 157], ["Lentivirus", "ORGANISM", 159, 169], ["lentiviral", "ORGANISM", 209, 219], ["pLvx-P2A-mCherry-IKK\u03b5-Flag", "GENE_OR_GENE_PRODUCT", 239, 265], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 291, 295], ["Flag", "GENE_OR_GENE_PRODUCT", 305, 309], ["lentiviral", "ORGANISM", 341, 351], ["pLvx", "GENE_OR_GENE_PRODUCT", 359, 363], ["mCherry", "GENE_OR_GENE_PRODUCT", 368, 375], ["P2A", "GENE_OR_GENE_PRODUCT", 427, 430], ["mCherry", "GENE_OR_GENE_PRODUCT", 532, 539], ["lentiviral", "ORGANISM", 547, 557], ["TaKaRa", "GENE_OR_GENE_PRODUCT", 579, 585], ["glyceraldehyde-3-phosphate dehydrogenase", "PROTEIN", 110, 150], ["GAPDH", "PROTEIN", 152, 157], ["P2A", "PROTEIN", 244, 247], ["IKK\u03b5-Flag", "PROTEIN", 256, 265], ["IKK\u03b5", "PROTEIN", 291, 295], ["Flag tag", "PROTEIN", 305, 313], ["C-terminus", "PROTEIN", 321, 331], ["pLvx", "DNA", 359, 363], ["P2A", "DNA", 364, 367], ["mCherry", "DNA", 368, 375], ["P2A sequence", "DNA", 427, 439], ["N-terminal of mCherry", "PROTEIN", 518, 539], ["mCherry", "DNA", 570, 577], ["Lentivirus", "SPECIES", 159, 169], ["glyceraldehyde", "TEST", 110, 124], ["phosphate dehydrogenase (GAPDH)", "PROBLEM", 127, 158], ["Methods", "TEST", 198, 205], ["The lentiviral expression plasmid", "TEST", 205, 238], ["the Flag tag", "TEST", 301, 313], ["the P2A sequence", "TREATMENT", 423, 439], ["Flag tag", "OBSERVATION", 305, 313], ["lentiviral vector", "OBSERVATION", 547, 564]]], ["Lentivirus-assisted plasmids pLP1, pLP2, and pLP-VSV-G were kindly provided by Dr. Xing Liu at the Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Sciences.", [["plasmids", "ANATOMY", 20, 28], ["Lentivirus", "ORGANISM", 0, 10], ["plasmids", "ORGANISM", 20, 28], ["pLP1", "GENE_OR_GENE_PRODUCT", 29, 33], ["pLP2", "GENE_OR_GENE_PRODUCT", 35, 39], ["pLP-VSV-G", "ORGANISM", 45, 54], ["Lentivirus-assisted plasmids", "DNA", 0, 28], ["pLP1", "DNA", 29, 33], ["pLP2", "DNA", 35, 39], ["pLP", "DNA", 45, 48], ["Lentivirus", "SPECIES", 0, 10], ["Lentivirus-assisted plasmids pLP1", "TREATMENT", 0, 33], ["pLP2", "TEST", 35, 39], ["pLP", "TEST", 45, 48]]], ["The recombinant lentiviruses were packaged as described previously (Ke et al., 2017).", [["lentiviruses", "ORGANISM", 16, 28], ["The recombinant lentiviruses", "TREATMENT", 0, 28], ["recombinant", "OBSERVATION_MODIFIER", 4, 15], ["lentiviruses", "OBSERVATION", 16, 28]]], ["For the establishment of a cell line overexpressing IKK\u03b5-Flag, IPI-2I cells cultured in 24-well plates were inoculated with the recombinant lentivirus expressing IKK\u03b5-Flag.", [["cell line", "ANATOMY", 27, 36], ["IPI-2I cells", "ANATOMY", 63, 75], ["cell line", "CELL", 27, 36], ["IKK", "GENE_OR_GENE_PRODUCT", 52, 55], ["Flag", "GENE_OR_GENE_PRODUCT", 57, 61], ["IPI-2I cells", "CELL", 63, 75], ["lentivirus", "ORGANISM", 140, 150], ["IKK", "GENE_OR_GENE_PRODUCT", 162, 165], ["Flag", "GENE_OR_GENE_PRODUCT", 167, 171], ["IKK", "PROTEIN", 52, 55], ["\u03b5", "PROTEIN", 55, 56], ["Flag", "PROTEIN", 57, 61], ["IPI-2I cells", "CELL_LINE", 63, 75], ["IKK\u03b5-Flag", "PROTEIN", 162, 171], ["lentivirus", "SPECIES", 140, 150], ["a cell line", "TREATMENT", 25, 36], ["IPI", "TEST", 63, 66], ["2I cells", "TEST", 67, 75], ["the recombinant lentivirus", "TREATMENT", 124, 150], ["cell line", "OBSERVATION", 27, 36]]], ["After 24 h, the cells were passaged and 1 \u03bcg/ml of puromycin (Sigma, MA, USA) was added to the cell culture for positive cell selection.", [["cells", "ANATOMY", 16, 21], ["cell", "ANATOMY", 95, 99], ["cell", "ANATOMY", 121, 125], ["puromycin", "CHEMICAL", 51, 60], ["puromycin", "CHEMICAL", 51, 60], ["cells", "CELL", 16, 21], ["puromycin", "SIMPLE_CHEMICAL", 51, 60], ["cell", "CELL", 95, 99], ["cell", "CELL", 121, 125], ["the cells", "TREATMENT", 12, 21], ["puromycin", "TREATMENT", 51, 60], ["the cell culture", "TEST", 91, 107], ["positive cell selection", "PROBLEM", 112, 135], ["positive cell selection", "OBSERVATION", 112, 135]]], ["The positive cells were further cloned by the limited dilution method continuously and the obtained cell clones overexpressing IKK\u03b5-Flag were confirmed by fluorescence microscopy and a western blot assay.IFN Bioassay ::: Materials and MethodsIFN bioassays were performed in HEK-293T cells by using recombinant VSV-GFP as described previously (Cardenas et al., 2006; Fang et al., 2018).Co-immunoprecipitation (Co-IP) and Western Blot Analysis ::: Materials and MethodsFor the Co-IP experiment, cells grown in 60-mm dishes were co-transfected with the appropriate expression constructs encoding Flag, HA, or Myc-tagged proteins for 24 h.", [["cells", "ANATOMY", 13, 18], ["cell clones", "ANATOMY", 100, 111], ["HEK-293T cells", "ANATOMY", 274, 288], ["cells", "ANATOMY", 493, 498], ["cells", "CELL", 13, 18], ["cell clones", "CELL", 100, 111], ["IKK", "GENE_OR_GENE_PRODUCT", 127, 130], ["Flag", "GENE_OR_GENE_PRODUCT", 132, 136], ["HEK-293T cells", "CELL", 274, 288], ["VSV", "ORGANISM", 310, 313], ["GFP", "GENE_OR_GENE_PRODUCT", 314, 317], ["cells", "CELL", 493, 498], ["Flag", "GENE_OR_GENE_PRODUCT", 593, 597], ["HA", "GENE_OR_GENE_PRODUCT", 599, 601], ["positive cells", "CELL_TYPE", 4, 18], ["cell clones", "CELL_LINE", 100, 111], ["IKK", "PROTEIN", 127, 130], ["\u03b5-Flag", "PROTEIN", 130, 136], ["IFN", "PROTEIN", 204, 207], ["HEK-293T cells", "CELL_LINE", 274, 288], ["GFP", "PROTEIN", 314, 317], ["expression constructs", "DNA", 562, 583], ["Flag", "PROTEIN", 593, 597], ["HA", "PROTEIN", 599, 601], ["Myc-tagged proteins", "PROTEIN", 606, 625], ["VSV", "SPECIES", 310, 313], ["The positive cells", "PROBLEM", 0, 18], ["fluorescence microscopy", "TEST", 155, 178], ["a western blot assay", "TEST", 183, 203], ["MethodsIFN bioassays", "TEST", 235, 255], ["Methods", "TREATMENT", 460, 467], ["the Co-IP experiment", "TEST", 471, 491], ["cells", "TEST", 493, 498], ["HA", "PROBLEM", 599, 601], ["positive cells", "OBSERVATION", 4, 18]]], ["The cells were washed with phosphate-buffered saline (PBS) and then lysed for 40 min at 4\u00b0C with 0.5 ml of lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 10% glycerin, 0.1% SDS, 2 mM Na2EDTA, pH 7.4).", [["cells", "ANATOMY", 4, 9], ["phosphate", "CHEMICAL", 27, 36], ["Tris-HCl", "CHEMICAL", 127, 135], ["NaCl", "CHEMICAL", 144, 148], ["NP-40", "CHEMICAL", 153, 158], ["glycerin", "CHEMICAL", 164, 172], ["Na2EDTA", "CHEMICAL", 189, 196], ["phosphate", "CHEMICAL", 27, 36], ["Tris-HCl", "CHEMICAL", 127, 135], ["NaCl", "CHEMICAL", 144, 148], ["glycerin", "CHEMICAL", 164, 172], ["Na2EDTA", "CHEMICAL", 189, 196], ["cells", "CELL", 4, 9], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 27, 52], ["Tris-HCl", "SIMPLE_CHEMICAL", 127, 135], ["glycerin", "SIMPLE_CHEMICAL", 164, 172], ["Na2EDTA", "SIMPLE_CHEMICAL", 189, 196], ["phosphate-buffered saline (PBS", "TREATMENT", 27, 57], ["lysis buffer", "TREATMENT", 107, 119], ["NaCl", "TREATMENT", 144, 148], ["1% NP", "TREATMENT", 150, 155], ["glycerin", "TREATMENT", 164, 172], ["pH", "TEST", 198, 200]]], ["A portion of each supernatant from the lysed cells was used in the whole-cell extract assay.", [["supernatant", "ANATOMY", 18, 29], ["cells", "ANATOMY", 45, 50], ["cell", "ANATOMY", 73, 77], ["cells", "CELL", 45, 50], ["cell", "CELL", 73, 77], ["lysed cells", "CELL_LINE", 39, 50], ["the lysed cells", "TREATMENT", 35, 50], ["lysed cells", "OBSERVATION", 39, 50]]], ["The remaining portions of the supernatants were immunoprecipitated with indicated antibodies overnight at 4\u00b0C, followed by the addition with protein A+G agarose beads (Beyotime, Shanghai, China) for 4 h at 4\u00b0C. The agarose beads containing immunocomplexes were washed three times with 1 ml of lysis buffer.", [["supernatants", "ANATOMY", 30, 42], ["agarose", "SIMPLE_CHEMICAL", 215, 222], ["antibodies", "PROTEIN", 82, 92], ["immunocomplexes", "PROTEIN", 240, 255], ["antibodies", "TEST", 82, 92], ["protein A+G agarose beads", "TREATMENT", 141, 166], ["The agarose beads containing immunocomplexes", "TREATMENT", 211, 255], ["lysis buffer", "TREATMENT", 293, 305], ["agarose beads", "OBSERVATION", 215, 228], ["immunocomplexes", "OBSERVATION", 240, 255]]], ["Whole-cell lysates (WCL) and immunoprecipitation (IP) complexes were separated by 12% SDS-PAGE and transferred to a polyvinylidene difluoride membrane (Millipore, Darmstadt, Germany).", [["Whole-cell lysates", "ANATOMY", 0, 18], ["WCL", "ANATOMY", 20, 23], ["polyvinylidene", "CHEMICAL", 116, 130], ["difluoride", "CHEMICAL", 131, 141], ["cell lysates", "ORGANISM_SUBSTANCE", 6, 18], ["WCL", "CELL", 20, 23], ["membrane", "CELLULAR_COMPONENT", 142, 150], ["WCL", "PROTEIN", 20, 23], ["immunoprecipitation (IP) complexes", "PROTEIN", 29, 63], ["Whole-cell lysates (WCL)", "TREATMENT", 0, 24], ["immunoprecipitation (IP) complexes", "TREATMENT", 29, 63], ["a polyvinylidene difluoride membrane", "TREATMENT", 114, 150]]], ["The membrane containing proteins were blocked with 5% nonfat milk in PBST with 0.1% polysorbate-20, followed by treatment with the indicated primary antibodies.", [["membrane", "ANATOMY", 4, 12], ["nonfat milk", "ANATOMY", 54, 65], ["polysorbate-20", "CHEMICAL", 84, 98], ["polysorbate-20", "CHEMICAL", 84, 98], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["milk", "ORGANISM_SUBSTANCE", 61, 65], ["polysorbate-20", "SIMPLE_CHEMICAL", 84, 98], ["primary antibodies", "PROTEIN", 141, 159], ["PBST", "TEST", 69, 73], ["0.1% polysorbate", "TREATMENT", 79, 95], ["treatment", "TREATMENT", 112, 121]]], ["Four hours later at room temperature, the membranes were washed three times with PBST, and then incubated with HRP-conjugated secondary antibodies (Beyotime, Shanghai, China).", [["membranes", "ANATOMY", 42, 51], ["membranes", "CELLULAR_COMPONENT", 42, 51], ["HRP", "SIMPLE_CHEMICAL", 111, 114], ["HRP", "PROTEIN", 111, 114], ["PBST", "TREATMENT", 81, 85], ["HRP", "TEST", 111, 114]]], ["After 45 min at room temperature, the membrane was washed three times and then visualized via enhanced chemiluminescence reagents (Bio-Rad, California, USA). \u03b2-actin served as a protein loading control and was detected with a mouse anti-\u03b2-actin monoclonal antibody.Indirect Immunofluorescence Assay (IFA) ::: Materials and MethodsThe IFA was performed as described previously (Fang et al., 2018).", [["membrane", "ANATOMY", 38, 46], ["membrane", "CELLULAR_COMPONENT", 38, 46], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 158, 165], ["mouse", "ORGANISM", 226, 231], ["\u03b2-actin", "PROTEIN", 158, 165], ["mouse anti-\u03b2-actin monoclonal antibody", "PROTEIN", 226, 264], ["mouse", "SPECIES", 226, 231], ["mouse", "SPECIES", 226, 231], ["enhanced chemiluminescence reagents", "TREATMENT", 94, 129], ["\u03b2-actin", "TREATMENT", 158, 165], ["a protein loading control", "TREATMENT", 176, 201], ["a mouse anti-\u03b2-actin monoclonal antibody", "TREATMENT", 224, 264], ["Indirect Immunofluorescence Assay", "TEST", 265, 298], ["The IFA", "TEST", 330, 337]]], ["Briefly, cells seeded onto coverslips in 24-well plates were treated according to various experiments.", [["cells", "ANATOMY", 9, 14], ["coverslips", "ANATOMY", 27, 37], ["cells", "CELL", 9, 14], ["coverslips", "TEST", 27, 37]]], ["At the indicted time, the cells were harvested and fixed with 4% paraformaldehyde for 15 min and then permeated with methyl alcohol for 10 min at room temperature.", [["cells", "ANATOMY", 26, 31], ["methyl alcohol", "CHEMICAL", 117, 131], ["paraformaldehyde", "CHEMICAL", 65, 81], ["methyl alcohol", "CHEMICAL", 117, 131], ["cells", "CELL", 26, 31], ["paraformaldehyde", "SIMPLE_CHEMICAL", 65, 81], ["methyl alcohol", "SIMPLE_CHEMICAL", 117, 131], ["4% paraformaldehyde", "TREATMENT", 62, 81]]], ["The cells were washed with PBST and then blocked with 5% bovine serum albumin for 1 h at 37\u00b0C. The cells were incubated separately with primary antibodies for 1 h at 37\u00b0C followed by treatment with Alexa Fluor 594-conjugated donkey anti-mouse IgG and Alexa Fluor 488-conjugated donkey anti-rabbit IgG as secondary antibodies for 1 h at 37\u00b0C. Subsequently, the above treated cells were stained with DAPI for 15 min at room temperature.", [["cells", "ANATOMY", 4, 9], ["serum", "ANATOMY", 64, 69], ["cells", "ANATOMY", 99, 104], ["cells", "ANATOMY", 374, 379], ["Alexa Fluor 594", "CHEMICAL", 198, 213], ["Alexa Fluor 594", "CHEMICAL", 198, 213], ["Alexa Fluor 488", "CHEMICAL", 251, 266], ["DAPI", "CHEMICAL", 398, 402], ["cells", "CELL", 4, 9], ["bovine", "ORGANISM", 57, 63], ["serum", "ORGANISM_SUBSTANCE", 64, 69], ["albumin", "ORGANISM_SUBSTANCE", 70, 77], ["cells", "CELL", 99, 104], ["Alexa Fluor 594", "SIMPLE_CHEMICAL", 198, 213], ["Alexa Fluor 488", "SIMPLE_CHEMICAL", 251, 266], ["cells", "CELL", 374, 379], ["DAPI", "SIMPLE_CHEMICAL", 398, 402], ["primary antibodies", "PROTEIN", 136, 154], ["Alexa Fluor 594-conjugated donkey anti-mouse IgG", "PROTEIN", 198, 246], ["Alexa Fluor 488-conjugated donkey anti-rabbit IgG", "PROTEIN", 251, 300], ["secondary antibodies", "PROTEIN", 304, 324], ["treated cells", "CELL_LINE", 366, 379], ["bovine", "SPECIES", 57, 63], ["donkey", "SPECIES", 225, 231], ["anti-mouse", "SPECIES", 232, 242], ["donkey", "SPECIES", 278, 284], ["anti-rabbit", "SPECIES", 285, 296], ["bovine", "SPECIES", 57, 63], ["Alexa Fluor 594", "SPECIES", 198, 213], ["donkey", "SPECIES", 225, 231], ["anti-rabbit", "SPECIES", 285, 296], ["PBST", "TREATMENT", 27, 31], ["5% bovine serum albumin", "TREATMENT", 54, 77], ["Alexa Fluor", "TEST", 198, 209], ["conjugated donkey anti-mouse IgG", "TEST", 214, 246], ["Alexa Fluor", "TEST", 251, 262], ["conjugated donkey anti-rabbit IgG", "TREATMENT", 267, 300], ["secondary antibodies", "PROBLEM", 304, 324], ["the above treated cells", "TREATMENT", 356, 379], ["DAPI", "TREATMENT", 398, 402]]], ["Fluorescent images were visualized by using a confocal laser scanning microscope (Fluoviewver.3.1; Olympus, Japan) after three washes with PBS.Statistical Analysis ::: Materials and MethodsStatistical differences were determined by one-way ANOVAs using GraphPad Prism 5.0 software.", [["Fluorescent images", "TEST", 0, 18], ["a confocal laser scanning microscope", "TEST", 44, 80], ["Olympus", "TREATMENT", 99, 106], ["PBS", "TREATMENT", 139, 142]]], ["For all experiments, differences were considered to be statistically significant when p-values were < 0.05.PDCoV NS7a Impairs SeV-Induced IFN-\u03b2 Production ::: ResultsTo determine whether PDCoV NS7a inhibits IFN-\u03b2 production, HEK-293T cells, LLC-PK1 cells, or IPI-2I were co-transfected with increasing amounts of pCAGGS-HA-NS7a or empty vector along with the firefly luciferase reporter plasmid IFN-\u03b2-Luc and Renilla luciferase reporter plasmid pRL-TK (as an internal control) for 24 h, and this was followed by treatment with SeV for 12 h.", [["HEK-293T cells", "ANATOMY", 225, 239], ["LLC-PK1 cells", "ANATOMY", 241, 254], ["IPI-2I", "ANATOMY", 259, 265], ["SeV", "ORGANISM", 126, 129], ["PDCoV NS7a", "GENE_OR_GENE_PRODUCT", 187, 197], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 207, 212], ["HEK-293T cells", "CELL", 225, 239], ["LLC-PK1 cells", "CELL", 241, 254], ["IPI-2I", "CELL", 259, 265], ["pCAGGS-HA-NS7a", "GENE_OR_GENE_PRODUCT", 313, 327], ["luciferase", "GENE_OR_GENE_PRODUCT", 367, 377], ["IFN-\u03b2-Luc", "GENE_OR_GENE_PRODUCT", 395, 404], ["luciferase", "GENE_OR_GENE_PRODUCT", 417, 427], ["pRL-TK", "GENE_OR_GENE_PRODUCT", 445, 451], ["SeV", "ORGANISM", 527, 530], ["NS7a", "PROTEIN", 113, 117], ["IFN", "PROTEIN", 138, 141], ["PDCoV NS7a", "PROTEIN", 187, 197], ["IFN", "PROTEIN", 207, 210], ["HEK-293T cells", "CELL_LINE", 225, 239], ["LLC-PK1 cells", "CELL_LINE", 241, 254], ["IPI-2I", "CELL_LINE", 259, 265], ["pCAGGS-HA-NS7a or empty vector", "DNA", 313, 343], ["firefly luciferase reporter plasmid IFN-\u03b2-Luc and Renilla luciferase reporter plasmid pRL-TK", "DNA", 359, 451], ["PDCoV", "SPECIES", 107, 112], ["PDCoV", "SPECIES", 187, 192], ["p-values", "TEST", 86, 94], ["PDCoV", "TEST", 187, 192], ["IFN", "TEST", 207, 210], ["HEK", "TEST", 225, 228], ["cells", "TEST", 234, 239], ["LLC", "TEST", 241, 244], ["PK1 cells", "TEST", 245, 254], ["IPI", "TEST", 259, 262], ["pCAGGS", "TEST", 313, 319], ["HA", "PROBLEM", 320, 322], ["NS7a", "TREATMENT", 323, 327], ["empty vector", "TREATMENT", 331, 343], ["the firefly luciferase", "TREATMENT", 355, 377], ["Renilla luciferase", "TEST", 409, 427], ["plasmid pRL", "TEST", 437, 448], ["an internal control", "TREATMENT", 456, 475], ["LLC", "ANATOMY", 241, 244]]], ["The cell lysates were collected and subjected to the dual-luciferase reporter assay.", [["cell lysates", "ANATOMY", 4, 16], ["cell lysates", "CELL", 4, 16], ["luciferase", "GENE_OR_GENE_PRODUCT", 58, 68], ["The cell lysates", "TEST", 0, 16], ["cell lysates", "OBSERVATION", 4, 16]]], ["The results showed that SeV significantly induced the activation of the IFN-\u03b2-Luc promoter, but upregulation of IFN-\u03b2 promoter activation was impaired by NS7a protein expression in all three tested cell lines (Figures 1A\u2013C, Supplementary Tables 1\u20133).", [["cell lines", "ANATOMY", 198, 208], ["SeV", "ORGANISM", 24, 27], ["IFN-\u03b2-Luc", "GENE_OR_GENE_PRODUCT", 72, 81], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 112, 117], ["NS7a", "GENE_OR_GENE_PRODUCT", 154, 158], ["cell lines", "CELL", 198, 208], ["IFN-\u03b2-Luc promoter", "DNA", 72, 90], ["IFN-\u03b2 promoter", "DNA", 112, 126], ["NS7a", "PROTEIN", 154, 158], ["cell lines", "CELL_LINE", 198, 208], ["Luc promoter", "TREATMENT", 78, 90], ["IFN-\u03b2 promoter activation", "TREATMENT", 112, 137], ["NS7a protein expression", "TREATMENT", 154, 177], ["cell lines", "OBSERVATION", 198, 208]]], ["Additionally, an IFN bioassay was performed using an IFN-sensitive VSV-GFP in HEK-293T cells.", [["HEK-293T cells", "ANATOMY", 78, 92], ["IFN-", "GENE_OR_GENE_PRODUCT", 53, 57], ["VSV", "ORGANISM", 67, 70], ["GFP", "GENE_OR_GENE_PRODUCT", 71, 74], ["HEK-293T cells", "CELL", 78, 92], ["IFN", "PROTEIN", 17, 20], ["IFN-", "PROTEIN", 53, 57], ["GFP", "PROTEIN", 71, 74], ["HEK-293T cells", "CELL_LINE", 78, 92], ["VSV", "SPECIES", 67, 70], ["an IFN bioassay", "TEST", 14, 29], ["an IFN-sensitive VSV", "TEST", 50, 70], ["293T cells", "OBSERVATION", 82, 92]]], ["Consistent with the results from the IFN-\u03b2-Luc reporter assay, cellular supernatants from SeV-infected cells notably restricted the replication of VSV-GFP (Figure 1D).", [["cellular supernatants", "ANATOMY", 63, 84], ["cells", "ANATOMY", 103, 108], ["cellular", "CELL", 63, 71], ["SeV", "ORGANISM", 90, 93], ["cells", "CELL", 103, 108], ["VSV", "ORGANISM", 147, 150], ["GFP", "GENE_OR_GENE_PRODUCT", 151, 154], ["IFN", "PROTEIN", 37, 40], ["SeV-infected cells", "CELL_LINE", 90, 108], ["GFP", "PROTEIN", 151, 154], ["SeV", "SPECIES", 90, 93], ["VSV", "SPECIES", 147, 150], ["Luc reporter assay", "TEST", 43, 61], ["cellular supernatants", "TEST", 63, 84], ["SeV-infected cells", "TREATMENT", 90, 108], ["infected cells", "OBSERVATION", 94, 108]]], ["However, the natural replication of VSV-GFP was, to a large extent, restored via the presence of supernatants from cells expressing NS7a when compared with that of supernatants from empty vector-transfected cells.", [["supernatants", "ANATOMY", 97, 109], ["cells", "ANATOMY", 115, 120], ["supernatants", "ANATOMY", 164, 176], ["cells", "ANATOMY", 207, 212], ["VSV", "ORGANISM", 36, 39], ["GFP", "GENE_OR_GENE_PRODUCT", 40, 43], ["cells", "CELL", 115, 120], ["NS7a", "GENE_OR_GENE_PRODUCT", 132, 136], ["cells", "CELL", 207, 212], ["GFP", "PROTEIN", 40, 43], ["NS7a", "PROTEIN", 132, 136], ["transfected cells", "CELL_LINE", 195, 212], ["VSV", "SPECIES", 36, 39], ["supernatants from cells", "PROBLEM", 97, 120], ["large", "OBSERVATION_MODIFIER", 54, 59], ["extent", "OBSERVATION_MODIFIER", 60, 66], ["transfected cells", "OBSERVATION", 195, 212]]], ["In line with the results from Figure 1D, western blot results showed that the expression of EGFP was significantly inhibited by cellular supernatants from SeV-infected cells but was partially rescued in the presence of supernatants from cells expressing NS7a (Figure 1E).", [["cellular supernatants", "ANATOMY", 128, 149], ["cells", "ANATOMY", 168, 173], ["supernatants", "ANATOMY", 219, 231], ["cells", "ANATOMY", 237, 242], ["EGFP", "GENE_OR_GENE_PRODUCT", 92, 96], ["cellular", "CELL", 128, 136], ["SeV", "ORGANISM", 155, 158], ["cells", "CELL", 168, 173], ["cells", "CELL", 237, 242], ["NS7a", "GENE_OR_GENE_PRODUCT", 254, 258], ["Figure 1E", "GENE_OR_GENE_PRODUCT", 260, 269], ["EGFP", "PROTEIN", 92, 96], ["SeV-infected cells", "CELL_LINE", 155, 173], ["NS7a", "PROTEIN", 254, 258], ["western blot", "TEST", 41, 53], ["the expression of EGFP", "PROBLEM", 74, 96], ["cellular supernatants", "PROBLEM", 128, 149], ["SeV-infected cells", "PROBLEM", 155, 173], ["infected cells", "OBSERVATION", 159, 173]]], ["To confirm the inhibition of IFN-\u03b2 production on the mRNA level by PDCoV NS7a, the real-time RT-PCR assay was performed in HEK-293T cells.", [["HEK-293T cells", "ANATOMY", 123, 137], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 29, 34], ["HEK-293T cells", "CELL", 123, 137], ["IFN", "PROTEIN", 29, 32], ["\u03b2", "PROTEIN", 33, 34], ["PDCoV NS7a", "PROTEIN", 67, 77], ["HEK-293T cells", "CELL_LINE", 123, 137], ["PDCoV", "SPECIES", 67, 72], ["IFN", "PROBLEM", 29, 32], ["PCR assay", "TEST", 96, 105]]], ["As shown in Figure 1F, ectopic expression of NS7a notably inhibited SeV-induced IFN-\u03b2 mRNA expression levels.", [["NS7a", "GENE_OR_GENE_PRODUCT", 45, 49], ["SeV", "ORGANISM", 68, 71], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 80, 85], ["NS7a", "PROTEIN", 45, 49], ["IFN", "PROTEIN", 80, 83], ["ectopic expression of NS7a", "PROBLEM", 23, 49], ["mRNA expression levels", "PROBLEM", 86, 108]]], ["These results strongly indicate that PDCoV NS7a antagonizes IFN-\u03b2 production.PDCoV NS7a Inhibits Activation of IRF3 but Not NF-\u03baB ::: ResultsTwo key transcription factors IRF3 and NF-\u03baB that bind to distinct regulatory domains in the IFN-\u03b2 promoter are essential for the induction of IFN-\u03b2 production.", [["PDCoV NS7a", "GENE_OR_GENE_PRODUCT", 37, 47], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 60, 65], ["IRF3", "GENE_OR_GENE_PRODUCT", 111, 115], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 124, 129], ["IRF3", "GENE_OR_GENE_PRODUCT", 171, 175], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 180, 185], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 234, 239], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 284, 289], ["NS7a", "PROTEIN", 43, 47], ["IFN", "PROTEIN", 60, 63], ["\u03b2", "PROTEIN", 64, 65], ["NS7a", "PROTEIN", 83, 87], ["IRF3", "PROTEIN", 111, 115], ["Not NF-\u03baB", "PROTEIN", 120, 129], ["transcription factors", "PROTEIN", 149, 170], ["IRF3", "PROTEIN", 171, 175], ["NF-\u03baB", "PROTEIN", 180, 185], ["regulatory domains", "DNA", 208, 226], ["IFN-\u03b2 promoter", "DNA", 234, 248], ["IFN", "PROTEIN", 284, 287], ["\u03b2", "PROTEIN", 288, 289], ["PDCoV", "SPECIES", 37, 42], ["PDCoV", "SPECIES", 77, 82], ["IRF3", "TEST", 171, 175], ["NF", "TEST", 180, 182], ["IFN", "PROBLEM", 284, 287]]], ["Since PDCoV NS7a inhibits IFN-\u03b2 production, we further investigated the effect of NS7a on SeV-induced activation of IRF3 and NF-\u03baB.", [["PDCoV NS7a", "GENE_OR_GENE_PRODUCT", 6, 16], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 26, 31], ["NS7a", "GENE_OR_GENE_PRODUCT", 82, 86], ["SeV", "ORGANISM", 90, 93], ["IRF3", "GENE_OR_GENE_PRODUCT", 116, 120], ["NF-\u03baB.", "GENE_OR_GENE_PRODUCT", 125, 131], ["PDCoV NS7a", "PROTEIN", 6, 16], ["IFN", "PROTEIN", 26, 29], ["\u03b2", "PROTEIN", 30, 31], ["NS7a", "PROTEIN", 82, 86], ["IRF3", "PROTEIN", 116, 120], ["NF-\u03baB.", "PROTEIN", 125, 131], ["PDCoV", "SPECIES", 6, 11], ["IFN", "PROBLEM", 26, 29], ["NS7a", "TREATMENT", 82, 86], ["SeV", "TREATMENT", 90, 93]]], ["To this end, HEK-293T cells, LLC-PK1 cells, or IPI-2I cells were co-transfected with the NS7a expression plasmid and reporter plasmid IRF3-Luc or NF-\u03baB-Luc along with the internal control plasmid pRL-TK for 24 h, and this was followed by stimulation with SeV for 12 h.", [["HEK-293T cells", "ANATOMY", 13, 27], ["LLC-PK1 cells", "ANATOMY", 29, 42], ["IPI-2I cells", "ANATOMY", 47, 59], ["HEK-293T cells", "CELL", 13, 27], ["LLC-PK1 cells", "CELL", 29, 42], ["IPI-2I cells", "CELL", 47, 59], ["NS7a", "GENE_OR_GENE_PRODUCT", 89, 93], ["IRF3", "GENE_OR_GENE_PRODUCT", 134, 138], ["Luc", "GENE_OR_GENE_PRODUCT", 139, 142], ["NF-\u03baB-Luc", "GENE_OR_GENE_PRODUCT", 146, 155], ["SeV", "ORGANISM", 255, 258], ["HEK-293T cells", "CELL_LINE", 13, 27], ["LLC-PK1 cells", "CELL_LINE", 29, 42], ["IPI-2I cells", "CELL_LINE", 47, 59], ["NS7a expression plasmid", "DNA", 89, 112], ["reporter plasmid IRF3-Luc or NF-\u03baB-Luc", "DNA", 117, 155], ["internal control plasmid pRL", "DNA", 171, 199], ["HEK", "TEST", 13, 16], ["cells", "TEST", 22, 27], ["LLC", "TEST", 29, 32], ["PK1 cells", "TEST", 33, 42], ["IPI", "TEST", 47, 50], ["2I cells", "PROBLEM", 51, 59], ["the NS7a expression plasmid", "TREATMENT", 85, 112], ["reporter plasmid IRF3", "TEST", 117, 138], ["NF", "TEST", 146, 148], ["the internal control plasmid pRL", "TREATMENT", 167, 199], ["LLC", "ANATOMY", 29, 32]]], ["As shown in Figure 2, SeV infection induced promoter activities of IRF3 and NF-\u03baB significantly, whereas overexpression of NS7a remarkably impaired the SeV-induced promoter activities of IRF3 (Figures 2A,C,E, Supplementary Tables 4, 6, 8) in a dose-dependent manner; however, NS7a did not inhibit NF-\u03baB promoter activation (Figures 2B,D,F, Supplementary Tables 5, 7, 9).PDCoV NS7a Inhibits Activation of IRF3 but Not NF-\u03baB ::: ResultsIRF3 is a key transcription factor for the induction of type I IFN, which is activated via phosphorylation and nuclear translocation, followed by the coordinated assembly of activated transcription factors and its binding to the promoter of specific defense genes to improve their transcription in the cell nucleus (Sato et al., 1998).", [["nuclear", "ANATOMY", 545, 552], ["cell nucleus", "ANATOMY", 736, 748], ["infection", "DISEASE", 26, 35], ["SeV", "ORGANISM", 22, 25], ["IRF3", "GENE_OR_GENE_PRODUCT", 67, 71], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 76, 81], ["NS7a", "GENE_OR_GENE_PRODUCT", 123, 127], ["SeV", "ORGANISM", 152, 155], ["IRF3", "GENE_OR_GENE_PRODUCT", 187, 191], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 297, 302], ["IRF3", "GENE_OR_GENE_PRODUCT", 404, 408], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 417, 422], ["ResultsIRF3", "GENE_OR_GENE_PRODUCT", 427, 438], ["type I IFN", "GENE_OR_GENE_PRODUCT", 490, 500], ["nuclear", "CELLULAR_COMPONENT", 545, 552], ["cell nucleus", "CELLULAR_COMPONENT", 736, 748], ["IRF3", "PROTEIN", 67, 71], ["NF-\u03baB", "PROTEIN", 76, 81], ["NS7a", "PROTEIN", 123, 127], ["IRF3", "PROTEIN", 187, 191], ["NS7a", "PROTEIN", 276, 280], ["NF-\u03baB promoter", "DNA", 297, 311], ["NS7a", "PROTEIN", 376, 380], ["IRF3", "PROTEIN", 404, 408], ["Not NF-\u03baB", "PROTEIN", 413, 422], ["ResultsIRF3", "PROTEIN", 427, 438], ["transcription factor", "PROTEIN", 448, 468], ["type I IFN", "PROTEIN", 490, 500], ["transcription factors", "PROTEIN", 618, 639], ["defense genes", "DNA", 684, 697], ["SeV", "SPECIES", 22, 25], ["PDCoV", "SPECIES", 370, 375], ["SeV infection", "PROBLEM", 22, 35], ["IRF3", "TEST", 67, 71], ["NF", "TEST", 76, 78], ["C,E, Supplementary Tables", "TREATMENT", 204, 229], ["type I IFN", "PROBLEM", 490, 500], ["activated transcription factors", "PROBLEM", 608, 639], ["infection", "OBSERVATION", 26, 35], ["cell nucleus", "ANATOMY", 736, 748]]], ["Because NS7a blocks SeV-induced IRF3-dependent promoter activity, the effect of NS7a on the phosphorylation and nuclear translocation of IRF3 was further investigated via western blotting and IFA.", [["nuclear", "ANATOMY", 112, 119], ["NS7a", "GENE_OR_GENE_PRODUCT", 8, 12], ["SeV", "ORGANISM", 20, 23], ["IRF3", "GENE_OR_GENE_PRODUCT", 32, 36], ["NS7a", "GENE_OR_GENE_PRODUCT", 80, 84], ["nuclear", "CELLULAR_COMPONENT", 112, 119], ["IRF3", "GENE_OR_GENE_PRODUCT", 137, 141], ["NS7a", "PROTEIN", 8, 12], ["IRF3", "PROTEIN", 32, 36], ["NS7a", "PROTEIN", 80, 84], ["IRF3", "PROTEIN", 137, 141], ["NS7a blocks", "TREATMENT", 8, 19], ["IRF3-dependent promoter activity", "TREATMENT", 32, 64], ["NS7a", "TREATMENT", 80, 84], ["the phosphorylation", "TREATMENT", 88, 107], ["IRF3", "PROBLEM", 137, 141]]], ["As expected, SeV infection significantly upregulated the level of IRF3 phosphorylation when compared with that of the mock-treated cells; however, the increase was inhibited by NS7a markedly (Figure 2G).", [["cells", "ANATOMY", 131, 136], ["infection", "DISEASE", 17, 26], ["SeV", "ORGANISM", 13, 16], ["IRF3", "GENE_OR_GENE_PRODUCT", 66, 70], ["cells", "CELL", 131, 136], ["NS7a", "SIMPLE_CHEMICAL", 177, 181], ["IRF3", "PROTEIN", 66, 70], ["mock-treated cells", "CELL_LINE", 118, 136], ["NS7a", "PROTEIN", 177, 181], ["SeV", "SPECIES", 13, 16], ["SeV infection", "PROBLEM", 13, 26], ["IRF3 phosphorylation", "PROBLEM", 66, 86], ["SeV", "OBSERVATION_MODIFIER", 13, 16], ["infection", "OBSERVATION", 17, 26], ["IRF3 phosphorylation", "OBSERVATION", 66, 86], ["increase", "OBSERVATION_MODIFIER", 151, 159]]], ["Consistent with the western blot results, the nuclear translocation of IRF3 was also blocked by NS7a (Figure 2H).", [["nuclear", "ANATOMY", 46, 53], ["nuclear", "CELLULAR_COMPONENT", 46, 53], ["IRF3", "GENE_OR_GENE_PRODUCT", 71, 75], ["IRF3", "PROTEIN", 71, 75], ["NS7a", "PROTEIN", 96, 100], ["IRF3", "PROBLEM", 71, 75]]], ["To further verify the results from IFA in Figure 2H, we performed nuclear and cytoplasmic fractionation of the cells following SeV treatment according to the manufacturer's protocol.", [["nuclear", "ANATOMY", 66, 73], ["cytoplasmic", "ANATOMY", 78, 89], ["cells", "ANATOMY", 111, 116], ["nuclear", "CELLULAR_COMPONENT", 66, 73], ["cytoplasmic", "ORGANISM_SUBSTANCE", 78, 89], ["cells", "CELL", 111, 116], ["SeV", "ORGANISM", 127, 130], ["SeV", "SPECIES", 127, 130], ["SeV treatment", "TREATMENT", 127, 140], ["the manufacturer's protocol", "TREATMENT", 154, 181]]], ["As expected, higher levels of IRF3 were found in the nuclear fraction than in the cytoplasmic fraction after SeV treatment of vector-transfected cells (Figure 2I, lanes 2 and 6).", [["nuclear fraction", "ANATOMY", 53, 69], ["cytoplasmic fraction", "ANATOMY", 82, 102], ["cells", "ANATOMY", 145, 150], ["IRF3", "GENE_OR_GENE_PRODUCT", 30, 34], ["nuclear", "CELLULAR_COMPONENT", 53, 60], ["cytoplasmic", "ORGANISM_SUBSTANCE", 82, 93], ["SeV", "ORGANISM", 109, 112], ["cells", "CELL", 145, 150], ["IRF3", "PROTEIN", 30, 34], ["transfected cells", "CELL_LINE", 133, 150], ["SeV", "SPECIES", 109, 112], ["higher levels of IRF3", "PROBLEM", 13, 34], ["SeV treatment of vector", "TREATMENT", 109, 132], ["transfected cells", "PROBLEM", 133, 150], ["IRF3", "OBSERVATION", 30, 34]]], ["In contrast, in the NS7a-transfected cells after SeV stimulation, more IRF3 proteins were detected in the cytoplasmic fraction than in the nuclear fraction (Figure 2I, lanes 4 and 8).", [["cells", "ANATOMY", 37, 42], ["cytoplasmic fraction", "ANATOMY", 106, 126], ["nuclear fraction", "ANATOMY", 139, 155], ["NS7a", "GENE_OR_GENE_PRODUCT", 20, 24], ["cells", "CELL", 37, 42], ["SeV", "ORGANISM", 49, 52], ["IRF3", "GENE_OR_GENE_PRODUCT", 71, 75], ["cytoplasmic", "ORGANISM_SUBSTANCE", 106, 117], ["NS7a-transfected cells", "CELL_LINE", 20, 42], ["IRF3 proteins", "PROTEIN", 71, 84], ["SeV stimulation", "TREATMENT", 49, 64], ["more IRF3 proteins", "PROBLEM", 66, 84], ["the cytoplasmic fraction", "TEST", 102, 126], ["transfected cells", "OBSERVATION", 25, 42], ["IRF3 proteins", "OBSERVATION", 71, 84], ["cytoplasmic fraction", "OBSERVATION", 106, 126], ["nuclear fraction", "ANATOMY", 139, 155]]], ["Taken together, these results strongly support the notion that PDCoV NS7a is an IFN antagonist that impairs the activation of IRF3.NS7a Disrupts IFN-\u03b2 Promoter Activation Driven by RIG-I, MDA5, MAVS, TBK1, and IKK\u03b5 but Not IRF3 ::: ResultsBecause NS7a inhibits the SeV-induced activation of IRF3 and IFN-\u03b2 production, and SeV is a strong inducer of the RIG-I-like receptor (RLR)-mediated IFN signaling pathway (Yoshida et al., 2018), we hypothesized that NS7a targets one or several molecules among the RLR pathway to inhibit IFN-\u03b2 production.", [["PDCoV NS7a", "GENE_OR_GENE_PRODUCT", 63, 73], ["IFN", "GENE_OR_GENE_PRODUCT", 80, 83], ["IRF3", "GENE_OR_GENE_PRODUCT", 126, 130], ["NS7a", "GENE_OR_GENE_PRODUCT", 131, 135], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 145, 150], ["RIG-I", "GENE_OR_GENE_PRODUCT", 181, 186], ["MDA5", "GENE_OR_GENE_PRODUCT", 188, 192], ["MAVS", "GENE_OR_GENE_PRODUCT", 194, 198], ["TBK1", "GENE_OR_GENE_PRODUCT", 200, 204], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 210, 214], ["IRF3", "GENE_OR_GENE_PRODUCT", 223, 227], ["NS7a", "GENE_OR_GENE_PRODUCT", 247, 251], ["SeV", "ORGANISM", 265, 268], ["IRF3", "GENE_OR_GENE_PRODUCT", 291, 295], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 300, 305], ["SeV", "ORGANISM", 322, 325], ["RIG-I-like receptor", "GENE_OR_GENE_PRODUCT", 353, 372], ["RLR", "GENE_OR_GENE_PRODUCT", 374, 377], ["IFN", "GENE_OR_GENE_PRODUCT", 388, 391], ["NS7a", "GENE_OR_GENE_PRODUCT", 455, 459], ["RLR", "GENE_OR_GENE_PRODUCT", 503, 506], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 526, 531], ["PDCoV NS7a", "PROTEIN", 63, 73], ["IRF3", "PROTEIN", 126, 130], ["NS7a", "PROTEIN", 131, 135], ["IFN", "PROTEIN", 145, 148], ["RIG-I", "PROTEIN", 181, 186], ["MDA5", "PROTEIN", 188, 192], ["MAVS", "PROTEIN", 194, 198], ["TBK1", "PROTEIN", 200, 204], ["IKK\u03b5", "PROTEIN", 210, 214], ["IRF3", "PROTEIN", 223, 227], ["NS7a", "PROTEIN", 247, 251], ["IRF3", "PROTEIN", 291, 295], ["IFN", "PROTEIN", 300, 303], ["\u03b2", "PROTEIN", 304, 305], ["SeV", "PROTEIN", 322, 325], ["RIG-I-like receptor", "PROTEIN", 353, 372], ["RLR", "PROTEIN", 374, 377], ["IFN", "PROTEIN", 388, 391], ["NS7a", "PROTEIN", 455, 459], ["RLR", "PROTEIN", 503, 506], ["IFN", "PROTEIN", 526, 529], ["\u03b2", "PROTEIN", 530, 531], ["SeV", "SPECIES", 322, 325], ["PDCoV NS7a", "TREATMENT", 63, 73], ["an IFN antagonist", "TREATMENT", 77, 94], ["IRF3", "PROBLEM", 126, 130], ["IRF3", "PROBLEM", 291, 295], ["IFN", "TEST", 300, 303], ["IFN", "PROBLEM", 526, 529]]], ["To test this hypothesis, HEK-293T cells were co-transfected with pCAGGS-HA-NS7a and a series of expression plasmids encoding the key molecules of the RLR signaling pathway, including RIG-I, RIG-IN (a constitutively activated RIG-I mutant), MDA-5, MAVS, TBK1, IKK\u03b5, and IRF3 along with the IFN-\u03b2-Luc reporter plasmid and pRL-TK.", [["HEK-293T cells", "ANATOMY", 25, 39], ["plasmids", "ANATOMY", 107, 115], ["HEK-293T cells", "CELL", 25, 39], ["pCAGGS-HA-NS7a", "GENE_OR_GENE_PRODUCT", 65, 79], ["RLR", "GENE_OR_GENE_PRODUCT", 150, 153], ["RIG-I", "GENE_OR_GENE_PRODUCT", 183, 188], ["RIG-IN", "GENE_OR_GENE_PRODUCT", 190, 196], ["RIG-I", "GENE_OR_GENE_PRODUCT", 225, 230], ["MDA-5", "GENE_OR_GENE_PRODUCT", 240, 245], ["MAVS", "GENE_OR_GENE_PRODUCT", 247, 251], ["TBK1", "GENE_OR_GENE_PRODUCT", 253, 257], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 259, 263], ["IRF3", "GENE_OR_GENE_PRODUCT", 269, 273], ["IFN-\u03b2-Luc", "GENE_OR_GENE_PRODUCT", 289, 298], ["pRL-TK", "GENE_OR_GENE_PRODUCT", 320, 326], ["HEK-293T cells", "CELL_LINE", 25, 39], ["pCAGGS", "PROTEIN", 65, 71], ["HA", "PROTEIN", 72, 74], ["NS7a", "DNA", 75, 79], ["expression plasmids", "DNA", 96, 115], ["RLR", "PROTEIN", 150, 153], ["RIG-I", "PROTEIN", 183, 188], ["RIG-IN", "PROTEIN", 190, 196], ["constitutively activated RIG-I mutant", "PROTEIN", 200, 237], ["MDA", "PROTEIN", 240, 243], ["MAVS", "PROTEIN", 247, 251], ["TBK1", "PROTEIN", 253, 257], ["IKK\u03b5", "PROTEIN", 259, 263], ["IRF3", "PROTEIN", 269, 273], ["IFN-\u03b2-Luc reporter plasmid", "DNA", 289, 315], ["pRL-TK", "DNA", 320, 326], ["HEK", "TEST", 25, 28], ["pCAGGS", "TEST", 65, 71], ["HA", "PROBLEM", 72, 74], ["NS7a", "TREATMENT", 75, 79], ["expression plasmids", "TREATMENT", 96, 115], ["RIG", "TEST", 190, 193], ["MDA", "TEST", 240, 243], ["MAVS", "PROBLEM", 247, 251], ["TBK1", "TEST", 253, 257], ["IKK\u03b5", "TEST", 259, 263], ["IRF3", "TEST", 269, 273], ["the IFN", "TEST", 285, 292], ["Luc reporter plasmid", "TEST", 295, 315], ["pRL", "TEST", 320, 323], ["IRF3", "ANATOMY", 269, 273], ["TK", "ANATOMY", 324, 326]]], ["The results of the dual-luciferase reporter assay indicated that all tested molecules of the RLR signaling pathway induced a significant activation of the IFN-\u03b2 promoter (Figures 3A\u2013D, Supplementary Tables 10, 11).", [["luciferase", "GENE_OR_GENE_PRODUCT", 24, 34], ["RLR", "GENE_OR_GENE_PRODUCT", 93, 96], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 155, 160], ["RLR", "PROTEIN", 93, 96], ["IFN-\u03b2 promoter", "DNA", 155, 169], ["the dual-luciferase reporter assay", "TEST", 15, 49], ["the IFN-\u03b2 promoter", "TREATMENT", 151, 169], ["significant", "OBSERVATION_MODIFIER", 125, 136]]], ["However, RIG-I/RIG-IN-, MDA-5-, MAVS-, TBK1-, and IKK\u03b5-mediated activation of the IFN-\u03b2 promoter was notably blocked by the expression of NS7a.", [["RIG-I", "GENE_OR_GENE_PRODUCT", 9, 14], ["RIG-IN", "GENE_OR_GENE_PRODUCT", 15, 21], ["MDA-5", "GENE_OR_GENE_PRODUCT", 24, 29], ["MAVS", "GENE_OR_GENE_PRODUCT", 32, 36], ["TBK1", "GENE_OR_GENE_PRODUCT", 39, 43], ["IKK", "GENE_OR_GENE_PRODUCT", 50, 53], ["\u03b5", "GENE_OR_GENE_PRODUCT", 53, 54], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 82, 87], ["NS7a", "GENE_OR_GENE_PRODUCT", 138, 142], ["RIG", "PROTEIN", 15, 18], ["MAVS", "PROTEIN", 32, 36], ["TBK1", "PROTEIN", 39, 43], ["IKK\u03b5", "PROTEIN", 50, 54], ["IFN-\u03b2 promoter", "DNA", 82, 96], ["NS7a", "PROTEIN", 138, 142], ["RIG", "TEST", 9, 12], ["RIG", "TEST", 15, 18], ["MDA", "TEST", 24, 27], ["MAVS", "TEST", 32, 36], ["TBK1", "TEST", 39, 43], ["IKK", "TEST", 50, 53]]], ["In contrast, NS7a did not inhibit IRF3-mediated IFN-\u03b2 promoter activation (Figure 3D).", [["NS7a", "GENE_OR_GENE_PRODUCT", 13, 17], ["IRF3", "GENE_OR_GENE_PRODUCT", 34, 38], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 48, 53], ["NS7a", "PROTEIN", 13, 17], ["IRF3", "PROTEIN", 34, 38], ["IFN", "PROTEIN", 48, 51], ["\u03b2 promoter", "DNA", 52, 62], ["IRF3", "PROBLEM", 34, 38]]], ["These results suggested that NS7a targets the RLR signaling pathway at the level of TBK1/IKK\u03b5.NS7a Interacts With IKK\u03b5 but Not TBK1 ::: ResultsThe potential interaction of NS7a with selected components of the RLR signaling pathway was investigated to further identify the molecule(s) targeted by NS7a.", [["NS7a", "GENE_OR_GENE_PRODUCT", 29, 33], ["RLR", "GENE_OR_GENE_PRODUCT", 46, 49], ["TBK1", "GENE_OR_GENE_PRODUCT", 84, 88], ["IKK", "GENE_OR_GENE_PRODUCT", 89, 92], ["\u03b5", "GENE_OR_GENE_PRODUCT", 92, 93], ["NS7a", "GENE_OR_GENE_PRODUCT", 94, 98], ["IKK", "GENE_OR_GENE_PRODUCT", 114, 117], ["TBK1", "GENE_OR_GENE_PRODUCT", 127, 131], ["NS7a", "GENE_OR_GENE_PRODUCT", 172, 176], ["RLR", "GENE_OR_GENE_PRODUCT", 209, 212], ["NS7a", "GENE_OR_GENE_PRODUCT", 296, 300], ["NS7a", "PROTEIN", 29, 33], ["RLR", "PROTEIN", 46, 49], ["TBK1", "PROTEIN", 84, 88], ["IKK\u03b5", "PROTEIN", 89, 93], ["NS7a", "PROTEIN", 94, 98], ["IKK\u03b5", "PROTEIN", 114, 118], ["TBK1", "PROTEIN", 127, 131], ["NS7a", "PROTEIN", 172, 176], ["RLR", "PROTEIN", 209, 212], ["NS7a", "PROTEIN", 296, 300], ["NS7a", "TREATMENT", 29, 33]]], ["Co-IP experiments were performed by co-transfecting pCAGGS-HA-NS7a and Flag-tagged expression plasmids encoding RIG-I, MDA5, MAVS, TRAF3, TBK1/IKK\u03b5, or IRF3.", [["plasmids", "ANATOMY", 94, 102], ["pCAGGS-HA-NS7a", "GENE_OR_GENE_PRODUCT", 52, 66], ["Flag", "GENE_OR_GENE_PRODUCT", 71, 75], ["RIG-I", "GENE_OR_GENE_PRODUCT", 112, 117], ["MDA5", "GENE_OR_GENE_PRODUCT", 119, 123], ["MAVS", "GENE_OR_GENE_PRODUCT", 125, 129], ["TRAF3", "GENE_OR_GENE_PRODUCT", 131, 136], ["TBK1", "GENE_OR_GENE_PRODUCT", 138, 142], ["IKK", "GENE_OR_GENE_PRODUCT", 143, 146], ["\u03b5", "GENE_OR_GENE_PRODUCT", 146, 147], ["IRF3", "GENE_OR_GENE_PRODUCT", 152, 156], ["pCAGGS-HA-NS7a and Flag-tagged expression plasmids", "DNA", 52, 102], ["RIG-I", "PROTEIN", 112, 117], ["MDA5", "PROTEIN", 119, 123], ["MAVS", "PROTEIN", 125, 129], ["TRAF3", "PROTEIN", 131, 136], ["TBK1", "PROTEIN", 138, 142], ["IKK\u03b5", "PROTEIN", 143, 147], ["IRF3", "PROTEIN", 152, 156], ["IP experiments", "TEST", 3, 17], ["HA", "PROBLEM", 59, 61], ["Flag-tagged expression plasmids", "TREATMENT", 71, 102], ["TRAF3", "TREATMENT", 131, 136], ["IRF3", "PROBLEM", 152, 156]]], ["The results showed that IKK\u03b5 was specifically detected in isolated immunocomplexes with the anti-HA MAb but not the closely related TBK1 and other signaling molecules (Figure 4A).", [["immunocomplexes", "ANATOMY", 67, 82], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 24, 28], ["TBK1", "GENE_OR_GENE_PRODUCT", 132, 136], ["IKK\u03b5", "PROTEIN", 24, 28], ["HA MAb", "PROTEIN", 97, 103], ["TBK1", "PROTEIN", 132, 136], ["signaling molecules", "PROTEIN", 147, 166], ["Figure 4A", "PROTEIN", 168, 177], ["IKK", "TEST", 24, 27], ["isolated immunocomplexes", "PROBLEM", 58, 82], ["the anti-HA MAb", "TREATMENT", 88, 103], ["immunocomplexes", "OBSERVATION", 67, 82]]], ["In a reverse Co-IP experiment, NS7a was also efficiently co-immunoprecipitated with IKK\u03b5 via the anti-Flag MAb (Figure 4B).", [["NS7a", "GENE_OR_GENE_PRODUCT", 31, 35], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 84, 88], ["NS7a", "PROTEIN", 31, 35], ["IKK\u03b5", "PROTEIN", 84, 88], ["anti-Flag MAb", "PROTEIN", 97, 110], ["Figure 4B", "PROTEIN", 112, 121], ["IKK", "TREATMENT", 84, 87], ["the anti-Flag MAb", "TREATMENT", 93, 110]]], ["Furthermore, IFAs also demonstrated that Flag-IKK\u03b5 colocalizes with HA-NS7a, which was distributed in the cytoplasm predominately (Figure 4C).", [["cytoplasm", "ANATOMY", 106, 115], ["IFAs", "GENE_OR_GENE_PRODUCT", 13, 17], ["Flag-IKK\u03b5", "GENE_OR_GENE_PRODUCT", 41, 50], ["HA-NS7a", "GENE_OR_GENE_PRODUCT", 68, 75], ["cytoplasm", "ORGANISM_SUBSTANCE", 106, 115], ["IFAs", "PROTEIN", 13, 17], ["Flag", "PROTEIN", 41, 45], ["IKK\u03b5", "PROTEIN", 46, 50], ["HA", "PROTEIN", 68, 70], ["NS7a", "PROTEIN", 71, 75], ["IFAs", "TEST", 13, 17], ["Flag", "TEST", 41, 45], ["HA", "PROBLEM", 68, 70], ["NS7a", "PROBLEM", 71, 75]]], ["To further test the effect of NS7a on IKK\u03b5-mediated IFN-\u03b2 production, the level of IRF3 phosphorylation induced by IKK\u03b5 was analyzed in the presence or absence of NS7a.", [["NS7a", "GENE_OR_GENE_PRODUCT", 30, 34], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 38, 42], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 52, 57], ["IRF3", "GENE_OR_GENE_PRODUCT", 83, 87], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 115, 119], ["NS7a", "GENE_OR_GENE_PRODUCT", 163, 167], ["NS7a", "PROTEIN", 30, 34], ["IKK\u03b5", "PROTEIN", 38, 42], ["IFN", "PROTEIN", 52, 55], ["IRF3", "PROTEIN", 83, 87], ["IKK\u03b5", "PROTEIN", 115, 119], ["NS7a", "PROTEIN", 163, 167], ["NS7a", "TREATMENT", 30, 34], ["IKK", "TEST", 38, 41], ["IFN", "TREATMENT", 52, 55], ["IRF3 phosphorylation", "PROBLEM", 83, 103], ["NS7a", "PROBLEM", 163, 167]]], ["The results showed that IKK\u03b5 overexpression markedly promoted the level of IRF3 phosphorylation when compared with that of the empty vector-transfected cells.", [["cells", "ANATOMY", 152, 157], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 24, 28], ["IRF3", "GENE_OR_GENE_PRODUCT", 75, 79], ["cells", "CELL", 152, 157], ["IKK\u03b5", "PROTEIN", 24, 28], ["IRF3", "PROTEIN", 75, 79], ["transfected cells", "CELL_LINE", 140, 157], ["IKK", "PROBLEM", 24, 27], ["IRF3 phosphorylation", "PROBLEM", 75, 95], ["IRF3 phosphorylation", "OBSERVATION", 75, 95], ["transfected cells", "OBSERVATION", 140, 157]]], ["However, the increase was inhibited significantly in the presence of NS7a (Figure 4D).", [["NS7a", "PROTEIN", 69, 73], ["increase", "OBSERVATION_MODIFIER", 13, 21]]], ["Taken together, these results indicated that NS7a specifically interacts with IKK\u03b5 but not the closely related TBK1, leading to the inhibition of IKK\u03b5 function.NS7a Competes With TRAF3 and IRF3 for Binding to IKK\u03b5 ::: ResultsIKK\u03b5 is a crucial kinase in the RLR pathway that is recruited by the upstream TRAF3 to MAVS; IKK\u03b5 then recruits downstream transcription factor IRF3, leading to IRF3 activation and subsequent IFN production (Prins et al., 2009; Fang R. et al., 2017).", [["NS7a", "GENE_OR_GENE_PRODUCT", 45, 49], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 78, 82], ["TBK1", "GENE_OR_GENE_PRODUCT", 111, 115], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 146, 150], ["TRAF3", "GENE_OR_GENE_PRODUCT", 179, 184], ["IRF3", "GENE_OR_GENE_PRODUCT", 189, 193], ["IKK", "GENE_OR_GENE_PRODUCT", 209, 212], ["ResultsIKK\u03b5", "GENE_OR_GENE_PRODUCT", 218, 229], ["RLR", "GENE_OR_GENE_PRODUCT", 257, 260], ["TRAF3", "GENE_OR_GENE_PRODUCT", 303, 308], ["MAVS", "GENE_OR_GENE_PRODUCT", 312, 316], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 318, 322], ["IRF3", "GENE_OR_GENE_PRODUCT", 369, 373], ["IRF3", "GENE_OR_GENE_PRODUCT", 386, 390], ["IFN", "GENE_OR_GENE_PRODUCT", 417, 420], ["NS7a", "PROTEIN", 45, 49], ["IKK\u03b5", "PROTEIN", 78, 82], ["TBK1", "PROTEIN", 111, 115], ["IKK\u03b5", "PROTEIN", 146, 150], ["NS7a", "PROTEIN", 160, 164], ["TRAF3", "PROTEIN", 179, 184], ["IRF3", "PROTEIN", 189, 193], ["IKK\u03b5", "PROTEIN", 209, 213], ["ResultsIKK\u03b5", "PROTEIN", 218, 229], ["RLR", "PROTEIN", 257, 260], ["TRAF3", "PROTEIN", 303, 308], ["MAVS", "PROTEIN", 312, 316], ["IKK\u03b5", "PROTEIN", 318, 322], ["transcription factor", "PROTEIN", 348, 368], ["IRF3", "PROTEIN", 369, 373], ["IRF3", "PROTEIN", 386, 390], ["IFN", "PROTEIN", 417, 420], ["the closely related TBK1", "PROBLEM", 91, 115], ["a crucial kinase in the RLR pathway", "PROBLEM", 233, 268], ["IKK", "PROBLEM", 318, 321], ["IRF3 activation", "PROBLEM", 386, 401], ["subsequent IFN production", "PROBLEM", 406, 431], ["RLR", "ANATOMY", 257, 260], ["IRF3 activation", "OBSERVATION", 386, 401]]], ["Due to the specific interaction of NS7a with IKK\u03b5, we tested whether NS7a is capable of disrupting the interaction of IKK\u03b5 with its vital upstream signaling component TRAF3 or downstream molecule IRF3.", [["NS7a", "GENE_OR_GENE_PRODUCT", 35, 39], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 45, 49], ["NS7a", "GENE_OR_GENE_PRODUCT", 69, 73], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 118, 122], ["TRAF3", "GENE_OR_GENE_PRODUCT", 167, 172], ["IRF3", "GENE_OR_GENE_PRODUCT", 196, 200], ["NS7a", "PROTEIN", 35, 39], ["IKK\u03b5", "PROTEIN", 45, 49], ["NS7a", "PROTEIN", 69, 73], ["IKK\u03b5", "PROTEIN", 118, 122], ["vital upstream signaling component", "PROTEIN", 132, 166], ["TRAF3", "PROTEIN", 167, 172], ["downstream molecule", "PROTEIN", 176, 195], ["IRF3", "PROTEIN", 196, 200], ["downstream molecule IRF3", "PROBLEM", 176, 200], ["molecule IRF3", "OBSERVATION", 187, 200]]], ["To this end, a competitive Co-IP experiment was performed.", [["a competitive Co-IP experiment", "TEST", 13, 43]]], ["HEK-293T cells were co-transfected with HA-tagged IKK\u03b5 and Flag-tagged TRAF3/IRF3 expression constructs along with pCAGGS-Myc-NS7a or the empty vector.", [["HEK-293T cells", "ANATOMY", 0, 14], ["HEK-293T cells", "CELL", 0, 14], ["HA-tagged IKK\u03b5", "GENE_OR_GENE_PRODUCT", 40, 54], ["Flag", "GENE_OR_GENE_PRODUCT", 59, 63], ["TRAF3", "GENE_OR_GENE_PRODUCT", 71, 76], ["IRF3", "GENE_OR_GENE_PRODUCT", 77, 81], ["pCAGGS-Myc-NS7a", "GENE_OR_GENE_PRODUCT", 115, 130], ["HEK-293T cells", "CELL_LINE", 0, 14], ["IKK\u03b5 and Flag-tagged TRAF3/IRF3 expression constructs", "DNA", 50, 103], ["pCAGGS", "PROTEIN", 115, 121], ["Myc", "PROTEIN", 122, 125], ["NS7a", "DNA", 126, 130], ["empty vector", "DNA", 138, 150], ["HEK", "TEST", 0, 3], ["HA", "TEST", 40, 42], ["tagged IKK", "TEST", 43, 53], ["Flag", "TEST", 59, 63], ["tagged TRAF3/IRF3 expression constructs", "TREATMENT", 64, 103], ["pCAGGS", "TEST", 115, 121], ["293T cells", "OBSERVATION", 4, 14], ["empty vector", "OBSERVATION", 138, 150]]], ["At 24 h post-transfection, the cell lysates were prepared, and subjected to the Co-IP assay with the anti-HA MAb.", [["cell lysates", "ANATOMY", 31, 43], ["cell lysates", "CELL", 31, 43], ["HA MAb", "PROTEIN", 106, 112], ["the cell lysates", "TEST", 27, 43], ["the Co-IP assay", "TEST", 76, 91], ["the anti-HA MAb", "TREATMENT", 97, 112]]], ["As shown in Figure 5, TRAF3 (Figure 5A) and IRF3 (Figure 5B) were clearly co-immunoprecipitated by IKK\u03b5 in the absence of NS7a.", [["TRAF3", "GENE_OR_GENE_PRODUCT", 22, 27], ["Figure 5A", "GENE_OR_GENE_PRODUCT", 29, 38], ["IRF3 (Figure 5B", "GENE_OR_GENE_PRODUCT", 44, 59], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 99, 103], ["NS7a", "GENE_OR_GENE_PRODUCT", 122, 126], ["TRAF3", "PROTEIN", 22, 27], ["Figure 5A", "PROTEIN", 29, 38], ["IRF3", "PROTEIN", 44, 48], ["Figure 5B", "PROTEIN", 50, 59], ["IKK\u03b5", "PROTEIN", 99, 103], ["NS7a", "PROTEIN", 122, 126], ["TRAF3 (Figure 5A", "TREATMENT", 22, 38], ["IRF3 (Figure 5B", "TREATMENT", 44, 59]]], ["However, a significantly lower quantity of TRAF3 or IRF3 in the isolated immunocomplexes was detected in the presence of NS7a when compared with that of the empty vector control (Figures 5A,B).NS7a Interacts With KD and SDD of IKK\u03b5 ::: ResultsIKK\u03b5 contains two key domains, KD and SDD, which are responsible for interacting with TRAF3 and IRF3, respectively (Prins et al., 2009; Fang R. et al., 2017) (Figure 6A).", [["immunocomplexes", "ANATOMY", 73, 88], ["TRAF3", "GENE_OR_GENE_PRODUCT", 43, 48], ["IRF3", "GENE_OR_GENE_PRODUCT", 52, 56], ["immunocomplexes", "GENE_OR_GENE_PRODUCT", 73, 88], ["NS7a", "GENE_OR_GENE_PRODUCT", 121, 125], ["IKK", "GENE_OR_GENE_PRODUCT", 227, 230], ["ResultsIKK\u03b5", "GENE_OR_GENE_PRODUCT", 236, 247], ["SDD", "GENE_OR_GENE_PRODUCT", 281, 284], ["TRAF3", "GENE_OR_GENE_PRODUCT", 329, 334], ["IRF3", "GENE_OR_GENE_PRODUCT", 339, 343], ["TRAF3", "PROTEIN", 43, 48], ["IRF3", "PROTEIN", 52, 56], ["NS7a", "PROTEIN", 121, 125], ["NS7a", "PROTEIN", 193, 197], ["IKK\u03b5", "PROTEIN", 227, 231], ["ResultsIKK\u03b5", "PROTEIN", 236, 247], ["SDD", "PROTEIN", 281, 284], ["TRAF3", "PROTEIN", 329, 334], ["IRF3", "PROTEIN", 339, 343], ["a significantly lower quantity of TRAF3", "PROBLEM", 9, 48], ["IRF3", "PROBLEM", 52, 56], ["the isolated immunocomplexes", "PROBLEM", 60, 88], ["NS7a", "TREATMENT", 121, 125], ["SDD", "PROBLEM", 281, 284], ["significantly", "OBSERVATION_MODIFIER", 11, 24], ["lower", "OBSERVATION_MODIFIER", 25, 30], ["quantity", "OBSERVATION_MODIFIER", 31, 39], ["TRAF3", "OBSERVATION", 43, 48], ["IRF3", "OBSERVATION", 52, 56], ["isolated", "OBSERVATION_MODIFIER", 64, 72], ["immunocomplexes", "OBSERVATION", 73, 88]]], ["Because NS7a competes with TRAF3 and IRF3 for binding to IKK\u03b5, it is possible that NS7a simultaneously binds to the KD and SDD of IKK\u03b5.", [["NS7a", "GENE_OR_GENE_PRODUCT", 8, 12], ["TRAF3", "GENE_OR_GENE_PRODUCT", 27, 32], ["IRF3", "GENE_OR_GENE_PRODUCT", 37, 41], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 57, 61], ["NS7a", "GENE_OR_GENE_PRODUCT", 83, 87], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 130, 134], ["NS7a", "PROTEIN", 8, 12], ["TRAF3", "PROTEIN", 27, 32], ["IRF3", "PROTEIN", 37, 41], ["IKK\u03b5", "PROTEIN", 57, 61], ["NS7a", "PROTEIN", 83, 87], ["IKK\u03b5", "PROTEIN", 130, 134], ["TRAF3", "TREATMENT", 27, 32], ["IRF3", "TREATMENT", 37, 41]]], ["To confirm this hypothesis, a Co-IP experiment was performed by co-transfecting pCAGGS-HA-NS7a with Flag-tagged full-length IKK\u03b5, KD or SDD expression plasmid, respectively.", [["pCAGGS-HA-NS7a", "GENE_OR_GENE_PRODUCT", 80, 94], ["Flag", "GENE_OR_GENE_PRODUCT", 100, 104], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 124, 128], ["pCAGGS-HA-NS7a with Flag-tagged full-length IKK\u03b5, KD or SDD expression plasmid", "DNA", 80, 158], ["this hypothesis", "PROBLEM", 11, 26], ["a Co-IP experiment", "TEST", 28, 46], ["HA", "PROBLEM", 87, 89], ["Flag", "TEST", 100, 104], ["SDD expression plasmid", "TREATMENT", 136, 158]]], ["Flag-tagged TBK1 was used as a negative control.", [["Flag", "GENE_OR_GENE_PRODUCT", 0, 4], ["TBK1", "GENE_OR_GENE_PRODUCT", 12, 16], ["Flag", "PROTEIN", 0, 4], ["TBK1", "PROTEIN", 12, 16], ["Flag-tagged TBK1", "TREATMENT", 0, 16], ["tagged TBK1", "OBSERVATION", 5, 16]]], ["The results showed that NS7a co-immunoprecipitated with SDD, KD and full-length IKK\u03b5.", [["NS7a", "GENE_OR_GENE_PRODUCT", 24, 28], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 80, 84], ["NS7a", "PROTEIN", 24, 28], ["SDD", "PROTEIN", 56, 59], ["IKK\u03b5", "PROTEIN", 80, 84], ["SDD", "PROBLEM", 56, 59]]], ["As expected, no association between NS7a and TBK1 was observed (Figure 6B), and this was in line with the results from Figure 4A.", [["NS7a", "GENE_OR_GENE_PRODUCT", 36, 40], ["TBK1", "GENE_OR_GENE_PRODUCT", 45, 49], ["NS7a", "PROTEIN", 36, 40], ["TBK1", "PROTEIN", 45, 49], ["TBK1", "PROBLEM", 45, 49]]], ["In a reverse Co-IP experiment, SDD and KD also co-immunoprecipitated with NS7a by the anti-Flag MAb efficiently (Figures 6C,D).", [["NS7a", "GENE_OR_GENE_PRODUCT", 74, 78], ["NS7a", "PROTEIN", 74, 78], ["anti-Flag MAb", "PROTEIN", 86, 99], ["SDD", "PROBLEM", 31, 34], ["NS7a", "TREATMENT", 74, 78], ["the anti-Flag MAb", "TREATMENT", 82, 99]]], ["Competitive Co-IP experiments were performed with the anti-HA MAb to further determine whether NS7a impedes the interaction of TRAF3-SDD and KD-IRF3.", [["NS7a", "GENE_OR_GENE_PRODUCT", 95, 99], ["TRAF3", "GENE_OR_GENE_PRODUCT", 127, 132], ["SDD", "GENE_OR_GENE_PRODUCT", 133, 136], ["KD-IRF3", "GENE_OR_GENE_PRODUCT", 141, 148], ["anti-HA MAb", "PROTEIN", 54, 65], ["NS7a", "PROTEIN", 95, 99], ["TRAF3", "PROTEIN", 127, 132], ["SDD", "PROTEIN", 133, 136], ["KD", "PROTEIN", 141, 143], ["IRF3", "PROTEIN", 144, 148], ["the anti-HA MAb", "TREATMENT", 50, 65], ["SDD", "PROBLEM", 133, 136], ["IRF3", "PROBLEM", 144, 148]]], ["The results clearly showed that TRAF3 (Figure 6E) and IRF3 (Figure 6F) are co-immunoprecipitated by SDD and KD in the absence of NS7a, respectively.", [["TRAF3", "GENE_OR_GENE_PRODUCT", 32, 37], ["Figure 6E", "GENE_OR_GENE_PRODUCT", 39, 48], ["IRF3 (Figure 6F", "GENE_OR_GENE_PRODUCT", 54, 69], ["NS7a", "GENE_OR_GENE_PRODUCT", 129, 133], ["TRAF3", "PROTEIN", 32, 37], ["Figure 6E", "PROTEIN", 39, 48], ["IRF3", "PROTEIN", 54, 58], ["Figure 6F", "PROTEIN", 60, 69], ["NS7a", "PROTEIN", 129, 133], ["TRAF3", "TEST", 32, 37], ["IRF3 (Figure 6F", "TREATMENT", 54, 69]]], ["However, a significantly lower amount of TRAF3 or IRF3 was detected in isolated immunocomplexes in the presence of NS7a when compared with that of the empty vector control.", [["immunocomplexes", "ANATOMY", 80, 95], ["TRAF3", "GENE_OR_GENE_PRODUCT", 41, 46], ["IRF3", "GENE_OR_GENE_PRODUCT", 50, 54], ["immunocomplexes", "GENE_OR_GENE_PRODUCT", 80, 95], ["NS7a", "GENE_OR_GENE_PRODUCT", 115, 119], ["TRAF3", "PROTEIN", 41, 46], ["IRF3", "PROTEIN", 50, 54], ["NS7a", "PROTEIN", 115, 119], ["a significantly lower amount of TRAF3", "PROBLEM", 9, 46], ["IRF3", "PROBLEM", 50, 54], ["isolated immunocomplexes", "PROBLEM", 71, 95], ["NS7a", "TREATMENT", 115, 119], ["the empty vector control", "TREATMENT", 147, 171], ["significantly", "OBSERVATION_MODIFIER", 11, 24], ["lower", "OBSERVATION_MODIFIER", 25, 30], ["amount", "OBSERVATION_MODIFIER", 31, 37], ["TRAF3", "OBSERVATION", 41, 46], ["IRF3", "OBSERVATION", 50, 54], ["immunocomplexes", "OBSERVATION", 80, 95], ["empty", "OBSERVATION", 151, 156]]], ["These results indicated that NS7a competes with TRAF3 and IRF3 for binding to the SDD and KD of IKK\u03b5, respectively.PDCoV Infection Attenuates the Interaction of IKK\u03b5 With TRAF3 and IRF3 ::: ResultsThe results in the overexpression system clearly showed that PDCoV NS7a interacts with IKK\u03b5 and weakens the interactions of TRAF3-IKK\u03b5 and IKK\u03b5-IRF3.", [["NS7a", "GENE_OR_GENE_PRODUCT", 29, 33], ["TRAF3", "GENE_OR_GENE_PRODUCT", 48, 53], ["IRF3", "GENE_OR_GENE_PRODUCT", 58, 62], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 96, 100], ["IKK", "GENE_OR_GENE_PRODUCT", 161, 164], ["TRAF3", "GENE_OR_GENE_PRODUCT", 171, 176], ["IRF3", "GENE_OR_GENE_PRODUCT", 181, 185], ["PDCoV NS7a", "GENE_OR_GENE_PRODUCT", 258, 268], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 284, 288], ["TRAF3", "GENE_OR_GENE_PRODUCT", 321, 326], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 327, 331], ["IKK\u03b5-IRF3", "GENE_OR_GENE_PRODUCT", 336, 345], ["NS7a", "PROTEIN", 29, 33], ["TRAF3", "PROTEIN", 48, 53], ["IRF3", "PROTEIN", 58, 62], ["IKK\u03b5", "PROTEIN", 96, 100], ["IKK", "PROTEIN", 161, 164], ["TRAF3", "PROTEIN", 171, 176], ["IRF3", "PROTEIN", 181, 185], ["PDCoV NS7a", "PROTEIN", 258, 268], ["IKK\u03b5", "PROTEIN", 284, 288], ["TRAF3", "PROTEIN", 321, 326], ["IKK\u03b5", "PROTEIN", 327, 331], ["IKK", "PROTEIN", 336, 339], ["\u03b5", "PROTEIN", 339, 340], ["IRF3", "PROTEIN", 341, 345], ["TRAF3", "TREATMENT", 48, 53], ["IRF3", "TREATMENT", 58, 62], ["PDCoV Infection", "PROBLEM", 115, 130], ["the overexpression system", "TEST", 212, 237], ["TRAF3", "TEST", 321, 326], ["IKK", "TEST", 336, 339], ["IRF3", "PROBLEM", 341, 345], ["Infection", "OBSERVATION", 121, 130]]], ["Whether NS7a interacts with IKK\u03b5 under the conditions of PDCoV infection remains unclear.", [["PDCoV infection", "DISEASE", 57, 72], ["NS7a", "GENE_OR_GENE_PRODUCT", 8, 12], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 28, 32], ["PDCoV", "CANCER", 57, 62], ["NS7a", "PROTEIN", 8, 12], ["IKK\u03b5", "PROTEIN", 28, 32], ["PDCoV infection", "PROBLEM", 57, 72], ["infection", "OBSERVATION", 63, 72]]], ["Because an antibody against endogenic IKK\u03b5 is ineffective, an IPI-2I cell line stably expressing Flag-tagged IKK\u03b5 was established by a recombinant lentivirus.", [["IPI-2I cell line", "ANATOMY", 62, 78], ["antibody against endogenic IKK\u03b5", "GENE_OR_GENE_PRODUCT", 11, 42], ["IPI-2I cell line", "CELL", 62, 78], ["Flag", "GENE_OR_GENE_PRODUCT", 97, 101], ["IKK", "GENE_OR_GENE_PRODUCT", 109, 112], ["\u03b5", "GENE_OR_GENE_PRODUCT", 112, 113], ["lentivirus", "ORGANISM", 147, 157], ["endogenic IKK\u03b5", "PROTEIN", 28, 42], ["IPI-2I cell line", "CELL_LINE", 62, 78], ["Flag", "PROTEIN", 97, 101], ["IKK\u03b5", "PROTEIN", 109, 113], ["lentivirus", "SPECIES", 147, 157], ["an antibody", "TEST", 8, 19], ["endogenic IKK", "TEST", 28, 41], ["an IPI", "TEST", 59, 65], ["2I cell line", "TREATMENT", 66, 78], ["a recombinant lentivirus", "TREATMENT", 133, 157], ["lentivirus", "OBSERVATION", 147, 157]]], ["As shown in Figure 7A, Flag-tagged IKK\u03b5 was clearly detected via a Co-IP experiment with a MAb against NS7a rather than a MAb against nucleocapsid (N) protein in PDCoV-infected IPI-2I cells stably expressing Flag-IKK\u03b5.", [["IPI-2I cells", "ANATOMY", 177, 189], ["Flag", "GENE_OR_GENE_PRODUCT", 23, 27], ["IKK", "GENE_OR_GENE_PRODUCT", 35, 38], ["\u03b5", "GENE_OR_GENE_PRODUCT", 38, 39], ["NS7a", "GENE_OR_GENE_PRODUCT", 103, 107], ["MAb", "GENE_OR_GENE_PRODUCT", 122, 125], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 134, 150], ["PDCoV", "CELL", 162, 167], ["IPI-2I cells", "CELL", 177, 189], ["Flag-IKK\u03b5", "GENE_OR_GENE_PRODUCT", 208, 217], ["Flag", "PROTEIN", 23, 27], ["IKK\u03b5", "PROTEIN", 35, 39], ["NS7a", "PROTEIN", 103, 107], ["MAb", "PROTEIN", 122, 125], ["nucleocapsid (N) protein", "PROTEIN", 134, 158], ["PDCoV-infected IPI-2I cells", "CELL_LINE", 162, 189], ["Flag", "PROTEIN", 208, 212], ["IKK\u03b5", "PROTEIN", 213, 217], ["a MAb", "TREATMENT", 89, 94], ["a MAb", "TEST", 120, 125], ["nucleocapsid", "TEST", 134, 146], ["protein", "TEST", 151, 158], ["PDCoV", "TEST", 162, 167], ["infected IPI", "PROBLEM", 168, 180]]], ["We also examined whether NS7a interacts with IKK\u03b5 but not with other components (RIG-I, MDA5, MAVS, TRAF3, TBK1, and IRF3) in PDCoV-infected cells.", [["cells", "ANATOMY", 141, 146], ["NS7a", "GENE_OR_GENE_PRODUCT", 25, 29], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 45, 49], ["RIG-I", "GENE_OR_GENE_PRODUCT", 81, 86], ["MDA5", "GENE_OR_GENE_PRODUCT", 88, 92], ["MAVS", "GENE_OR_GENE_PRODUCT", 94, 98], ["TRAF3", "GENE_OR_GENE_PRODUCT", 100, 105], ["TBK1", "GENE_OR_GENE_PRODUCT", 107, 111], ["IRF3", "GENE_OR_GENE_PRODUCT", 117, 121], ["PDCoV", "GENE_OR_GENE_PRODUCT", 126, 131], ["cells", "CELL", 141, 146], ["NS7a", "PROTEIN", 25, 29], ["IKK\u03b5", "PROTEIN", 45, 49], ["RIG-I", "PROTEIN", 81, 86], ["MDA5", "PROTEIN", 88, 92], ["MAVS", "PROTEIN", 94, 98], ["TRAF3", "PROTEIN", 100, 105], ["TBK1", "PROTEIN", 107, 111], ["IRF3", "PROTEIN", 117, 121], ["PDCoV-infected cells", "CELL_LINE", 126, 146], ["MDA5", "TEST", 88, 92], ["MAVS", "TEST", 94, 98], ["TRAF3", "TEST", 100, 105], ["TBK1", "PROBLEM", 107, 111], ["IRF3", "PROBLEM", 117, 121], ["infected cells", "PROBLEM", 132, 146], ["infected cells", "OBSERVATION", 132, 146]]], ["The results showed that only IKK\u03b5 was specifically detected in the isolated immunocomplexes with the anti-NS7a MAb but not in other components tested, suggesting that NS7a specifically interacts with IKK\u03b5 (Figure 7B).", [["immunocomplexes", "ANATOMY", 76, 91], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 29, 33], ["anti-NS7a MAb", "GENE_OR_GENE_PRODUCT", 101, 114], ["NS7a", "GENE_OR_GENE_PRODUCT", 167, 171], ["IKK", "GENE_OR_GENE_PRODUCT", 200, 203], ["IKK\u03b5", "PROTEIN", 29, 33], ["anti-NS7a MAb", "PROTEIN", 101, 114], ["NS7a", "PROTEIN", 167, 171], ["IKK", "PROTEIN", 200, 203], ["the anti-NS7a MAb", "TREATMENT", 97, 114], ["immunocomplexes", "OBSERVATION", 76, 91]]], ["We further examined whether the interaction between IKK\u03b5 and TRAF3 or IRF3 are similarly impaired under PDCoV infection.", [["infection", "DISEASE", 110, 119], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 52, 56], ["TRAF3", "GENE_OR_GENE_PRODUCT", 61, 66], ["IRF3", "GENE_OR_GENE_PRODUCT", 70, 74], ["PDCoV", "CANCER", 104, 109], ["IKK\u03b5", "PROTEIN", 52, 56], ["TRAF3", "PROTEIN", 61, 66], ["IRF3", "PROTEIN", 70, 74], ["PDCoV", "SPECIES", 104, 109], ["IKK", "TEST", 52, 55], ["TRAF3", "PROBLEM", 61, 66], ["IRF3", "PROBLEM", 70, 74], ["PDCoV infection", "PROBLEM", 104, 119], ["infection", "OBSERVATION", 110, 119]]], ["IPI-2I cells stably expressing Flag-IKK\u03b5 were infected or mock-infected with PDCoV, and Co-IP experiments were then performed with the anti-Flag antibody.", [["IPI-2I cells", "ANATOMY", 0, 12], ["Co", "CHEMICAL", 88, 90], ["IPI-2I cells", "CELL", 0, 12], ["Flag-IKK\u03b5", "GENE_OR_GENE_PRODUCT", 31, 40], ["PDCoV", "CELL", 77, 82], ["Co-IP", "SIMPLE_CHEMICAL", 88, 93], ["anti-Flag", "GENE_OR_GENE_PRODUCT", 135, 144], ["IPI-2I cells", "CELL_LINE", 0, 12], ["Flag", "PROTEIN", 31, 35], ["IKK\u03b5", "PROTEIN", 36, 40], ["anti-Flag antibody", "PROTEIN", 135, 153], ["IPI", "TEST", 0, 3], ["PDCoV", "TREATMENT", 77, 82], ["Co-IP experiments", "TEST", 88, 105], ["the anti-Flag antibody", "TEST", 131, 153]]], ["As shown in Figure 7C, the endogenous TRAF3 and IRF3 co-immunoprecipitated by Flag-IKK\u03b5 were clearly lower in the PDCoV-infected group when compared with that of the mock-infected group.", [["TRAF3", "GENE_OR_GENE_PRODUCT", 38, 43], ["IRF3", "GENE_OR_GENE_PRODUCT", 48, 52], ["Flag-IKK\u03b5", "GENE_OR_GENE_PRODUCT", 78, 87], ["PDCoV", "GENE_OR_GENE_PRODUCT", 114, 119], ["TRAF3", "PROTEIN", 38, 43], ["IRF3", "PROTEIN", 48, 52], ["Flag", "PROTEIN", 78, 82], ["IKK\u03b5", "PROTEIN", 83, 87], ["the endogenous TRAF3", "PROBLEM", 23, 43], ["lower", "OBSERVATION_MODIFIER", 101, 106], ["infected", "OBSERVATION", 120, 128], ["infected", "OBSERVATION", 171, 179]]], ["Taken together, these results indicated that PDCoV NS7a at least partially functions to disrupt the binding of IKK\u03b5 to TRAF3 and IRF3, leading to the inhibition of IFN-\u03b2 production (Figure 7D).DiscussionCoV accessory proteins are species-specific and have been investigated widely over the past decade, and their immune regulation functions, particularly roles in regulating IFN production, and signaling transduction, have been revealed.", [["PDCoV", "CHEMICAL", 45, 50], ["PDCoV NS7a", "GENE_OR_GENE_PRODUCT", 45, 55], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 111, 115], ["TRAF3", "GENE_OR_GENE_PRODUCT", 119, 124], ["IRF3", "GENE_OR_GENE_PRODUCT", 129, 133], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 164, 169], ["IFN", "GENE_OR_GENE_PRODUCT", 375, 378], ["PDCoV NS7a", "PROTEIN", 45, 55], ["IKK\u03b5", "PROTEIN", 111, 115], ["TRAF3", "PROTEIN", 119, 124], ["IRF3", "PROTEIN", 129, 133], ["IFN", "PROTEIN", 164, 167], ["\u03b2", "PROTEIN", 168, 169], ["DiscussionCoV accessory proteins", "PROTEIN", 193, 225], ["IFN", "PROTEIN", 375, 378], ["PDCoV NS7a", "TREATMENT", 45, 55], ["TRAF3", "PROBLEM", 119, 124], ["IRF3", "PROBLEM", 129, 133], ["IFN", "PROBLEM", 164, 167], ["DiscussionCoV accessory proteins", "PROBLEM", 193, 225], ["signaling transduction", "TEST", 395, 417]]], ["Moreover, some previously unknown accessory proteins from CoVs have been found in virus-infected cells [e.g., IR ORF from IBV (Bentley et al., 2013), the ORFX encoded by the SARS-like coronavirus (Zeng et al., 2016) and NS7a from PDCoV (Fang P. et al., 2017), highlighting that CoVs possess a larger coding capacity than previously thought].", [["cells", "ANATOMY", 97, 102], ["CoVs", "GENE_OR_GENE_PRODUCT", 58, 62], ["cells", "CELL", 97, 102], ["IBV", "ORGANISM", 122, 125], ["ORFX", "GENE_OR_GENE_PRODUCT", 154, 158], ["SARS-like coronavirus", "ORGANISM", 174, 195], ["NS7a", "GENE_OR_GENE_PRODUCT", 220, 224], ["CoVs", "GENE_OR_GENE_PRODUCT", 278, 282], ["accessory proteins", "PROTEIN", 34, 52], ["CoVs", "PROTEIN", 58, 62], ["virus-infected cells", "CELL_TYPE", 82, 102], ["IR ORF", "DNA", 110, 116], ["ORFX", "DNA", 154, 158], ["CoVs", "PROTEIN", 278, 282], ["IBV", "SPECIES", 122, 125], ["accessory proteins", "PROBLEM", 34, 52], ["CoVs", "PROBLEM", 58, 62], ["virus", "PROBLEM", 82, 87], ["infected cells", "PROBLEM", 88, 102], ["IR ORF", "PROBLEM", 110, 116], ["the SARS", "PROBLEM", 170, 178], ["coronavirus", "PROBLEM", 184, 195], ["a larger coding capacity", "PROBLEM", 291, 315], ["infected cells", "OBSERVATION", 88, 102]]], ["In this study, we provided evidence that PDCoV NS7a is an IFN antagonist that targets the kinase IKK\u03b5, which differs to the mechanism used by the PDCoV accessory protein NS6.DiscussionPDCoV NS7a is a unique accessory protein that is translated via an independent subgenomic RNA, and its coding sequence is identical to the C-terminus of NS7 within the N gene (Fang P. et al., 2017).", [["C", "CHEMICAL", 323, 324], ["PDCoV NS7a", "GENE_OR_GENE_PRODUCT", 41, 51], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 97, 101], ["PDCoV", "GENE_OR_GENE_PRODUCT", 146, 151], ["NS6", "GENE_OR_GENE_PRODUCT", 170, 173], ["NS7a", "GENE_OR_GENE_PRODUCT", 190, 194], ["NS7", "GENE_OR_GENE_PRODUCT", 337, 340], ["PDCoV NS7a", "PROTEIN", 41, 51], ["IFN", "PROTEIN", 58, 61], ["kinase IKK\u03b5", "PROTEIN", 90, 101], ["PDCoV accessory protein", "PROTEIN", 146, 169], ["NS6", "PROTEIN", 170, 173], ["NS7a", "PROTEIN", 190, 194], ["subgenomic RNA", "RNA", 263, 277], ["C-terminus", "PROTEIN", 323, 333], ["NS7", "PROTEIN", 337, 340], ["N gene", "DNA", 352, 358], ["PDCoV", "SPECIES", 41, 46], ["this study", "TEST", 3, 13], ["PDCoV NS7a", "TREATMENT", 41, 51], ["an IFN antagonist", "TREATMENT", 55, 72], ["the kinase IKK\u03b5", "TEST", 86, 101], ["a unique accessory protein", "PROBLEM", 198, 224], ["an independent subgenomic RNA", "PROBLEM", 248, 277], ["subgenomic RNA", "OBSERVATION", 263, 277]]], ["There are also several cases describing an alternative ORF encoding accessory protein inside the N gene in the genome of beta-CoVs, such as ORF9b of SARS-CoV and ORF I of MHV (Fischer et al., 1997; Meier et al., 2006; Liu et al., 2014).", [["SARS", "DISEASE", 149, 153], ["beta-CoVs", "GENE_OR_GENE_PRODUCT", 121, 130], ["ORF9b", "GENE_OR_GENE_PRODUCT", 140, 145], ["SARS-CoV", "ORGANISM", 149, 157], ["ORF I", "GENE_OR_GENE_PRODUCT", 162, 167], ["MHV", "ORGANISM", 171, 174], ["ORF", "DNA", 55, 58], ["accessory protein", "PROTEIN", 68, 85], ["N gene", "DNA", 97, 103], ["beta-CoVs", "DNA", 121, 130], ["ORF9b", "DNA", 140, 145], ["ORF I", "DNA", 162, 167], ["SARS-CoV", "SPECIES", 149, 157], ["MHV", "SPECIES", 171, 174], ["an alternative ORF", "PROBLEM", 40, 58]]], ["In this study, PDCoV NS7a was found to function as an IFN antagonist independent of cell type, as demonstrated using three different cell lines.", [["cell", "ANATOMY", 84, 88], ["cell lines", "ANATOMY", 133, 143], ["PDCoV", "ORGANISM", 15, 20], ["NS7a", "GENE_OR_GENE_PRODUCT", 21, 25], ["cell type", "CELL", 84, 93], ["cell lines", "CELL", 133, 143], ["PDCoV NS7a", "PROTEIN", 15, 25], ["IFN", "PROTEIN", 54, 57], ["cell lines", "CELL_LINE", 133, 143], ["PDCoV", "SPECIES", 15, 20], ["this study", "TEST", 3, 13], ["PDCoV NS7a", "TREATMENT", 15, 25], ["an IFN antagonist", "TREATMENT", 51, 68], ["three different cell lines", "TREATMENT", 117, 143], ["cell type", "OBSERVATION", 84, 93], ["cell lines", "OBSERVATION", 133, 143]]], ["Because NS7a is an in-frame, C-terminal peptide of the NS7 protein, we postulated that NS7 might also have IFN antagonistic property.", [["C", "CHEMICAL", 29, 30], ["NS7a", "GENE_OR_GENE_PRODUCT", 8, 12], ["NS7", "GENE_OR_GENE_PRODUCT", 55, 58], ["NS7", "GENE_OR_GENE_PRODUCT", 87, 90], ["IFN", "GENE_OR_GENE_PRODUCT", 107, 110], ["NS7a", "PROTEIN", 8, 12], ["NS7 protein", "PROTEIN", 55, 66], ["NS7", "PROTEIN", 87, 90], ["IFN", "PROTEIN", 107, 110], ["NS7a", "TREATMENT", 8, 12], ["IFN antagonistic property", "TREATMENT", 107, 132]]], ["Results from a luciferase reporter assay showed that NS7 also inhibited IFN production induced by SeV, but its antagonistic properties were significantly lower than that of NS7a although the expression level of NS7 was higher than that of NS7a under the same transfection condition (data no shown).", [["NS7", "CHEMICAL", 53, 56], ["luciferase", "GENE_OR_GENE_PRODUCT", 15, 25], ["NS7", "GENE_OR_GENE_PRODUCT", 53, 56], ["IFN", "GENE_OR_GENE_PRODUCT", 72, 75], ["SeV", "ORGANISM", 98, 101], ["NS7a", "GENE_OR_GENE_PRODUCT", 173, 177], ["NS7", "GENE_OR_GENE_PRODUCT", 211, 214], ["NS7a", "GENE_OR_GENE_PRODUCT", 239, 243], ["NS7", "PROTEIN", 53, 56], ["IFN", "PROTEIN", 72, 75], ["NS7a", "PROTEIN", 173, 177], ["NS7", "PROTEIN", 211, 214], ["NS7a", "PROTEIN", 239, 243], ["a luciferase reporter assay", "TEST", 13, 40], ["NS7", "PROBLEM", 53, 56], ["IFN production", "PROBLEM", 72, 86], ["NS7a", "TREATMENT", 173, 177], ["NS7a", "TREATMENT", 239, 243]]], ["We speculated that the N-terminal domain of NS7 may negatively regulate its C-terminal domain structure for antagonizing IFN production.", [["N", "CHEMICAL", 23, 24], ["C", "CHEMICAL", 76, 77], ["NS7", "GENE_OR_GENE_PRODUCT", 44, 47], ["IFN", "GENE_OR_GENE_PRODUCT", 121, 124], ["N-terminal domain", "PROTEIN", 23, 40], ["NS7", "PROTEIN", 44, 47], ["C-terminal domain structure", "PROTEIN", 76, 103], ["IFN", "PROTEIN", 121, 124], ["the N-terminal domain of NS7", "TREATMENT", 19, 47], ["antagonizing IFN production", "PROBLEM", 108, 135]]], ["Interestingly, the expression level of NS7a was higher than that of NS7 under the condition of PDCoV infection (Zhang et al., 2020).", [["PDCoV infection", "DISEASE", 95, 110], ["NS7a", "GENE_OR_GENE_PRODUCT", 39, 43], ["NS7", "GENE_OR_GENE_PRODUCT", 68, 71], ["NS7a", "PROTEIN", 39, 43], ["NS7", "PROTEIN", 68, 71], ["PDCoV", "SPECIES", 95, 100], ["PDCoV infection", "PROBLEM", 95, 110], ["infection", "OBSERVATION", 101, 110]]], ["Based on their differences of expression levels in PDCoV-infected cells and their ability to antagonize IFN, they appear not to be functionally redundant proteins for PDCoV infection.", [["cells", "ANATOMY", 66, 71], ["infection", "DISEASE", 173, 182], ["PDCoV", "CELL", 51, 56], ["cells", "CELL", 66, 71], ["IFN", "GENE_OR_GENE_PRODUCT", 104, 107], ["PDCoV", "GENE_OR_GENE_PRODUCT", 167, 172], ["PDCoV-infected cells", "CELL_LINE", 51, 71], ["IFN", "PROTEIN", 104, 107], ["expression levels", "TEST", 30, 47], ["PDCoV-infected cells", "TREATMENT", 51, 71], ["PDCoV infection", "PROBLEM", 167, 182], ["infected cells", "OBSERVATION", 57, 71], ["not to be", "UNCERTAINTY", 121, 130], ["infection", "OBSERVATION", 173, 182]]], ["However, a recent report indicated that the replication and pathogenicity of NS7 deletion mutants, which completely abolished both NS7 and NS7a gene expression via changing the initiation codon ATG of NS7 gene and its following seven downstream ATGs to ACGs, resembled those of wild type PDCoV (Zhang et al., 2020).", [["NS7", "GENE_OR_GENE_PRODUCT", 77, 80], ["NS7", "GENE_OR_GENE_PRODUCT", 131, 134], ["NS7a", "GENE_OR_GENE_PRODUCT", 139, 143], ["NS7", "GENE_OR_GENE_PRODUCT", 201, 204], ["ATGs", "GENE_OR_GENE_PRODUCT", 245, 249], ["ACGs", "GENE_OR_GENE_PRODUCT", 253, 257], ["NS7 deletion mutants", "DNA", 77, 97], ["NS7 and NS7a gene", "DNA", 131, 148], ["initiation codon ATG", "DNA", 177, 197], ["NS7 gene", "DNA", 201, 209], ["ACGs", "DNA", 253, 257], ["the replication", "PROBLEM", 40, 55], ["NS7 deletion mutants", "PROBLEM", 77, 97], ["the initiation codon ATG of NS7 gene", "TREATMENT", 173, 209]]], ["The result indicated the NS7 protein is not critical for PDCoV replication and virulence in vivo.", [["NS7", "GENE_OR_GENE_PRODUCT", 25, 28], ["PDCoV", "GENE_OR_GENE_PRODUCT", 57, 62], ["NS7 protein", "PROTEIN", 25, 36], ["PDCoV", "SPECIES", 57, 62], ["the NS7 protein", "TEST", 21, 36], ["PDCoV replication", "TREATMENT", 57, 74]]], ["This may not fully reflect the role of independent NS7 or NS7a protein on virus replication and pathogenicity but may reflect a combined effect of simultaneous depletion of NS7 and NS7a.", [["NS7", "GENE_OR_GENE_PRODUCT", 51, 54], ["NS7a", "GENE_OR_GENE_PRODUCT", 58, 62], ["NS7", "GENE_OR_GENE_PRODUCT", 173, 176], ["NS7a", "GENE_OR_GENE_PRODUCT", 181, 185], ["NS7", "PROTEIN", 51, 54], ["NS7a protein", "PROTEIN", 58, 70], ["NS7", "PROTEIN", 173, 176], ["NS7a", "PROTEIN", 181, 185], ["virus replication", "TREATMENT", 74, 91], ["pathogenicity", "PROBLEM", 96, 109], ["simultaneous depletion of NS7", "TREATMENT", 147, 176], ["NS7a", "TREATMENT", 181, 185], ["may not fully reflect", "UNCERTAINTY", 5, 26], ["simultaneous depletion", "OBSERVATION", 147, 169]]], ["Previous studies also indicated that certain accessory proteins encoded by coronaviruses, such as IFN antagonists, can play a role of positive or negative regulation in the virus replication (Cruz et al., 2011; Zhao et al., 2012).", [["IFN antagonists", "GENE_OR_GENE_PRODUCT", 98, 113], ["accessory proteins", "PROTEIN", 45, 63], ["IFN", "PROTEIN", 98, 101], ["Previous studies", "TEST", 0, 16], ["certain accessory proteins", "PROBLEM", 37, 63], ["coronaviruses", "PROBLEM", 75, 88], ["IFN antagonists", "TREATMENT", 98, 113]]], ["For example, the deletion of TGEV ORF7 facilitates the virus replication (Cruz et al., 2011), while the deletion of MHV ns2 significantly attenuates virus replication (Zhao et al., 2012).", [["TGEV", "ORGANISM", 29, 33], ["ORF7", "GENE_OR_GENE_PRODUCT", 34, 38], ["MHV ns2", "ORGANISM", 116, 123], ["TGEV ORF7", "PROTEIN", 29, 38], ["MHV ns2", "PROTEIN", 116, 123], ["TGEV", "SPECIES", 29, 33], ["MHV", "SPECIES", 116, 119], ["TGEV ORF7", "TREATMENT", 29, 38], ["the virus replication", "TREATMENT", 51, 72], ["MHV ns2", "TREATMENT", 116, 123]]], ["Certainly, whether various functions of NS7 and NS7a on viral replication contribute to the phenotype of the NS7 deletion mutants need to be confirmed further.DiscussionIKK\u03b5 and TBK1 are two critical kinases in the RLR signaling pathway for type I IFN production.", [["NS7", "GENE_OR_GENE_PRODUCT", 40, 43], ["NS7a", "GENE_OR_GENE_PRODUCT", 48, 52], ["NS7", "GENE_OR_GENE_PRODUCT", 109, 112], ["DiscussionIKK\u03b5", "GENE_OR_GENE_PRODUCT", 159, 173], ["TBK1", "GENE_OR_GENE_PRODUCT", 178, 182], ["RLR", "GENE_OR_GENE_PRODUCT", 215, 218], ["type I IFN", "GENE_OR_GENE_PRODUCT", 241, 251], ["NS7", "PROTEIN", 40, 43], ["NS7a", "PROTEIN", 48, 52], ["NS7 deletion mutants", "DNA", 109, 129], ["DiscussionIKK\u03b5", "PROTEIN", 159, 173], ["TBK1", "PROTEIN", 178, 182], ["RLR", "PROTEIN", 215, 218], ["IFN", "PROTEIN", 248, 251], ["NS7", "TREATMENT", 40, 43], ["NS7a", "TREATMENT", 48, 52], ["viral replication", "TREATMENT", 56, 73], ["the NS7 deletion mutants", "PROBLEM", 105, 129], ["type I IFN production", "PROBLEM", 241, 262]]], ["Thus, it is not surprising that many viruses have evolved various mechanisms that target these two kinases to antagonize IFN production.", [["IFN", "GENE_OR_GENE_PRODUCT", 121, 124], ["kinases", "PROTEIN", 99, 106], ["IFN", "PROTEIN", 121, 124], ["many viruses", "PROBLEM", 32, 44], ["IFN production", "PROBLEM", 121, 135], ["viruses", "OBSERVATION", 37, 44]]], ["For example, the SARS-CoV M protein binds to multiple key signaling molecules, including RIG-I, TBK1, IKK\u03b5, and TRAF3, and disrupts the formation of a complex between TRAF3 and IKK\u03b5/TBK1 (Siu et al., 2009).", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 17, 25], ["RIG-I", "GENE_OR_GENE_PRODUCT", 89, 94], ["TBK1", "GENE_OR_GENE_PRODUCT", 96, 100], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 102, 106], ["TRAF3", "GENE_OR_GENE_PRODUCT", 112, 117], ["TRAF3", "GENE_OR_GENE_PRODUCT", 167, 172], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 177, 181], ["TBK1", "GENE_OR_GENE_PRODUCT", 182, 186], ["SARS-CoV M protein", "PROTEIN", 17, 35], ["signaling molecules", "PROTEIN", 58, 77], ["RIG-I", "PROTEIN", 89, 94], ["TBK1", "PROTEIN", 96, 100], ["IKK\u03b5", "PROTEIN", 102, 106], ["TRAF3", "PROTEIN", 112, 117], ["TRAF3", "PROTEIN", 167, 172], ["IKK\u03b5", "PROTEIN", 177, 181], ["TBK1", "PROTEIN", 182, 186], ["SARS-CoV", "SPECIES", 17, 25], ["the SARS-CoV M protein binds", "PROBLEM", 13, 41], ["multiple key signaling molecules", "PROBLEM", 45, 77], ["TBK1", "PROBLEM", 96, 100], ["IKK\u03b5", "TEST", 102, 106], ["TRAF3", "TEST", 112, 117], ["signaling molecules", "OBSERVATION", 58, 77], ["TRAF3", "ANATOMY", 112, 117]]], ["There are also several reports showing that viral proteins inhibit interactions between TBK1 or IKK\u03b5 and their downstream molecules.", [["TBK1", "GENE_OR_GENE_PRODUCT", 88, 92], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 96, 100], ["viral proteins", "PROTEIN", 44, 58], ["TBK1", "PROTEIN", 88, 92], ["IKK\u03b5", "PROTEIN", 96, 100], ["downstream molecules", "PROTEIN", 111, 131], ["viral proteins", "PROBLEM", 44, 58]]], ["For example, Ebola virus protein VP35 interacts with both TBK1 and IKK\u03b5, disrupting the interaction of TBK1/IKK\u03b5 with IRF3 to inhibit type I IFN production (Prins et al., 2009).", [["Ebola virus", "ORGANISM", 13, 24], ["VP35", "GENE_OR_GENE_PRODUCT", 33, 37], ["TBK1", "GENE_OR_GENE_PRODUCT", 58, 62], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 67, 71], ["TBK1", "GENE_OR_GENE_PRODUCT", 103, 107], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 108, 112], ["IRF3", "GENE_OR_GENE_PRODUCT", 118, 122], ["type I IFN", "GENE_OR_GENE_PRODUCT", 134, 144], ["Ebola virus protein", "PROTEIN", 13, 32], ["VP35", "PROTEIN", 33, 37], ["TBK1", "PROTEIN", 58, 62], ["IKK\u03b5", "PROTEIN", 67, 71], ["TBK1", "PROTEIN", 103, 107], ["IKK\u03b5", "PROTEIN", 108, 112], ["IRF3", "PROTEIN", 118, 122], ["type I IFN", "PROTEIN", 134, 144], ["Ebola virus", "SPECIES", 13, 24], ["Ebola virus", "SPECIES", 13, 24], ["Ebola virus protein VP35", "PROBLEM", 13, 37], ["IRF3", "PROBLEM", 118, 122]]], ["PEDV N protein and Hepatitis C virus (HCV) NS3 bind to both TBK1 and IKK\u03b5, and antagonize IFN-\u03b2 production by impairing the interaction between TBK1 and IRF3 (Ding et al., 2014).", [["PEDV N protein", "GENE_OR_GENE_PRODUCT", 0, 14], ["Hepatitis C virus", "ORGANISM", 19, 36], ["HCV", "ORGANISM", 38, 41], ["NS3", "ORGANISM", 43, 46], ["TBK1", "GENE_OR_GENE_PRODUCT", 60, 64], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 69, 73], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 90, 95], ["TBK1", "GENE_OR_GENE_PRODUCT", 144, 148], ["IRF3", "GENE_OR_GENE_PRODUCT", 153, 157], ["PEDV N protein", "PROTEIN", 0, 14], ["Hepatitis C virus (HCV) NS3", "PROTEIN", 19, 46], ["TBK1", "PROTEIN", 60, 64], ["IKK\u03b5", "PROTEIN", 69, 73], ["IFN", "PROTEIN", 90, 93], ["\u03b2", "PROTEIN", 94, 95], ["TBK1", "PROTEIN", 144, 148], ["IRF3", "PROTEIN", 153, 157], ["Hepatitis C virus", "SPECIES", 19, 36], ["PEDV", "SPECIES", 0, 4], ["Hepatitis C virus", "SPECIES", 19, 36], ["HCV", "SPECIES", 38, 41], ["PEDV", "PROBLEM", 0, 4], ["Hepatitis C virus", "PROBLEM", 19, 36], ["NS3 bind", "TREATMENT", 43, 51], ["TBK1", "TEST", 60, 64], ["IKK\u03b5", "TEST", 69, 73]]], ["Other viral proteins, like the herpes simplex virus 1 (HSV-1) \u03b3134.5 protein, interact with TBK1 and block its association with downstream IRF3 (Verpooten et al., 2009).", [["herpes simplex", "DISEASE", 31, 45], ["herpes simplex virus 1", "ORGANISM", 31, 53], ["HSV-1", "ORGANISM", 55, 60], ["\u03b3134.5", "GENE_OR_GENE_PRODUCT", 62, 68], ["TBK1", "GENE_OR_GENE_PRODUCT", 92, 96], ["IRF3", "GENE_OR_GENE_PRODUCT", 139, 143], ["viral proteins", "PROTEIN", 6, 20], ["herpes simplex virus 1 (HSV-1) \u03b3134.5 protein", "PROTEIN", 31, 76], ["TBK1", "PROTEIN", 92, 96], ["IRF3", "PROTEIN", 139, 143], ["herpes simplex virus 1", "SPECIES", 31, 53], ["HSV-1", "SPECIES", 55, 60], ["herpes simplex virus 1", "SPECIES", 31, 53], ["HSV-1", "SPECIES", 55, 60], ["Other viral proteins", "TEST", 0, 20], ["the herpes simplex virus", "TEST", 27, 51], ["HSV", "TEST", 55, 58], ["TBK1", "PROBLEM", 92, 96], ["viral proteins", "OBSERVATION", 6, 20]]], ["However, whether formation of the IKK\u03b5-IRF3 complex is blocked by PEDV N, HCV NS3, and HSV-1 \u03b3134.5 remains poorly defined.", [["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 34, 38], ["IRF3", "GENE_OR_GENE_PRODUCT", 39, 43], ["PEDV N", "GENE_OR_GENE_PRODUCT", 66, 72], ["HCV NS3", "ORGANISM", 74, 81], ["HSV-1 \u03b3134.5", "GENE_OR_GENE_PRODUCT", 87, 99], ["IKK", "PROTEIN", 34, 37], ["\u03b5", "PROTEIN", 37, 38], ["IRF3 complex", "PROTEIN", 39, 51], ["PEDV N", "PROTEIN", 66, 72], ["HCV NS3", "PROTEIN", 74, 81], ["HSV-1", "SPECIES", 87, 92], ["HCV", "SPECIES", 74, 77], ["HSV-1", "SPECIES", 87, 92], ["the IKK", "TEST", 30, 37], ["IRF3 complex", "PROBLEM", 39, 51], ["PEDV", "PROBLEM", 66, 70], ["HCV NS3", "TEST", 74, 81], ["HSV", "TEST", 87, 90], ["poorly defined", "OBSERVATION_MODIFIER", 108, 122]]], ["In this study, we screened several key molecules in the RLR signaling pathway via a Co-IP assay and found that NS7a specifically targets IKK\u03b5 rather than the closely related TBK-1, which appears to be different from the action pattern found in the abovementioned examples.", [["Co", "CHEMICAL", 84, 86], ["Co", "CHEMICAL", 84, 86], ["RLR", "GENE_OR_GENE_PRODUCT", 56, 59], ["NS7a", "GENE_OR_GENE_PRODUCT", 111, 115], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 137, 141], ["TBK-1", "GENE_OR_GENE_PRODUCT", 174, 179], ["RLR", "PROTEIN", 56, 59], ["NS7a", "PROTEIN", 111, 115], ["IKK\u03b5", "PROTEIN", 137, 141], ["TBK-1", "DNA", 174, 179], ["this study", "TEST", 3, 13], ["a Co-IP assay", "TEST", 82, 95], ["TBK", "TEST", 174, 177], ["appears to be", "UNCERTAINTY", 187, 200]]], ["Indeed, there is a similar report for the arenavirus nucleoprotein, which specifically interacts with IKK\u03b5 but does not bind to TBK1, leading to the inhibition of IKK\u03b5-mediated IFN signaling (Pythoud et al., 2012).", [["arenavirus", "ORGANISM", 42, 52], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 102, 106], ["TBK1", "GENE_OR_GENE_PRODUCT", 128, 132], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 163, 167], ["IFN", "GENE_OR_GENE_PRODUCT", 177, 180], ["arenavirus nucleoprotein", "PROTEIN", 42, 66], ["IKK\u03b5", "PROTEIN", 102, 106], ["TBK1", "PROTEIN", 128, 132], ["IKK\u03b5", "PROTEIN", 163, 167], ["IFN", "PROTEIN", 177, 180], ["the arenavirus nucleoprotein", "PROBLEM", 38, 66], ["TBK1", "PROBLEM", 128, 132], ["IKK", "TEST", 163, 166]]], ["IKK\u03b5 and TBK1 are structurally and enzymatically similar and share over 60% sequence identity.", [["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 0, 4], ["TBK1", "GENE_OR_GENE_PRODUCT", 9, 13], ["IKK\u03b5", "PROTEIN", 0, 4], ["TBK1", "PROTEIN", 9, 13], ["IKK", "TEST", 0, 3], ["TBK1", "TEST", 9, 13]]], ["Initial evidence indicated a more important role for TBK1, rather than IKK\u03b5, in the induction of type I IFN in response to dsRNA and virus infection (Hemmi et al., 2004; McWhirter et al., 2004).", [["infection", "DISEASE", 139, 148], ["TBK1", "GENE_OR_GENE_PRODUCT", 53, 57], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 71, 75], ["type I IFN", "GENE_OR_GENE_PRODUCT", 97, 107], ["TBK1", "PROTEIN", 53, 57], ["IKK\u03b5", "PROTEIN", 71, 75], ["type I IFN", "PROTEIN", 97, 107], ["TBK1", "PROBLEM", 53, 57], ["type I IFN", "PROBLEM", 97, 107], ["dsRNA", "PROBLEM", 123, 128], ["virus infection", "PROBLEM", 133, 148]]], ["However, follow-up studies demonstrated that IKK\u03b5 is also critically involved in IFN-\u03b2 induction, and both IKK\u03b5 and TBK1 are required for optimal IFN induction upon virus infection, suggesting important non-redundant roles for IKK\u03b5, and TBK1 (Pythoud et al., 2012).", [["infection", "DISEASE", 171, 180], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 45, 49], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 81, 86], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 107, 111], ["TBK1", "GENE_OR_GENE_PRODUCT", 116, 120], ["IFN", "GENE_OR_GENE_PRODUCT", 146, 149], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 227, 231], ["TBK1", "GENE_OR_GENE_PRODUCT", 237, 241], ["IKK\u03b5", "PROTEIN", 45, 49], ["IFN", "PROTEIN", 81, 84], ["\u03b2", "PROTEIN", 85, 86], ["IKK\u03b5", "PROTEIN", 107, 111], ["TBK1", "PROTEIN", 116, 120], ["IFN", "PROTEIN", 146, 149], ["IKK\u03b5", "PROTEIN", 227, 231], ["TBK1", "PROTEIN", 237, 241], ["follow-up studies", "TEST", 9, 26], ["IFN", "TEST", 81, 84], ["IKK", "TEST", 107, 110], ["TBK1", "PROBLEM", 116, 120], ["optimal IFN induction", "TREATMENT", 138, 159], ["virus infection", "PROBLEM", 165, 180]]], ["Furthermore, a previous report showed that virus-inducible IKK\u03b5, but not TBK1, is strongly recruited to the mitochondria via MAVS (Lin et al., 2006).", [["mitochondria", "ANATOMY", 108, 120], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 59, 63], ["TBK1", "GENE_OR_GENE_PRODUCT", 73, 77], ["mitochondria", "CELLULAR_COMPONENT", 108, 120], ["MAVS", "GENE_OR_GENE_PRODUCT", 125, 129], ["IKK\u03b5", "PROTEIN", 59, 63], ["TBK1", "PROTEIN", 73, 77], ["MAVS", "PROTEIN", 125, 129], ["virus-inducible IKK\u03b5", "PROBLEM", 43, 63], ["TBK1", "PROBLEM", 73, 77], ["not", "UNCERTAINTY", 69, 72], ["TBK1", "OBSERVATION", 73, 77]]], ["The specificity of PDCoV NS7a (this study) and arenavirus nucleoprotein (Pythoud et al., 2012) for IKK\u03b5, but not TBK1, are very interesting and deserve further investigation.DiscussionThe interaction between IKK\u03b5 and NS7a raises two possibilities that NS7a disrupts the association of IKK\u03b5 with its upstream adaptors, as observed for the mechanism used by the SARS-CoV M protein that blocks the formation of the TRAF3-TBK1/IKK\u03b5 complex (Siu et al., 2009), or prevents the recruitment of IKK\u03b5 to its downstream transcription factors, as observed for the mechanism used by the Ebola virus protein VP35, which interacts with IKK\u03b5 to inhibit IKK\u03b5-IRF3 interaction (Prins et al., 2009).", [["PDCoV NS7a", "GENE_OR_GENE_PRODUCT", 19, 29], ["arenavirus", "ORGANISM", 47, 57], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 99, 103], ["TBK1", "GENE_OR_GENE_PRODUCT", 113, 117], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 208, 212], ["NS7a", "GENE_OR_GENE_PRODUCT", 217, 221], ["NS7a", "GENE_OR_GENE_PRODUCT", 252, 256], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 285, 289], ["SARS-CoV M", "GENE_OR_GENE_PRODUCT", 360, 370], ["TRAF3", "GENE_OR_GENE_PRODUCT", 412, 417], ["TBK1", "GENE_OR_GENE_PRODUCT", 418, 422], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 423, 427], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 487, 491], ["Ebola virus", "ORGANISM", 575, 586], ["VP35", "GENE_OR_GENE_PRODUCT", 595, 599], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 622, 626], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 638, 642], ["IRF3", "GENE_OR_GENE_PRODUCT", 643, 647], ["PDCoV NS7a", "PROTEIN", 19, 29], ["arenavirus nucleoprotein", "PROTEIN", 47, 71], ["IKK\u03b5", "PROTEIN", 99, 103], ["TBK1", "PROTEIN", 113, 117], ["IKK\u03b5", "PROTEIN", 208, 212], ["NS7a", "PROTEIN", 217, 221], ["NS7a", "PROTEIN", 252, 256], ["IKK\u03b5", "PROTEIN", 285, 289], ["upstream adaptors", "PROTEIN", 299, 316], ["SARS-CoV M protein", "PROTEIN", 360, 378], ["TRAF3", "PROTEIN", 412, 417], ["TBK1", "PROTEIN", 418, 422], ["IKK", "PROTEIN", 423, 426], ["\u03b5 complex", "PROTEIN", 426, 435], ["IKK\u03b5", "PROTEIN", 487, 491], ["transcription factors", "PROTEIN", 510, 531], ["Ebola virus protein", "PROTEIN", 575, 594], ["VP35", "PROTEIN", 595, 599], ["IKK\u03b5", "PROTEIN", 622, 626], ["IKK", "PROTEIN", 638, 641], ["\u03b5", "PROTEIN", 641, 642], ["IRF3", "PROTEIN", 643, 647], ["Ebola virus", "SPECIES", 575, 586], ["PDCoV", "SPECIES", 19, 24], ["SARS-CoV", "SPECIES", 360, 368], ["Ebola virus", "SPECIES", 575, 586], ["PDCoV NS7a", "TREATMENT", 19, 29], ["this study", "TEST", 31, 41], ["TBK1", "PROBLEM", 113, 117], ["further investigation", "TEST", 152, 173], ["IKK", "PROBLEM", 285, 288], ["its upstream adaptors", "TREATMENT", 295, 316], ["CoV M protein", "TREATMENT", 365, 378], ["the TRAF3", "TEST", 408, 417], ["the Ebola virus protein VP35", "TREATMENT", 571, 599]]], ["In this study, both TRAF3 and IRF3 coimmunoprecipitated by IKK\u03b5 decreased notably under the conditions of NS7a overexpression and PDCoV infection.", [["infection", "DISEASE", 136, 145], ["TRAF3", "GENE_OR_GENE_PRODUCT", 20, 25], ["IRF3", "GENE_OR_GENE_PRODUCT", 30, 34], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 59, 63], ["NS7a", "GENE_OR_GENE_PRODUCT", 106, 110], ["PDCoV", "GENE_OR_GENE_PRODUCT", 130, 135], ["TRAF3", "PROTEIN", 20, 25], ["IRF3", "PROTEIN", 30, 34], ["IKK\u03b5", "PROTEIN", 59, 63], ["NS7a", "PROTEIN", 106, 110], ["PDCoV", "SPECIES", 130, 135], ["this study", "TEST", 3, 13], ["NS7a overexpression", "PROBLEM", 106, 125], ["PDCoV infection", "PROBLEM", 130, 145], ["infection", "OBSERVATION", 136, 145]]], ["These results suggest that NS7a acts as a competitor of both TRAF3 and IRF3 for IKK\u03b5 binding, leading to the inhibition of type I IFN production.", [["NS7a", "GENE_OR_GENE_PRODUCT", 27, 31], ["TRAF3", "GENE_OR_GENE_PRODUCT", 61, 66], ["IRF3", "GENE_OR_GENE_PRODUCT", 71, 75], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 80, 84], ["type I IFN", "GENE_OR_GENE_PRODUCT", 123, 133], ["NS7a", "PROTEIN", 27, 31], ["TRAF3", "PROTEIN", 61, 66], ["IRF3", "PROTEIN", 71, 75], ["IKK\u03b5", "PROTEIN", 80, 84], ["type I IFN", "PROTEIN", 123, 133], ["IKK\u03b5 binding", "PROBLEM", 80, 92], ["type I IFN production", "PROBLEM", 123, 144]]], ["IKK\u03b5 kinase contains two key functional domains, SDD and KD, which have been confirmed to mediate the interaction of TRAF3-IKK\u03b5 and IKK\u03b5-IRF3, respectively (Prins et al., 2009; Fang R. et al., 2017).", [["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 0, 4], ["SDD", "GENE_OR_GENE_PRODUCT", 49, 52], ["TRAF3", "GENE_OR_GENE_PRODUCT", 117, 122], ["IKK", "GENE_OR_GENE_PRODUCT", 123, 126], ["\u03b5", "GENE_OR_GENE_PRODUCT", 126, 127], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 132, 136], ["IRF3", "GENE_OR_GENE_PRODUCT", 137, 141], ["IKK\u03b5 kinase", "PROTEIN", 0, 11], ["SDD", "PROTEIN", 49, 52], ["KD", "PROTEIN", 57, 59], ["TRAF3", "PROTEIN", 117, 122], ["IKK", "PROTEIN", 123, 126], ["\u03b5", "PROTEIN", 126, 127], ["IKK\u03b5", "PROTEIN", 132, 136], ["IRF3", "PROTEIN", 137, 141], ["IKK\u03b5 kinase", "TEST", 0, 11], ["KD", "TEST", 57, 59], ["TRAF3", "TEST", 117, 122], ["IKK", "TEST", 123, 126], ["IKK\u03b5", "TEST", 132, 136]]], ["Previous studies also indicated that certain viral proteins interact with IKK\u03b5 KD to block IKK\u03b5-mediated IFN signaling and perturb innate antiviral defense.", [["IKK", "GENE_OR_GENE_PRODUCT", 74, 77], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 91, 95], ["IFN", "GENE_OR_GENE_PRODUCT", 105, 108], ["viral proteins", "PROTEIN", 45, 59], ["IKK", "PROTEIN", 74, 77], ["IKK\u03b5", "PROTEIN", 91, 95], ["IFN", "PROTEIN", 105, 108], ["Previous studies", "TEST", 0, 16], ["antiviral defense", "OBSERVATION", 138, 155]]], ["For example, the lymphocytic choriomeningitis virus (LCMV) nucleoprotein specifically binds to the KD of IKK\u03b5, which inhibits IKK\u03b5 activity to phosphorylate IRF3 (Pythoud et al., 2012).", [["lymphocytic choriomeningitis virus", "ORGANISM", 17, 51], ["LCMV", "ORGANISM", 53, 57], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 105, 109], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 126, 130], ["IRF3", "GENE_OR_GENE_PRODUCT", 157, 161], ["IKK\u03b5", "PROTEIN", 105, 109], ["IKK\u03b5", "PROTEIN", 126, 130], ["IRF3", "PROTEIN", 157, 161], ["lymphocytic choriomeningitis virus", "SPECIES", 17, 51], ["lymphocytic choriomeningitis virus", "SPECIES", 17, 51], ["LCMV", "SPECIES", 53, 57], ["the lymphocytic choriomeningitis virus", "PROBLEM", 13, 51], ["phosphorylate IRF3", "TEST", 143, 161], ["lymphocytic choriomeningitis virus", "OBSERVATION", 17, 51]]], ["The nonstructural 2B/3 (NS2B/3) protease encoded by the Dengue virus potentially interacts with the IKK\u03b5 KD and affects its functionality, facilitating inhibition of the IFN signaling response (Anglero-Rodriguez et al., 2014).", [["Dengue", "DISEASE", 56, 62], ["nonstructural 2B/3", "GENE_OR_GENE_PRODUCT", 4, 22], ["NS2B/3", "GENE_OR_GENE_PRODUCT", 24, 30], ["Dengue virus", "ORGANISM", 56, 68], ["IKK", "GENE_OR_GENE_PRODUCT", 100, 103], ["IFN", "GENE_OR_GENE_PRODUCT", 170, 173], ["nonstructural 2B/3 (NS2B/3) protease", "PROTEIN", 4, 40], ["IKK\u03b5", "PROTEIN", 100, 104], ["IFN", "PROTEIN", 170, 173], ["Dengue virus", "SPECIES", 56, 68], ["The nonstructural 2B/3 (NS2B/3) protease", "TREATMENT", 0, 40], ["the Dengue virus", "PROBLEM", 52, 68]]], ["In addition, the human T-cell leukemia virus type 1 (HTLV-1) HBZ protein, and the P protein encoded by rabies virus (RABV) street strains also specifically interact with IKK\u03b5 and further inhibit IKK\u03b5-mediated IRF3 activation; a detail mechanism is, however, missing (Masatani et al., 2016; Narulla et al., 2017).", [["human T-cell leukemia virus type 1", "ORGANISM", 17, 51], ["HTLV-1", "ORGANISM", 53, 59], ["HBZ", "GENE_OR_GENE_PRODUCT", 61, 64], ["rabies virus", "ORGANISM", 103, 115], ["RABV", "ORGANISM", 117, 121], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 170, 174], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 195, 199], ["IRF3", "GENE_OR_GENE_PRODUCT", 209, 213], ["human T-cell leukemia virus type 1 (HTLV-1) HBZ protein", "PROTEIN", 17, 72], ["P protein", "PROTEIN", 82, 91], ["IKK\u03b5", "PROTEIN", 170, 174], ["IKK\u03b5", "PROTEIN", 195, 199], ["IRF3", "PROTEIN", 209, 213], ["human", "SPECIES", 17, 22], ["T-cell leukemia virus type 1", "SPECIES", 23, 51], ["HTLV-1", "SPECIES", 53, 59], ["rabies virus", "SPECIES", 103, 115], ["human T-cell leukemia virus type 1", "SPECIES", 17, 51], ["HTLV-1", "SPECIES", 53, 59], ["rabies virus", "SPECIES", 103, 115], ["RABV", "SPECIES", 117, 121], ["the human T-cell leukemia virus type", "TEST", 13, 49], ["HTLV", "TEST", 53, 57], ["HBZ protein", "TEST", 61, 72], ["the P protein", "TEST", 78, 91], ["rabies virus", "PROBLEM", 103, 115], ["IKK", "TEST", 195, 198], ["IRF3 activation", "PROBLEM", 209, 224], ["cell leukemia virus", "OBSERVATION", 25, 44], ["IRF3 activation", "OBSERVATION", 209, 224]]], ["In contrast to the above reported mechanisms, NS7a not only binds to the KD but also the SDD of IKK\u03b5, competing with TRAF3 and IRF3 for their binding, respectively.", [["NS7a", "GENE_OR_GENE_PRODUCT", 46, 50], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 96, 100], ["TRAF3", "GENE_OR_GENE_PRODUCT", 117, 122], ["IRF3", "GENE_OR_GENE_PRODUCT", 127, 131], ["NS7a", "PROTEIN", 46, 50], ["IKK\u03b5", "PROTEIN", 96, 100], ["TRAF3", "PROTEIN", 117, 122], ["IRF3", "PROTEIN", 127, 131], ["the SDD of IKK\u03b5", "PROBLEM", 85, 100], ["TRAF3", "TREATMENT", 117, 122]]], ["Simultaneous interaction of NS7a with both the SDD and KD of IKK\u03b5 may afford a more stable complex that effectively impairs IKK\u03b5-mediated type I IFN signaling.DiscussionAs an emerging porcine enteric CoV with potential to cross the species barrier and even its zoonotic potential, PDCoV has received more attention and considerable progress in understanding the biology of PDCoV has been made in the past 5 years (Shang et al., 2018; Xiong et al., 2018; Zheng et al., 2018; Qin et al., 2019; Zhang et al., 2019).", [["PDCoV", "CHEMICAL", 281, 286], ["PDCoV", "DISEASE", 373, 378], ["NS7a", "GENE_OR_GENE_PRODUCT", 28, 32], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 61, 65], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 124, 128], ["type I IFN", "GENE_OR_GENE_PRODUCT", 138, 148], ["porcine enteric CoV", "ORGANISM", 184, 203], ["PDCoV", "CANCER", 373, 378], ["NS7a", "PROTEIN", 28, 32], ["IKK\u03b5", "PROTEIN", 61, 65], ["IKK\u03b5", "PROTEIN", 124, 128], ["IFN", "PROTEIN", 145, 148], ["NS7a", "TREATMENT", 28, 32]]], ["Currently, nonstructural proteins nsp5 (Zhu et al., 2017a,b) and nsp15 (Liu et al., 2019), structural nucleocapsid (N) protein (Chen et al., 2019; Likai et al., 2019), accessory proteins NS6 (Fang et al., 2018), and NS7a (this study) encoded by PDCoV have been identified as IFN antagonists.", [["PDCoV", "CHEMICAL", 245, 250], ["nsp5", "GENE_OR_GENE_PRODUCT", 34, 38], ["nsp15", "GENE_OR_GENE_PRODUCT", 65, 70], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 102, 118], ["NS7a", "GENE_OR_GENE_PRODUCT", 216, 220], ["PDCoV", "GENE_OR_GENE_PRODUCT", 245, 250], ["IFN antagonists", "GENE_OR_GENE_PRODUCT", 275, 290], ["nonstructural proteins", "PROTEIN", 11, 33], ["nsp5", "PROTEIN", 34, 38], ["nsp15", "PROTEIN", 65, 70], ["structural nucleocapsid (N) protein", "PROTEIN", 91, 126], ["accessory proteins", "PROTEIN", 168, 186], ["NS6", "PROTEIN", 187, 190], ["NS7a", "PROTEIN", 216, 220], ["PDCoV", "PROTEIN", 245, 250], ["IFN", "PROTEIN", 275, 278], ["nonstructural proteins", "TEST", 11, 33], ["structural nucleocapsid", "TEST", 91, 114], ["protein", "TEST", 119, 126], ["Likai et al.", "TEST", 147, 159], ["accessory proteins", "TEST", 168, 186], ["this study", "TEST", 222, 232], ["IFN antagonists", "TREATMENT", 275, 290]]], ["However, it is noteworthy that several studies indicated that PDCoV induces type I IFN production in infected piglets.", [["PDCoV", "CHEMICAL", 62, 67], ["PDCoV", "SIMPLE_CHEMICAL", 62, 67], ["type I IFN", "GENE_OR_GENE_PRODUCT", 76, 86], ["piglets", "ORGANISM", 110, 117], ["IFN", "PROTEIN", 83, 86], ["piglets", "SPECIES", 110, 117], ["several studies", "TEST", 31, 46], ["PDCoV", "PROBLEM", 62, 67], ["type I IFN production", "PROBLEM", 76, 97], ["infected piglets", "PROBLEM", 101, 117], ["infected piglets", "OBSERVATION", 101, 117]]], ["For example, Jung et al. detected serum cytokine responses of gnotobiotic pigs with acute PDCoV infection and found that serum IFN-\u03b1 and IL-22 were increased at 1 day post-inoculation (dpi) (Jung et al., 2018); Xu et al. reported that inoculating conventional weaned piglets with PDCoV at a high dose (1 \u00d7 109 TCID50/head) by oral feeding could induce mRNA expression of TLR3, IL-12, IFN-\u03b1, IFN-\u03b2, and PKR in Peyer's patches at 3 dpi, but not at 7 dpi, indicating that PDCoV infection induces innate immune responses during the early infection in vivo, while it overcomes the antiviral innate immunity to infect the body at the late infection (Xu et al., 2019).", [["serum", "ANATOMY", 34, 39], ["serum", "ANATOMY", 121, 126], ["head", "ANATOMY", 317, 321], ["oral", "ANATOMY", 326, 330], ["body", "ANATOMY", 616, 620], ["PDCoV infection", "DISEASE", 90, 105], ["PDCoV", "CHEMICAL", 280, 285], ["PDCoV", "CHEMICAL", 469, 474], ["infection", "DISEASE", 475, 484], ["infection", "DISEASE", 534, 543], ["infection", "DISEASE", 633, 642], ["serum", "ORGANISM_SUBSTANCE", 34, 39], ["gnotobiotic pigs", "ORGANISM", 62, 78], ["serum", "ORGANISM_SUBSTANCE", 121, 126], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 127, 132], ["IL-22", "GENE_OR_GENE_PRODUCT", 137, 142], ["piglets", "ORGANISM", 267, 274], ["PDCoV", "SIMPLE_CHEMICAL", 280, 285], ["head", "ORGANISM_SUBDIVISION", 317, 321], ["oral", "ORGANISM_SUBDIVISION", 326, 330], ["TLR3", "GENE_OR_GENE_PRODUCT", 371, 375], ["IL-12", "GENE_OR_GENE_PRODUCT", 377, 382], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 384, 389], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 391, 396], ["PKR", "GENE_OR_GENE_PRODUCT", 402, 405], ["Peyer's patches", "ORGANISM", 409, 424], ["PDCoV", "GENE_OR_GENE_PRODUCT", 469, 474], ["body", "ORGANISM_SUBDIVISION", 616, 620], ["serum cytokine", "PROTEIN", 34, 48], ["IFN", "PROTEIN", 127, 130], ["IL", "PROTEIN", 137, 139], ["TLR3", "PROTEIN", 371, 375], ["IL-12", "PROTEIN", 377, 382], ["IFN", "PROTEIN", 384, 387], ["\u03b1", "PROTEIN", 388, 389], ["IFN", "PROTEIN", 391, 394], ["\u03b2", "PROTEIN", 395, 396], ["PKR", "PROTEIN", 402, 405], ["gnotobiotic pigs", "SPECIES", 62, 78], ["piglets", "SPECIES", 267, 274], ["pigs", "SPECIES", 74, 78], ["PDCoV", "SPECIES", 90, 95], ["PDCoV", "SPECIES", 280, 285], ["PDCoV", "SPECIES", 469, 474], ["serum cytokine responses", "TEST", 34, 58], ["gnotobiotic pigs", "TREATMENT", 62, 78], ["acute PDCoV infection", "PROBLEM", 84, 105], ["serum IFN", "TEST", 121, 130], ["IL", "TEST", 137, 139], ["PDCoV", "TREATMENT", 280, 285], ["oral feeding", "TREATMENT", 326, 338], ["TLR3", "TEST", 371, 375], ["IL", "TEST", 377, 379], ["IFN", "TEST", 384, 387], ["IFN", "TEST", 391, 394], ["PKR", "TREATMENT", 402, 405], ["PDCoV infection", "PROBLEM", 469, 484], ["the early infection", "PROBLEM", 524, 543], ["the antiviral innate immunity", "TREATMENT", 572, 601], ["gnotobiotic pigs", "OBSERVATION_MODIFIER", 62, 78], ["acute", "OBSERVATION_MODIFIER", 84, 89], ["PDCoV", "OBSERVATION_MODIFIER", 90, 95], ["infection", "OBSERVATION", 96, 105], ["infection", "OBSERVATION", 475, 484], ["early", "OBSERVATION_MODIFIER", 528, 533], ["infection", "OBSERVATION", 534, 543], ["late", "OBSERVATION_MODIFIER", 628, 632], ["infection", "OBSERVATION", 633, 642]]], ["In our previous study, we found that PDCoV infection did not induced IFN-\u03b2 expression at 24 h post-infection and even suppressed SeV-induced IFN-\u03b2 production in cell cultures (Luo et al., 2016).", [["cell cultures", "ANATOMY", 161, 174], ["PDCoV", "CHEMICAL", 37, 42], ["infection", "DISEASE", 43, 52], ["infection", "DISEASE", 99, 108], ["PDCoV", "SIMPLE_CHEMICAL", 37, 42], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 69, 74], ["SeV", "ORGANISM", 129, 132], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 141, 146], ["cell cultures", "CELL", 161, 174], ["IFN", "PROTEIN", 69, 72], ["\u03b2", "PROTEIN", 73, 74], ["IFN", "PROTEIN", 141, 144], ["\u03b2", "PROTEIN", 145, 146], ["SeV", "SPECIES", 129, 132], ["our previous study", "TEST", 3, 21], ["PDCoV infection", "PROBLEM", 37, 52], ["IFN", "PROBLEM", 69, 72], ["infection", "PROBLEM", 99, 108], ["IFN", "PROBLEM", 141, 144], ["\u03b2 production", "PROBLEM", 145, 157], ["cell cultures", "TEST", 161, 174], ["infection", "OBSERVATION", 43, 52], ["infection", "OBSERVATION", 99, 108]]], ["Indeed, in PDCoV-infected cells (LLC-PK1), low levels of mRNA expression of IFN-\u03b2 could also be detected.", [["cells", "ANATOMY", 26, 31], ["LLC-PK1", "ANATOMY", 33, 40], ["PDCoV", "GENE_OR_GENE_PRODUCT", 11, 16], ["cells", "CELL", 26, 31], ["LLC-PK1", "CELL", 33, 40], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 76, 81], ["PDCoV-infected cells", "CELL_LINE", 11, 31], ["LLC", "CELL_LINE", 33, 36], ["PK1", "CELL_LINE", 37, 40], ["IFN", "PROTEIN", 76, 79], ["\u03b2", "PROTEIN", 80, 81], ["low levels of mRNA expression of IFN", "PROBLEM", 43, 79], ["infected cells", "OBSERVATION", 17, 31], ["low levels", "OBSERVATION_MODIFIER", 43, 53]]], ["Similar observations were also reported for other CoVs, such as PEDV, SARS-CoV, and MERS-CoV (Chen et al., 2010; Annamalai et al., 2015; Mahallawi et al., 2018).", [["CoVs", "GENE_OR_GENE_PRODUCT", 50, 54], ["PEDV", "GENE_OR_GENE_PRODUCT", 64, 68], ["SARS-CoV", "ORGANISM", 70, 78], ["MERS-CoV", "ORGANISM", 84, 92], ["PEDV", "SPECIES", 64, 68], ["SARS-CoV", "SPECIES", 70, 78], ["MERS-CoV", "SPECIES", 84, 92], ["other CoVs", "PROBLEM", 44, 54], ["PEDV", "PROBLEM", 64, 68], ["SARS", "PROBLEM", 70, 74]]], ["For example, PEDV infection in suckling pigs leads to the increased serum IFN-\u03b1 in the early stages (Annamalai et al., 2015); In the early period of infection, a modest increase in the level of IFN-\u03b1 and IFN-\u03b2 can be detected in the lungs of SARS-CoV-infected BALB/c mice (Chen et al., 2010).", [["serum", "ANATOMY", 68, 73], ["lungs", "ANATOMY", 233, 238], ["PEDV", "CHEMICAL", 13, 17], ["infection", "DISEASE", 18, 27], ["infection", "DISEASE", 149, 158], ["PEDV", "GENE_OR_GENE_PRODUCT", 13, 17], ["suckling pigs", "ORGANISM", 31, 44], ["serum", "ORGANISM_SUBSTANCE", 68, 73], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 74, 79], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 194, 199], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 204, 209], ["lungs", "ORGAN", 233, 238], ["SARS-CoV", "ORGANISM", 242, 250], ["BALB/c mice", "ORGANISM", 260, 271], ["serum IFN-\u03b1", "PROTEIN", 68, 79], ["IFN", "PROTEIN", 194, 197], ["\u03b1", "PROTEIN", 198, 199], ["IFN", "PROTEIN", 204, 207], ["\u03b2", "PROTEIN", 208, 209], ["pigs", "SPECIES", 40, 44], ["mice", "SPECIES", 267, 271], ["PEDV", "SPECIES", 13, 17], ["pigs", "SPECIES", 40, 44], ["SARS-CoV", "SPECIES", 242, 250], ["mice", "SPECIES", 267, 271], ["PEDV infection", "PROBLEM", 13, 27], ["the increased serum IFN", "PROBLEM", 54, 77], ["infection", "PROBLEM", 149, 158], ["a modest increase", "PROBLEM", 160, 177], ["IFN", "TEST", 194, 197], ["IFN", "TEST", 204, 207], ["SARS", "PROBLEM", 242, 246], ["PEDV", "OBSERVATION_MODIFIER", 13, 17], ["infection", "OBSERVATION", 18, 27], ["increased", "OBSERVATION_MODIFIER", 58, 67], ["serum IFN", "OBSERVATION_MODIFIER", 68, 77], ["infection", "OBSERVATION", 149, 158], ["modest", "OBSERVATION_MODIFIER", 162, 168], ["increase", "OBSERVATION_MODIFIER", 169, 177], ["lungs", "ANATOMY", 233, 238]]], ["There is also an increase of plasma IFN-\u03b12 in MERS-CoV-infected patients (Mahallawi et al., 2018).", [["plasma", "ANATOMY", 29, 35], ["MERS-CoV-infected", "DISEASE", 46, 63], ["plasma", "ORGANISM_SUBSTANCE", 29, 35], ["IFN-\u03b12", "GENE_OR_GENE_PRODUCT", 36, 42], ["MERS-CoV", "ORGANISM", 46, 54], ["patients", "ORGANISM", 64, 72], ["IFN", "PROTEIN", 36, 39], ["patients", "SPECIES", 64, 72], ["MERS-CoV", "SPECIES", 46, 54], ["plasma IFN", "TEST", 29, 39], ["increase", "OBSERVATION_MODIFIER", 17, 25], ["plasma IFN", "OBSERVATION", 29, 39], ["infected", "OBSERVATION_MODIFIER", 55, 63]]], ["It is possible that the dsRNA replication intermediates generated during virus replication contribute to the induction of low or moderate level of IFN production before the expression of virus-encoded IFN antagonists, such as PDCoV NS7a in this study.", [["IFN", "GENE_OR_GENE_PRODUCT", 147, 150], ["IFN antagonists", "GENE_OR_GENE_PRODUCT", 201, 216], ["PDCoV NS7a", "GENE_OR_GENE_PRODUCT", 226, 236], ["IFN", "PROTEIN", 147, 150], ["IFN", "PROTEIN", 201, 204], ["PDCoV NS7a", "PROTEIN", 226, 236], ["PDCoV", "SPECIES", 226, 231], ["the dsRNA replication intermediates", "PROBLEM", 20, 55], ["virus replication", "TREATMENT", 73, 90], ["low or moderate level of IFN production", "PROBLEM", 122, 161], ["virus", "PROBLEM", 187, 192], ["encoded IFN antagonists", "TREATMENT", 193, 216], ["PDCoV NS7a", "TREATMENT", 226, 236], ["this study", "TEST", 240, 250], ["moderate", "OBSERVATION_MODIFIER", 129, 137]]], ["The immune system of the body is certainly more complex than that of cell culture system.", [["immune system", "ANATOMY", 4, 17], ["body", "ANATOMY", 25, 29], ["cell culture system", "ANATOMY", 69, 88], ["body", "ORGANISM_SUBDIVISION", 25, 29], ["cell", "CELL", 69, 73], ["cell culture system", "TEST", 69, 88], ["immune system", "OBSERVATION", 4, 17], ["body", "ANATOMY", 25, 29], ["more complex", "OBSERVATION_MODIFIER", 43, 55]]], ["Other unidentified factors may contribute to the differences observed in vivo and in vitro during virus infection.Data Availability StatementThe datasets generated for this study are available on request to the corresponding author.Author ContributionsPF, LF, and SXiao conceived and designed research.", [["infection", "DISEASE", 104, 113], ["vitro during virus infection", "PROBLEM", 85, 113], ["this study", "TEST", 168, 178]]], ["PF, SXia, JR, JZ, and DB performed the experiments.", [["PF", "PROBLEM", 0, 2], ["SXia", "PROBLEM", 4, 8]]], ["PF wrote the manuscript with critical input from LF, GP, SZ, and SXiao.", [["SZ", "PROBLEM", 57, 59], ["SXiao", "TREATMENT", 65, 70], ["LF", "ANATOMY", 49, 51], ["SZ", "OBSERVATION", 57, 59]]], ["All authors discussed results and contributed to manuscript preparation.Conflict of InterestThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [["manuscript preparation", "TREATMENT", 49, 71]]]], "9e0793211b41e0d786df224d6245c6415d903a91": [["In fact it is not uncommon for ten percent of curriculum time in English Catholic schools to be given over to classroom Religious Education, which often equates to up to three hours per week for every student.", [["not uncommon", "UNCERTAINTY", 14, 26]]], ["In order to deliver this level of Religious Education provision it means that well over twenty-five percent of all RE teachers in England and Wales, both primary and secondary, are to be found working in Catholic schools.", [["Religious Education provision", "TREATMENT", 34, 63]]], ["This article will offer an analysis and some likely explanations for this response.The importance of the Commission on Religious EducationIt is important to appreciate the significance of the Final Report from the Comission on Religious Education (CoRE).", [["an analysis", "TEST", 24, 35]]], ["These recommendations amount to a national entitlement that sets out what all pupils should be learning in Religious Education.", [["a national entitlement", "TREATMENT", 32, 54]]], ["As such it is also addressed to the Catholic community of England and Wales, because they are a significant provider of state education-which now includes an increasing number of non-Catholic children.", [["children", "ORGANISM", 192, 200], ["children", "SPECIES", 192, 200]]], ["However, the independence of the Commission needs to be emphasised, because the commissioners were appointed as individuals and not as representatives of particular groups or educational providers.What has been the Catholic response to the CoRE Final Report?When the Final Report was published in September 2018 the Catholic Education Service of England and Wales (CES) issued a statement in the form of a press release in response, in line with many other organisations who had a stake or interest in the provision of Religious Education.", [["a press release", "TREATMENT", 404, 419]]], ["The CES is an organisation appointed by the Catholic bishops of England and Wales, to represent and safeguard their interests in matters relating to Catholic Education and Catholic schools.", [["CES", "ANATOMY", 4, 7]]], ["It is the 'efforts' of the Final Report to improve the quality of Religious Education that is singled out to be praised, but the CES statement rejects it as an attempt to fundamentally change the character of this part of the curriculum.", [["Religious Education", "TREATMENT", 66, 85]]], ["The name change to Religion and Worldview Education is seen as emptying Religious Education of its academic value, and more worryingly its academic integrity.What has been the Catholic response to the CoRE Final Report?There is no real attempt to engage with the main recommendations of the Final Report and it could be maintained the tone is largely unexcited about the fruits of the CoRE.", [["fruits", "ANATOMY", 371, 377], ["fruits", "ORGANISM_SUBDIVISION", 371, 377], ["no", "UNCERTAINTY", 228, 230]]], ["A more detailed comment from the CES would have been helpful, at least in indicating where the supporting argument for their position might lie.", [["CES", "DNA", 33, 36], ["the CES", "TEST", 29, 36]]], ["In the next section attention will be given to some possible reasons which explain or make sense of this Catholic response to the CoRE.", [["CoRE", "DNA", 130, 134]]], ["In the last section it will be argued that this failure to provide a detailed engagement with the Final Report is a serious missed opportunity for Catholic education in England and Wales to play a leading role in safeguarding and enhancing the provision of Religious Education for all children in all schools.Possible reasons for the CES to be retiscent about the recommendations of the Final ReportThere are a number of possible reasons why a brief statement was the preferred response from the CES.", [["children", "ORGANISM", 285, 293], ["children", "SPECIES", 285, 293], ["this failure", "PROBLEM", 43, 55]]], ["In fairness, perhaps a main reason is eminently practical.", [["fairness", "OBSERVATION", 3, 11], ["main", "OBSERVATION_MODIFIER", 23, 27]]], ["Although the current version was only issued in 2012 the subsequent government led revision of the GCSE public examinations in 2016 triggered the need for a more fundamental review of the directory.", [["the GCSE public examinations", "TEST", 95, 123]]], ["The changes to these very important public examinations were heavily influenced by the then Education Secretary, Michael Gove.", [["public examinations", "TEST", 36, 55]]], ["Things became more complicated in the process of reforming the GCSE Religious Studies specifications because there were fresh concerns about social cohesion and the role Religious Education could play in mitigating it (see Whittle 2018a, b) .", [["more complicated", "OBSERVATION_MODIFIER", 14, 30]]], ["Ordinarily, in Catholic schools just Catholic Christianity and papers directly related to Chrisitianity were studied for this examination.", [["this examination", "TEST", 121, 137]]], ["In order to mitigate the effects of this decision and to safeguard against further incursions, a whole-scale review process has been undertaken.", [["further incursions", "TREATMENT", 75, 93]]], ["Thus, it could be argued that updating and fixing the Curriculum Directory has meant that there has been little time, or perhaps even inclination, to engage in a detailed way with the analysis and arguments of the Final Report.", [["the analysis", "TEST", 180, 192]]], ["Moreover, given the time consuming nature of this revision, stretching over many years, it may well help to explain why there has been no further statement about the Final Report since 2018.Possible reasons for the CES to be retiscent about the recommendations of the Final ReportHowever, the situation remains that a significant educational provider in England and Wales has responded in a way that lacks detail, and given the evidence of the CES statement, it has not adequately engaged with the Final Report.", [["this revision", "TREATMENT", 45, 58], ["revision", "OBSERVATION", 50, 58]]], ["There is, of course, abundant evidence of high quality Religious Education to be found from the special system for inspecting schools of Religious Character, that operate as Section 48 Inspections.", [["high", "OBSERVATION_MODIFIER", 42, 46]]], ["These targeted inspections are conducted every five years, and for over two decades the overwhelming majority have identified good or outstanding practice in the Religious Education provision of Catholic schools.", [["good", "OBSERVATION_MODIFIER", 126, 130]]], ["Reference has already been made to the hefty amount of curriculum time devoted to Religious Education lessons, with this provision continuing even into the Sixth Form in Catholic secondary schools and colleges.", [["this provision", "TREATMENT", 116, 130]]], ["In Catholic schools the role of RE Coordinator (in primary schools) or Head of Department (secondary) is an important post of responsibility, and the subject is typically regarded as akin to the core subjects of English, Maths and Science.", [["Head", "ANATOMY", 71, 75]]], ["Almost all students are entered for the public examination (GCSE Religious Studies) in the subject.", [["the public examination", "TEST", 36, 58], ["Religious Studies", "TEST", 65, 82]]], ["There are further levels of support, in that each Catholic diocese employs both primary and secondary Religious Education advisors to support schools and individual Religious Education teachers.", [["support", "TREATMENT", 28, 35]]], ["With the demise of Local Authorities in England in the wake of schools converting to academies, the levels of additional support for Religious Education teachers outside of Catholic schools is beginning to evaporate.", [["additional support", "TREATMENT", 110, 128]]], ["If the CES statement is read in the light of this metaphor, then it becomes clearer why there might be less of a need to give a detailed response to the Final Report.Possible reasons for the CES to be retiscent about the recommendations of the Final ReportHowever, instead of framing Religious Education in Catholic schools in terms of being in a lush oasis, an alternative metaphor might be that of being in a 'bubble'-a Catholic bubble.", [["CES", "DNA", 7, 10], ["Catholic bubble", "OBSERVATION", 422, 437]]], ["However, bubbles can be surprisingly large and extend over time.", [["bubbles", "PROBLEM", 9, 16], ["bubbles", "OBSERVATION", 9, 16], ["surprisingly", "OBSERVATION_MODIFIER", 24, 36], ["large", "OBSERVATION_MODIFIER", 37, 42]]], ["Recently it has become clear that in dealing with the Covid-19 pandemic belonging to a supportive bubble is an important way of ensuring safety and security in the short and long term.", [["clear", "OBSERVATION", 23, 28]]], ["Despite political upheavals, a distinct Catholic system of education has continued up to present times in England and Wales.Possible reasons for the CES to be retiscent about the recommendations of the Final ReportThis political settlement in 1945 allowed for very high levels of state funding for Catholic schools but also mandated a considerable degree of autonomy on the part of the Catholic bishops when it comes to determining the nature, scope and content of Religious Education (Morris 2012) .", [["political upheavals", "TREATMENT", 8, 27], ["distinct", "OBSERVATION_MODIFIER", 31, 39]]], ["Since 1945 Catholic schools have developed along parallel lines to the other types of schooling and the emphasis given to Religious Education has become a fundamental part of this.", [["parallel lines", "OBSERVATION", 49, 63]]], ["These inspections, like OFSTED ones are funded by central government.", [["These inspections", "TEST", 0, 17], ["central government", "OBSERVATION", 50, 68]]], ["It is important to recognise that the bubble reflects the Catholic sector as a whole, rather than maintaining that Catholic schools are bubble like in only having Catholic Children enrolled.", [["Children", "SPECIES", 172, 180]]], ["In recent decades there has been a growing proportion of non-Catholic children attending Catholic schools (see the annual CES census data 2019, for further evidence of this trend).Possible reasons for the CES to be retiscent about the recommendations of the Final ReportOf course a danger is that bubbles can be burst and thus they need to be carefully protected.", [["children", "ORGANISM", 70, 78], ["children", "SPECIES", 70, 78]]], ["Hence even something as superficial, such as changing the name of the subject to Religion and Worldview Education, would need to be treated with the upmost skepticism and rejection.Possible reasons for the CES to be retiscent about the recommendations of the Final ReportProtecting the bubble is the key priority.", [["the upmost skepticism", "TREATMENT", 145, 166], ["rejection", "PROBLEM", 171, 180], ["rejection", "OBSERVATION", 171, 180]]], ["The concern over the name change is somewhat paradoxical, as within living memory in Catholic schools the name of the subject has changed from Religious Instruction to Religious Education.", [["somewhat paradoxical", "PROBLEM", 36, 56], ["somewhat", "OBSERVATION_MODIFIER", 36, 44], ["paradoxical", "OBSERVATION", 45, 56]]], ["Others have expressed grave reservations over the proposed new name, and the CES could appeal to, for example, Michael Hand (2018) who has raised cogent reservations over both the name change and the coherence of the notion of 'worldview'.", [["grave", "OBSERVATION_MODIFIER", 22, 27]]], ["The failure to supply this detail could fuel a suspicion that if you are inside the bubble, then you are free to name the subject in different terms, but others outside are not even allowed to tamper with the name, for fear of dire consequence.Possible reasons for the CES to be retiscent about the recommendations of the Final ReportThis idea of protecting the Catholic bubble in relation to Religious Education chimes with some deep-seated anxieties that are shared by many advocates of Catholic education in England and Wales.", [["The failure", "PROBLEM", 0, 11], ["some deep-seated anxieties", "PROBLEM", 425, 451], ["failure", "OBSERVATION", 4, 11]]], ["Although many have challenged Arthur's analysis [see Sullivan (1999) and Whittle (2018b) ] there has remained ever since a worry about the need to protect Catholic education, particularly from any critical voices.", [["Catholic education", "TREATMENT", 155, 173]]], ["Whilst there are many legitimate concerns over faith schools (see Whittle 2014) for many advocates of Catholic education the ongoing nature of this sort of debate triggers a concern about Catholic education being unfairly under attack (Pring 2017) .", [["Catholic education", "TREATMENT", 102, 120]]], ["This allows for a defensiveness, where the default response is suspicion of any potential changes and being overly protective of current state of Catholic education.", [["Catholic education", "TREATMENT", 146, 164]]], ["Moreover, there is a popular and seductive myth that in England and Wales, Catholic education is rooted in earlier centuries to a desire from the Catholic hierarchy to educate poor and needy Irish immigrants fleeing to England in the wake of the potato famine (for an example of this see Grace 2002) .", [["potato", "SPECIES", 246, 252], ["potato", "SPECIES", 246, 252], ["popular", "OBSERVATION_MODIFIER", 21, 28]]], ["Thus in England and Wales a degree of suspicion and defensiveness has entered the DNA of the Catholic Church and matters of education remain a touch point for this.", [["DNA", "CELLULAR_COMPONENT", 82, 85], ["defensiveness", "PROBLEM", 52, 65]]], ["One trivial example of this is found in the decision, less than a decade ago, to name a brand new Catholic school in West London after a Catholic who had died during the English Reformation, over three hundred years ago.", [["trivial", "OBSERVATION", 4, 11]]], ["4 The choice of this name is perhaps indicative of a defensive or siege like stance, where old wounds are recalled and young people are subtly reminded of anti-Catholic tensions.Possible reasons for the CES to be retiscent about the recommendations of the Final ReportIt may well be likely that the Final Report, despite its desire to bring about positive change for all English children, has not been responded to in a detailed way because it too was viewed with some level of suspicion.", [["wounds", "ANATOMY", 95, 101], ["wounds", "PATHOLOGICAL_FORMATION", 95, 101], ["people", "ORGANISM", 125, 131], ["children", "ORGANISM", 379, 387], ["people", "SPECIES", 125, 131], ["children", "SPECIES", 379, 387], ["a defensive or siege like stance", "PROBLEM", 51, 83], ["old wounds", "PROBLEM", 91, 101], ["perhaps indicative of", "UNCERTAINTY", 29, 50], ["wounds", "OBSERVATION", 95, 101], ["may well be likely", "UNCERTAINTY", 271, 289]]], ["A sense of service to society is taken to be a defining characteristic of a Catholic education.", [["a Catholic education", "TREATMENT", 74, 94]]], ["In England and Wales the sense in which Catholic schools serve the wider society has increased in recent decades because these schools are no longer the preserve of just the children of Catholic parents.", [["children", "ORGANISM", 174, 182], ["children", "SPECIES", 174, 182], ["increased", "OBSERVATION_MODIFIER", 85, 94]]], ["The annual Catholic school census conducted by the CES reveals an ever increasing decline in the number of Catholic children attending Catholic school, just sixty-eight percent in the most recent count (CES 2019).", [["children", "ORGANISM", 116, 124], ["children", "SPECIES", 116, 124], ["the CES", "TEST", 47, 54], ["increasing", "OBSERVATION_MODIFIER", 71, 81], ["decline", "OBSERVATION_MODIFIER", 82, 89]]], ["As I have argued elsewhere (Whittle 2018b, c) this decline looks set to continue in England and Wales as Catholic parents adopt more middle class attitudes to the schooling of their children.", [["children", "ORGANISM", 182, 190], ["children", "SPECIES", 182, 190]]], ["The sociologist Hornsby-Smith has repeatedly shown evidence of social embourgeoisement among the Catholic community in England (1978 England ( , 1999 England ( , 2009 ).", [["embourgeoisement", "DISEASE", 70, 86]]], ["The CES statement offered no practical proposals of help with implementing the main recommendations in other schools, and certainly no commitment to review or check that they are indeed being fully met in the Religious Education in Catholic schools.What ought to have been the response of Catholic education to the Final Report?There is a strong case, grounded in Catholic doctrine, for why those leading and involved with Catholic education ought to be very attentive to the poor state of Religious Education in other schools.", [["strong", "OBSERVATION_MODIFIER", 339, 345]]], ["These words state that:What ought to have been the response of Catholic education to the Final Report?The joys and the hopes, the griefs and the anxieties of the people of this age, especially those who are poor or in any way afflicted, these are the joys and hopes, the griefs and anxieties of the followers of Christ.", [["people", "ORGANISM", 162, 168], ["people", "SPECIES", 162, 168]]], ["Indeed, nothing genuinely human fails to raise an echo in their hearts.", [["hearts", "ANATOMY", 64, 70], ["human", "ORGANISM", 26, 31], ["hearts", "ORGAN", 64, 70], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 26, 31], ["an echo", "TEST", 47, 54], ["hearts", "ANATOMY", 64, 70]]], ["For theirs is a community composed of human beings.", [["human", "ORGANISM", 38, 43], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 38, 43]]], ["United in Christ, they are led by the Holy Spirit in their journey to the Kingdom of their Father and they have welcomed the news of salvation which is meant for every person.", [["person", "SPECIES", 168, 174]]], ["Thus the CES has a theological imperative, in the light of Gaudium et Spes, to both respond to and fully engage with the anxieties, fears and hopes raised by the Final Report.", [["Gaudium et Spes", "PROBLEM", 59, 74]]], ["The failure to do so is a serious shortfall.", [["The failure", "PROBLEM", 0, 11], ["failure", "OBSERVATION", 4, 11]]], ["The Final Report paints a dire picture about the provision of Religious Education in schools where too many children are missing out on what they are entitled to.", [["children", "ORGANISM", 108, 116], ["children", "SPECIES", 108, 116]]], ["Framing the Religious Education curriculum in Catholic schools around the recommendations of the Final Report would be a highly supportive gesture of solidarity and bring a harmony between the sort of Religious Education found in Catholic schools and what the CoRE is advocating as the entitlement for all children in all schools.", [["children", "ORGANISM", 306, 314], ["children", "SPECIES", 306, 314]]], ["In a similar vein the name change to Religious and Worldview Education could be seriously considered for use in Catholic schools.", [["vein", "ANATOMY", 13, 17], ["vein", "MULTI-TISSUE_STRUCTURE", 13, 17], ["vein", "ANATOMY", 13, 17]]], ["Both are suggestive of theological and moral challenges facing Catholic education in England and Wales and how it ought to have responded to the Final Report.", [["suggestive of", "UNCERTAINTY", 9, 22]]], ["First, if the metaphor of there being a Catholic bubble characterised by a defensiveness and unwillingness to engage is pushed further, then there is clearly a tension with the modern magisterium summed up in Gaudium et Spes.", [["a tension", "PROBLEM", 158, 167], ["the modern magisterium", "TREATMENT", 173, 195], ["tension", "OBSERVATION", 160, 167]]], ["A defensive stance, whilst understandable given historical contexts, cannot today be justified theologically.", [["defensive stance", "OBSERVATION", 2, 18]]]], "1e6910aae37c7d741c818a888dddabc2125d7252": [["Keyword COVID-19 cases; SARS-CoV-2; genomic epidemiology; L-lineage European branch I; D614G mutation After 56 days without COVID-19 cases, reemergent cases were reported in Beijing on June 11, 2020.", [["SARS-CoV", "SPECIES", 24, 32], ["Keyword COVID", "TEST", 0, 13], ["SARS", "TEST", 24, 28], ["CoV", "TEST", 29, 32], ["COVID", "TEST", 124, 129]]], ["From June 11th to July 4th, 334 COVID-19 cases were reported in Beijing.", [["COVID", "TEST", 32, 37]]], ["Of the patients affected, 47% were Xinfadi market staff, while others were people who have had contact with the market [1] .", [["patients", "ORGANISM", 7, 15], ["people", "ORGANISM", 75, 81], ["patients", "SPECIES", 7, 15], ["people", "SPECIES", 75, 81]]]], "d8057976f678a39462063d6e22ce0229b56f6581": [["Guillain-Barr\u00e9 syndrome (GBS) is an acute, immunemediated polyradiculoneuropathy with a wide range of clinical manifestation; neuromuscular respiratory failure occurs in up to 30% of patients, leading to mechanical ventilation and intensive care unit admission.", [["neuromuscular", "ANATOMY", 126, 139], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 0, 23], ["GBS", "DISEASE", 25, 28], ["polyradiculoneuropathy", "DISEASE", 58, 80], ["neuromuscular respiratory failure", "DISEASE", 126, 159], ["Guillain-Barr\u00e9", "ORGANISM", 0, 14], ["patients", "ORGANISM", 183, 191], ["patients", "SPECIES", 183, 191], ["Barr\u00e9 syndrome", "PROBLEM", 9, 23], ["GBS", "PROBLEM", 25, 28], ["an acute, immunemediated polyradiculoneuropathy", "PROBLEM", 33, 80], ["clinical manifestation", "PROBLEM", 102, 124], ["neuromuscular respiratory failure", "PROBLEM", 126, 159], ["mechanical ventilation", "TREATMENT", 204, 226], ["Barr\u00e9 syndrome", "OBSERVATION", 9, 23], ["acute", "OBSERVATION_MODIFIER", 36, 41], ["polyradiculoneuropathy", "OBSERVATION", 58, 80], ["wide range", "OBSERVATION_MODIFIER", 88, 98], ["respiratory failure", "OBSERVATION", 140, 159], ["mechanical ventilation", "OBSERVATION", 204, 226]]], ["60% cases are estimated to be related to an infection, most frequently with gastrointestinal or respiratory symptoms.", [["gastrointestinal", "ANATOMY", 76, 92], ["respiratory", "ANATOMY", 96, 107], ["infection", "DISEASE", 44, 53], ["gastrointestinal or respiratory symptoms", "DISEASE", 76, 116], ["gastrointestinal", "ORGANISM_SUBDIVISION", 76, 92], ["an infection", "PROBLEM", 41, 53], ["gastrointestinal or respiratory symptoms", "PROBLEM", 76, 116], ["infection", "OBSERVATION", 44, 53], ["respiratory", "ANATOMY", 96, 107], ["symptoms", "OBSERVATION", 108, 116]]], ["Besides the demonstration of molecular mimicry between epitopes of C. jejuni and nerves, many microorganisms have been investigated in its pathogenesis, e.g., the recent reports of Zika virus (ZIKV)-related GBS [1] .", [["nerves", "ANATOMY", 81, 87], ["GBS", "DISEASE", 207, 210], ["C. jejuni", "ORGANISM", 67, 76], ["nerves", "MULTI-TISSUE_STRUCTURE", 81, 87], ["Zika virus", "ORGANISM", 181, 191], ["epitopes", "PROTEIN", 55, 63], ["C. jejuni", "SPECIES", 67, 76], ["Zika virus", "SPECIES", 181, 191], ["C. jejuni", "SPECIES", 67, 76], ["Zika virus", "SPECIES", 181, 191], ["ZIKV", "SPECIES", 193, 197], ["C. jejuni and nerves", "PROBLEM", 67, 87], ["many microorganisms", "PROBLEM", 89, 108], ["Zika virus (ZIKV)", "PROBLEM", 181, 198], ["GBS", "PROBLEM", 207, 210], ["C. jejuni", "OBSERVATION", 67, 76], ["nerves", "ANATOMY", 81, 87]]], ["During the current pandemic, one adult case of GBS has been associated with Coronavirus disease 2019 (COVID-19) [2] , but it is not clear if this strain of coronavirus (severe acute respiratory syndrome coronavirus-2, SARS-CoV-2) might also have a potential for neurological complications rather than be coincidentally present in neurological patients.", [["neurological", "ANATOMY", 262, 274], ["neurological", "ANATOMY", 330, 342], ["GBS", "DISEASE", 47, 50], ["Coronavirus disease", "DISEASE", 76, 95], ["coronavirus", "DISEASE", 156, 167], ["acute respiratory syndrome coronavirus", "DISEASE", 176, 214], ["neurological complications", "DISEASE", 262, 288], ["coronavirus", "ORGANISM", 156, 167], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 169, 214], ["SARS-CoV-2", "ORGANISM", 218, 228], ["patients", "ORGANISM", 343, 351], ["patients", "SPECIES", 343, 351], ["coronavirus (severe acute respiratory syndrome coronavirus", "SPECIES", 156, 214], ["SARS-CoV", "SPECIES", 218, 226], ["GBS", "PROBLEM", 47, 50], ["Coronavirus disease", "PROBLEM", 76, 95], ["COVID", "TEST", 102, 107], ["coronavirus", "PROBLEM", 156, 167], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 169, 214], ["neurological complications", "PROBLEM", 262, 288], ["GBS", "OBSERVATION", 47, 50], ["associated with", "UNCERTAINTY", 60, 75], ["Coronavirus disease", "OBSERVATION", 76, 95]]]], "PMC4441753": [["IntroductionSince the Middle East respiratory syndrome coronavirus (MERS-CoV) was first described in September 2012,1 there have been a total of 206 cases of MERS-CoV infection with 86 deaths (41.7% mortality rate) reported to the WHO.2 All cases have had links to the Middle East and the majority of cases (156 with 63 deaths (40% mortality) have been reported from KSA as of March 15, 2014.", [["Middle East respiratory syndrome coronavirus", "DISEASE", 22, 66], ["MERS-CoV infection", "DISEASE", 158, 176], ["deaths", "DISEASE", 185, 191], ["deaths", "DISEASE", 320, 326], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 22, 66], ["MERS-CoV", "ORGANISM", 68, 76], ["MERS-CoV", "ORGANISM", 158, 166], ["Middle East respiratory syndrome coronavirus", "SPECIES", 22, 66], ["MERS-CoV", "SPECIES", 68, 76], ["MERS-CoV", "SPECIES", 158, 166], ["the Middle East respiratory syndrome coronavirus", "PROBLEM", 18, 66], ["MERS", "PROBLEM", 158, 162], ["CoV infection", "PROBLEM", 163, 176], ["mortality rate", "TEST", 199, 213], ["Middle", "ANATOMY_MODIFIER", 22, 28], ["respiratory syndrome", "OBSERVATION", 34, 54]]], ["We previously reported family3 and healthcare associated4 case clusters of MERS-CoV infections where human-to-human transmission occurred between index cases and their contacts.", [["MERS-CoV infections", "DISEASE", 75, 94], ["MERS-CoV", "ORGANISM", 75, 83], ["human", "ORGANISM", 101, 106], ["human", "ORGANISM", 110, 115], ["human", "SPECIES", 101, 106], ["human", "SPECIES", 110, 115], ["MERS-CoV", "SPECIES", 75, 83], ["human", "SPECIES", 101, 106], ["human", "SPECIES", 110, 115], ["CoV infections", "PROBLEM", 80, 94]]], ["Whilst camels have been implicated as the reservoir of MERS-CoV,5, 6, 7 the exact source(s) and mode of transmission for most patients remain unknown.", [["camels", "ORGANISM", 7, 13], ["MERS-CoV", "ORGANISM", 55, 63], ["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134], ["MERS-CoV", "SPECIES", 55, 63]]], ["Serology consistent with a common MERS-CoV like virus in camels has been demonstrated by several studies5, 6, 7 and recently evidence has emerged of a MERS-CoV infection in a camel and in humans in contact with these camels.8, 30", [["MERS-CoV infection", "DISEASE", 151, 169], ["MERS-CoV like virus", "ORGANISM", 34, 53], ["camels", "ORGANISM", 57, 63], ["MERS-CoV", "ORGANISM", 151, 159], ["camel", "ORGANISM", 175, 180], ["humans", "ORGANISM", 188, 194], ["camels", "ORGANISM", 217, 223], ["humans", "SPECIES", 188, 194], ["MERS-CoV", "SPECIES", 34, 42], ["MERS-CoV", "SPECIES", 151, 159], ["camel", "SPECIES", 175, 180], ["humans", "SPECIES", 188, 194], ["Serology", "TEST", 0, 8], ["a common MERS", "PROBLEM", 25, 38], ["CoV like virus in camels", "PROBLEM", 39, 63], ["a MERS-CoV infection", "PROBLEM", 149, 169], ["consistent with", "UNCERTAINTY", 9, 24], ["CoV", "OBSERVATION", 39, 42], ["virus", "OBSERVATION", 48, 53], ["CoV", "OBSERVATION_MODIFIER", 156, 159], ["infection", "OBSERVATION", 160, 169]]]]}